<!DOCTYPE html><html lang="en" class="scroll-smooth"><head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pharmacology Test - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / NEET PG Test Series Subject Wise / Year 2024 - 25
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">50</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls="">
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd"></path>
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z"></path>
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>const _0x2e8c1b=_0x3678;(function(_0x182fb5,_0x279b1d){const _0x5cd300=_0x3678,_0x3616dd=_0x182fb5();while(!![]){try{const _0x5bb7c1=parseInt(_0x5cd300(0x4ab))/0x1+-parseInt(_0x5cd300(0x3ff))/0x2+-parseInt(_0x5cd300(0x42a))/0x3+parseInt(_0x5cd300(0x1ff))/0x4+parseInt(_0x5cd300(0x359))/0x5*(parseInt(_0x5cd300(0x3d3))/0x6)+-parseInt(_0x5cd300(0x200))/0x7*(parseInt(_0x5cd300(0x3fb))/0x8)+parseInt(_0x5cd300(0x186))/0x9;if(_0x5bb7c1===_0x279b1d)break;else _0x3616dd['push'](_0x3616dd['shift']());}catch(_0x1b8fb8){_0x3616dd['push'](_0x3616dd['shift']());}}}(_0x53f1,0x6d35e));const _0x2ad82b=(function(){const _0x1a97a6=_0x3678,_0xfe8344={'LZiaR':function(_0x2fa32e,_0x232064){return _0x2fa32e!==_0x232064;},'MoiOC':_0x1a97a6(0x355)};let _0x5689c5=!![];return function(_0x2230e9,_0x419776){const _0x2d3b4f=_0x1a97a6;if(_0xfe8344[_0x2d3b4f(0x282)](_0xfe8344[_0x2d3b4f(0x234)],_0xfe8344[_0x2d3b4f(0x234)]))_0x2f2738[_0x2d3b4f(0x3a7)]+=_0x2d3b4f(0x286)+_0x18a194[_0x2d3b4f(0x2e1)]+_0x2d3b4f(0x3e3);else{const _0x5eb89c=_0x5689c5?function(){const _0x35efb8=_0x2d3b4f;if(_0x419776){const _0x14d0f9=_0x419776[_0x35efb8(0x441)](_0x2230e9,arguments);return _0x419776=null,_0x14d0f9;}}:function(){};return _0x5689c5=![],_0x5eb89c;}};}()),_0x5cfd25=_0x2ad82b(this,function(){const _0x4e495b=_0x3678,_0xea3223={'mHWsY':_0x4e495b(0x196)};return _0x5cfd25['toString']()[_0x4e495b(0x47a)](_0xea3223['mHWsY'])[_0x4e495b(0x1f7)]()[_0x4e495b(0x26c)](_0x5cfd25)[_0x4e495b(0x47a)](_0xea3223[_0x4e495b(0x2c3)]);});_0x5cfd25();const _0x100e65=(function(){let _0x35353e=!![];return function(_0x5b7c99,_0x4180fd){const _0x9f5558=_0x35353e?function(){const _0x2a2c1c=_0x3678;if(_0x4180fd){const _0x42ed92=_0x4180fd[_0x2a2c1c(0x441)](_0x5b7c99,arguments);return _0x4180fd=null,_0x42ed92;}}:function(){};return _0x35353e=![],_0x9f5558;};}()),_0x2465cd=_0x100e65(this,function(){const _0x1305f5=_0x3678,_0x5dc574={'VsDGD':function(_0x43311e,_0x2e6f7a){return _0x43311e(_0x2e6f7a);},'viqiz':function(_0xbb501f,_0x1faec7){return _0xbb501f+_0x1faec7;},'TcmKm':function(_0xc252dc,_0x9165e3){return _0xc252dc+_0x9165e3;},'QJQgJ':_0x1305f5(0x415),'TDujx':_0x1305f5(0x1d0),'EHoJN':function(_0x1ac3e0){return _0x1ac3e0();},'JRtjT':'custom_quiz.html','VpXZH':_0x1305f5(0x3e0),'VBbGG':function(_0x377080){return _0x377080();},'GxNqR':function(_0x558180,_0x17dbf7){return _0x558180!==_0x17dbf7;},'yXVJP':_0x1305f5(0x265),'RkmoL':function(_0x18f19b,_0x3dbab7){return _0x18f19b(_0x3dbab7);},'pmJPn':function(_0x1d3035){return _0x1d3035();},'rhGfp':_0x1305f5(0x23d),'hGZMC':_0x1305f5(0x3dd),'iAadR':_0x1305f5(0x39b),'CILcR':_0x1305f5(0x295),'EhVrj':_0x1305f5(0x46d),'IZNUz':function(_0x2e7e3a,_0x37d4cd){return _0x2e7e3a<_0x37d4cd;},'ZTIbi':function(_0x3f0676,_0x396644){return _0x3f0676===_0x396644;},'fvtxd':_0x1305f5(0x1c0)};let _0x42af70;try{if(_0x5dc574[_0x1305f5(0x304)](_0x1305f5(0x265),_0x5dc574[_0x1305f5(0x371)])){const _0x1fb525=_0x5dc574['VsDGD'](_0xc0fb12,_0x5dc574[_0x1305f5(0x34d)](_0x5dc574['TcmKm'](_0x5dc574[_0x1305f5(0x386)],_0x5dc574['TDujx']),');'));_0x10d7da=_0x5dc574[_0x1305f5(0x44a)](_0x1fb525);}else{const _0x11d20e=_0x5dc574['RkmoL'](Function,_0x5dc574['viqiz'](_0x5dc574[_0x1305f5(0x386)]+_0x5dc574[_0x1305f5(0x387)],');'));_0x42af70=_0x5dc574[_0x1305f5(0x1ae)](_0x11d20e);}}catch(_0x197840){_0x42af70=window;}const _0x14a3b4=_0x42af70['console']=_0x42af70[_0x1305f5(0x3fc)]||{},_0x493995=[_0x1305f5(0x465),_0x5dc574[_0x1305f5(0x26a)],_0x5dc574[_0x1305f5(0x1d8)],_0x5dc574[_0x1305f5(0x233)],_0x5dc574[_0x1305f5(0x262)],_0x5dc574[_0x1305f5(0x2ce)],_0x1305f5(0x3f5)];for(let _0x536143=0x0;_0x5dc574['IZNUz'](_0x536143,_0x493995['length']);_0x536143++){if(_0x5dc574[_0x1305f5(0x2ad)](_0x5dc574['fvtxd'],_0x5dc574[_0x1305f5(0x1eb)])){const _0x500158=_0x100e65['constructor'][_0x1305f5(0x39c)][_0x1305f5(0x47f)](_0x100e65),_0x134fe4=_0x493995[_0x536143],_0x51cd1a=_0x14a3b4[_0x134fe4]||_0x500158;_0x500158[_0x1305f5(0x3bf)]=_0x100e65[_0x1305f5(0x47f)](_0x100e65),_0x500158[_0x1305f5(0x1f7)]=_0x51cd1a['toString'][_0x1305f5(0x47f)](_0x51cd1a),_0x14a3b4[_0x134fe4]=_0x500158;}else _0x19fe0b[_0x1305f5(0x352)][_0x1305f5(0x430)][_0x1305f5(0x347)](_0x5dc574[_0x1305f5(0x3c4)])&&_0x482e6f[_0x1305f5(0x446)](_0x5dc574[_0x1305f5(0x393)]),_0x5dc574[_0x1305f5(0x2be)](_0x4a0788),_0x5f3695[_0x1305f5(0x3da)]();}});_0x2465cd();let questionsData=[{'text':_0x2e8c1b(0x384),'choices':[{'id':0x1,'text':_0x2e8c1b(0x2b8)},{'id':0x2,'text':_0x2e8c1b(0x332)},{'id':0x3,'text':_0x2e8c1b(0x45e)},{'id':0x4,'text':_0x2e8c1b(0x4a5)}],'correct_choice_id':0x2,'solution':'<p>The\x20correct\x20match\x20is;</p>\x0a<table\x20style=\x22width:\x20282px;\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2018px;\x22>\x0a<td\x20style=\x22width:\x20147.295px;\x20height:\x2018px;\x20text-align:\x20center;\x22><strong>Drugs</strong></td>\x0a<td\x20style=\x22width:\x20140.705px;\x20height:\x2018px;\x20text-align:\x20center;\x22><strong>Adverse\x20effects</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2035.3239px;\x22>\x0a<td\x20style=\x22width:\x20147.295px;\x20height:\x2035.3239px;\x22>1.\x20Bleomycin</td>\x0a<td\x20style=\x22width:\x20140.705px;\x20height:\x2035.3239px;\x22>\x0a<p>c.\x20Pulmonary\x20fibrosis</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2034px;\x22>\x0a<td\x20style=\x22width:\x20147.295px;\x20height:\x2034px;\x22>2.\x20Doxorubicin</td>\x0a<td\x20style=\x22width:\x20140.705px;\x20height:\x2034px;\x22>\x0a<p>d.\x20Cardiotoxicity</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2036px;\x22>\x0a<td\x20style=\x22width:\x20147.295px;\x20height:\x2036px;\x22>3.\x20Vincristine</td>\x0a<td\x20style=\x22width:\x20140.705px;\x20height:\x2036px;\x22>\x0a<p>a.\x20Peripheral\x20neuropathy</p>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2042px;\x22>\x0a<td\x20style=\x22width:\x20147.295px;\x20height:\x2042px;\x22>4.\x20Capecitabine</td>\x0a<td\x20style=\x22width:\x20140.705px;\x20height:\x2042px;\x22>\x0a<p>b.\x20Hand-foot\x20syndrome.</p>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Bleomycin\u00a0</strong>is\x20an\x20anticancer\x20antibiotic\x20used\x20for\x20the\x20treatment\x20of\x20squamous\x20cell\x20cancer\x20and\x20Hodgkin\x20lymphoma.\x20It\x20chelates\x20copper\x20or\x20iron\x20and\x20produces\x20superoxide\x20ions\x20that\x20damage\x20DNA.\x20Side\x20effects\x20are\x20mucocutaneous\x20toxicity\x20and\u00a0<strong>pulmonary\x20fibrosis.</strong></p>\x0a<p><strong>Doxorubicin</strong>\x20is\x20an\u00a0<strong>anthracycline</strong>\u00a0that\x20is\x20widely\x20used\x20in\x20clinical\x20practice\x20as\x20a\x20chemotherapeutic\x20agent.\x20It\x20is\x20most\x20commonly\x20used\x20as\x20a\x20part\x20of\x20regimens\x20with\x20other\x20agents\x20like\x20cyclophosphamide,\x20cisplatin,\x20and\x205-FU\x20in\x20several\x20malignancies\x20including:\u00a0</p>\x0a<ul>\x0a<li>Breast\x20cancer</li>\x0a<li>Endometrial\x20cancer</li>\x0a<li>Ovarian\x20cancer</li>\x0a<li>Soft-tissue\x20sarcoma</li>\x0a<li>Neuroblastoma</li>\x0a<li>Ewing\x27s\x20sarcoma</li>\x0a<li>Rhabdomyosarcoma</li>\x0a<li>ALL</li>\x0a<li>Multiple\x20myeloma</li>\x0a<li>Hodgkin\x27s\x20and\x20Non-Hodgkin\x27s\x20lymphoma</li>\x0a</ul>\x0a<p><strong>Cardiotoxicity</strong>\u00a0is\x20a\x20known\x20side-effect\x20of\x20doxorubicin.\x20Therefore,\x20careful\x20monitoring\x20is\x20required\x20for\x20doxorubicin.\x20Specifically,\x20doxorubicin\x20requires\x20dose\x20adjustment\x20during\x20or\x20after\x20radiotherapy\x20in\x20order\x20to\x20prevent\x20radiation\x20toxicity.</p>\x0a<p><strong>Vincristine</strong>\u00a0is\x20a\x20vinca\x20alkaloid\x20that\x20acts\x20during\x20the\u00a0<strong>M\x20phase</strong>\u00a0of\x20the\x20cell\x20cycle.\x20It\x20causes\x20microtubule\x20disruptions,\x20thereby\x20preventing\x20cellular\x20replication.\u00a0Side\x20effects\x20are\x20<strong>neuropathy</strong>\u00a0and\x20SIADH.</p>\x0a<p><strong>Capecitabine</strong>\u00a0is\x20a\u00a0<strong>pyrimidine\x20analog</strong>\u00a0that\x20is\x20classified\x20as\x20an\u00a0<strong>antimetabolite\x20agent</strong>.\x20Side\x20effects\x20are\x20diarrhea,\x20<strong>hand-foot\x20syndrome</strong>,\x20and\x20myelosuppression.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x2dd),'choices':[{'id':0x1,'text':_0x2e8c1b(0x1c6)},{'id':0x2,'text':_0x2e8c1b(0x340)},{'id':0x3,'text':_0x2e8c1b(0x2f7)},{'id':0x4,'text':_0x2e8c1b(0x1dc)}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x2de),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20young\x20patient\x20presented\x20with\x20symptoms\x20of\x20bronchial\x20asthma\x20and\x20cromolyn\x20sodium\x20was\x20prescribed.\x20It\x20should\x20be\x20administered\x20by\x20which\x20of\x20the\x20following\x20routes?','choices':[{'id':0x1,'text':_0x2e8c1b(0x35e)},{'id':0x2,'text':_0x2e8c1b(0x2d2)},{'id':0x3,'text':'IV'},{'id':0x4,'text':'IM'}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x231),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x42e),'choices':[{'id':0x1,'text':_0x2e8c1b(0x288)},{'id':0x2,'text':'Methotrexate'},{'id':0x3,'text':_0x2e8c1b(0x448)},{'id':0x4,'text':_0x2e8c1b(0x283)}],'correct_choice_id':0x4,'solution':_0x2e8c1b(0x211),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x3f4),'choices':[{'id':0x1,'text':_0x2e8c1b(0x32e)},{'id':0x2,'text':_0x2e8c1b(0x360)},{'id':0x3,'text':'It\x20promotes\x20weight\x20loss'},{'id':0x4,'text':_0x2e8c1b(0x190)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x3fe),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x310),'choices':[{'id':0x1,'text':_0x2e8c1b(0x3e5)},{'id':0x2,'text':_0x2e8c1b(0x2ee)},{'id':0x3,'text':_0x2e8c1b(0x390)},{'id':0x4,'text':_0x2e8c1b(0x3ed)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x452),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x382),'choices':[{'id':0x1,'text':_0x2e8c1b(0x293)},{'id':0x2,'text':_0x2e8c1b(0x2b2)},{'id':0x3,'text':_0x2e8c1b(0x3fd)},{'id':0x4,'text':'Warfarin,\x20lack\x20of\x20monitoring\x20needed'}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x368),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x46e),'choices':[{'id':0x1,'text':_0x2e8c1b(0x2af)},{'id':0x2,'text':'Anionic\x20site,\x20Esteratic\x20site'},{'id':0x3,'text':_0x2e8c1b(0x4a9)},{'id':0x4,'text':_0x2e8c1b(0x27b)}],'correct_choice_id':0x2,'solution':'<p><strong>Tacrine</strong>\x20binds\x20to\x20the\x20<strong>anionic\x20site</strong>\x20and\x20<strong>malathion</strong>\x20binds\x20to\x20the\x20<strong>esteratic\x20site\x20</strong>of\x20the\x20Acetylcholine\x20esterase\x20enzyme\x20and\x20inhibits\x20it.</p>\x0a<p><strong>Anticholinesterase\x20drugs:<br\x20/><br\x20/>Reversible\x20inhibitors<br\x20/></strong></p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100.046%;\x20height:\x2054.7578px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2030.875px;\x22>\x0a<td\x20style=\x22width:\x2045.3989%;\x20height:\x2030.875px;\x22><strong>Carbamates</strong></td>\x0a<td\x20style=\x22width:\x2054.6464%;\x20height:\x2030.875px;\x22><strong>Non-Carbamates</strong></td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2023.8828px;\x22>\x0a<td\x20style=\x22width:\x2045.3989%;\x20height:\x2023.8828px;\x22>Physostigmine,\x20Neostigmine,\x20Pyridostigmine,\x20Rivastigmine</td>\x0a<td\x20style=\x22width:\x2054.6464%;\x20height:\x2023.8828px;\x22>Edrophonium,\x20<strong>Tacrine</strong>,\x20Donepezil,\x20Galantamine</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong><br\x20/>Irreversible\x20inhibitors<br\x20/></strong></p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x20100%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2045.6897%;\x22><strong>Carbamates</strong></td>\x0a<td\x20style=\x22width:\x2054.4011%;\x22><strong>Organophosphates</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2045.6897%;\x22>Carbaryl,\x20Propoxur</td>\x0a<td\x20style=\x22width:\x2054.4011%;\x22>Dyflos,\x20Echthiophate,\x20<strong>Malathion</strong>,\x20Diazinon,\x20Tabun,\x20Sarin,\x20Soman</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><br\x20/>The\x20AChE\x20has\x20two\x20sites,\x20an\x20anionic\x20site,\x20and\x20an\x20esteratic\x20site.<strong>\x20</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22><strong>Edrophonium\x20and\x20tacrine\x20(Non-Carbamates)\x20</strong>attach\x20only\x20to\x20the\x20<strong>anionic\x20site\x20</strong>and\x20<strong>do\x20not\x20form</strong>\x20<strong>covalent\x20bonds</strong>\x20with\x20the\x20enzyme.\x20In\x20contrast,\x20<strong>organophosphates</strong>\x20attach\x20only\x20to\x20the\x20<strong>esteratic\x20site</strong>\x20forming\x20<strong>strong\x20covalent\x20bonds.\x20Carbamates</strong>\x20bind\x20to\x20both\x20<strong>anionic\x20and\x20esteratic\x20sites</strong>.</span></p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20133\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Reactivation</strong>\x20of\x20edrophonium­\x20inhibited\x20enzyme\x20occurs\x20in\x20<strong>&lt;\x2010\x20min</strong>,\x20because\x20the\x20interaction\x20is\x20by\x20forming\x20<strong>weak\x20hydrogen\x20bonds</strong>,\x20and\x20does\x20not\x20involve\x20hydrolysis\x20of\x20the\x20inhibitor,\x20but\x20only\x20its\x20diffusion.\x20<span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>The\x20<strong>reactivation</strong>\x20of\x20<strong>carbamylated\x20enzyme</strong>\x20(1/2\x20to\x206\x20hours)\x20is\x20<strong>less\x20than</strong>\x20that\x20of\x20the\x20<strong>synthesis</strong>\x20of\x20fresh\x20enzyme\x20protein.\x20In\x20contrast,\x20that\x20of\x20the<strong>\x20phosphorylated\x20enzyme</strong>\x20(in\x20days)\x20is\x20<strong>more\x20than\x20</strong>the\x20<strong>regeneration\x20time.\x20</strong></span><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>The\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>phosphorylated\x20enzyme</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>\x20may\x20also\x20undergo\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>‘ageing’\x20</strong><span\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>by\x20the\x20loss\x20of\x20one\x20of\x20the\x20alkyl\x20groups\x20and\x20become\x20</span><strong\x20style=\x22font-family:\x20-apple-system,\x20BlinkMacSystemFont,\x20\x27Segoe\x20UI\x27,\x20Roboto,\x20Oxygen,\x20Ubuntu,\x20Cantarell,\x20\x27Open\x20Sans\x27,\x20\x27Helvetica\x20Neue\x27,\x20sans-serif;\x22>resistant\x20to\x20hydrolysis.</strong></p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x221),'choices':[{'id':0x1,'text':_0x2e8c1b(0x26f)},{'id':0x2,'text':_0x2e8c1b(0x3f2)},{'id':0x3,'text':_0x2e8c1b(0x176)},{'id':0x4,'text':_0x2e8c1b(0x343)}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x2f5),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2016-year-old\x20girl\x20was\x20taken\x20to\x20the\x20emergency\x20department\x20with\x20palpitations\x20and\x20restlessness\x20after\x20using\x20a\x20salbutamol\x20inhaler\x2015\x20times\x20in\x20one\x20hour\x20following\x20an\x20asthma\x20attack.\x20Her\x20chest\x20examination\x20was\x20clear\x20on\x20auscultation,\x20and\x20cardiac\x20examination\x20showed\x20tachycardia\x20with\x20a\x20regular\x20rhythm,\x20without\x20murmurs.\x20What\x20features\x20are\x20likely\x20to\x20be\x20seen\x20in\x20this\x20case?','choices':[{'id':0x1,'text':'Tall\x20T\x20waves\x20on\x20ECG'},{'id':0x2,'text':_0x2e8c1b(0x1f0)},{'id':0x3,'text':_0x2e8c1b(0x16c)},{'id':0x4,'text':_0x2e8c1b(0x2e8)}],'correct_choice_id':0x4,'solution':'<p>Salbutamol\x20toxicity\x20can\x20cause\x20<strong>muscle\x20tremors</strong>\x20due\x20to\x20stimulation\x20of<strong>\u00a0β2-adrenergic</strong>\x20receptors\x20in\x20skeletal\x20muscle.\x20It\x20is\x20the\x20most\x20common\x20side\x20effect.\x20The\x20risk\x20is\x20higher\x20with\x20elderly\x20patients\x20and\x20those\x20with\x20COPD.</p>\x0a<p>Salbutamol\x20is\x20a\x20relatively\x20selective\x20β2-\x20adrenergic\x20receptor\x20agonist.\u00a0In\x20overdose,\x20receptor\x20specificity\x20may\x20be\x20lost\x20and\x20stimulation\x20of\x20cardiac\x20β2-receptors\x20may\x20cause\x20<strong>tachycardia</strong>,\x20cardiac\x20ischemia,\x20and\x20arrhythmias.\x20It\x20causes\x20<strong>hypokalemia\u00a0</strong>(option\x20C)\u00a0by\x20stimulating\x20β2-receptors\x20of\x20the\x20Na<sup>+</sup>/K<sup>+</sup>\x20ATPase\x20pump\x20in\x20the\x20skeletal\x20muscle,\x20shifting\x20K<sup>+</sup>\x20intracellularly.\x20This\x20can\x20produce\x20ECG\x20changes\x20such\x20as<strong>\x20flattening\x20and\x20inversion\x20of\x20T</strong>\x20<strong>waves\x20</strong>(option\x20A),\x20<strong>QT\x20prolongation,</strong>\x20and\x20<strong>U\x20waves</strong>.\u00a0</p>\x0a<p>Acute\x20salbutamol\x20toxicity\x20may\x20cause\x20<strong>lactic\x20acidosis</strong>.\x20β2-adrenergic\x20stimulation\x20increases\x20gluconeogenesis\x20and\x20lipolysis.\x20This\x20causes\x20increased\x20plasma\x20glucose,\x20leading\x20to\x20increased\x20conversion\x20of\x20pyruvate\x20and\x20lactate.\x20Overdose\x20can\x20result\x20in\x20<strong>hyperglycemia\x20</strong>(option\x20B),\x20<strong>lactic\x20acidosis</strong>,\x20and\x20<strong>cardiac\x20arrhythmias</strong>.\u00a0</p>\x0a<p>Other\x20adverse\x20effects\x20include\x20hypoxemia\x20and\x20metabolic\x20effects\x20such\x20as\x20an\x20<strong>increase\x20in\x20free\x20fatty\x20acids\x20</strong>and\u00a0insulin.\x20Desensitization\x20is\x20noted\x20in\x20the\x20long-term\x20use\x20of\x20salbutamol.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x402),'choices':[{'id':0x1,'text':_0x2e8c1b(0x38a)},{'id':0x2,'text':_0x2e8c1b(0x2f2)},{'id':0x3,'text':_0x2e8c1b(0x4a2)},{'id':0x4,'text':'Spironolactone'}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x1b2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x3ab),'choices':[{'id':0x1,'text':_0x2e8c1b(0x19f)},{'id':0x2,'text':_0x2e8c1b(0x25b)},{'id':0x3,'text':_0x2e8c1b(0x3f1)},{'id':0x4,'text':_0x2e8c1b(0x267)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x223),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20drugs\x20is\x20representative\x20of\x20the\x20graph\x20as\x20given\x20below?','choices':[{'id':0x1,'text':'Penicillin'},{'id':0x2,'text':_0x2e8c1b(0x481)},{'id':0x3,'text':_0x2e8c1b(0x294)},{'id':0x4,'text':_0x2e8c1b(0x2e3)}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x2f6),'explanation_video':'','question_images':[_0x2e8c1b(0x40a)],'explanation_images':['https://dhmbxeygs57ff.cloudfront.net/uploads/de59935081ef433c99266fa547e42bb2x866x722.PNG',_0x2e8c1b(0x35f)]},{'text':_0x2e8c1b(0x495),'choices':[{'id':0x1,'text':_0x2e8c1b(0x406)},{'id':0x2,'text':_0x2e8c1b(0x36a)},{'id':0x3,'text':_0x2e8c1b(0x170)},{'id':0x4,'text':'Propantheline'}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x2f1),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x20patient\x20with\x20peptic\x20ulcer\x20disease\x20was\x20prescribed\x20ranitidine\x20and\x20sucralfate.\x20The\x20combination\x20is\x20incorrect\x20because','choices':[{'id':0x1,'text':_0x2e8c1b(0x25d)},{'id':0x2,'text':_0x2e8c1b(0x313)},{'id':0x3,'text':_0x2e8c1b(0x2b6)},{'id':0x4,'text':_0x2e8c1b(0x28b)}],'correct_choice_id':0x4,'solution':_0x2e8c1b(0x259),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x3b0),'choices':[{'id':0x1,'text':_0x2e8c1b(0x246)},{'id':0x2,'text':_0x2e8c1b(0x44c)},{'id':0x3,'text':_0x2e8c1b(0x268)},{'id':0x4,'text':_0x2e8c1b(0x1ec)}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x404),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x33d),'choices':[{'id':0x1,'text':_0x2e8c1b(0x3ee)},{'id':0x2,'text':_0x2e8c1b(0x316)},{'id':0x3,'text':_0x2e8c1b(0x4b6)},{'id':0x4,'text':'Allopurinol'}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x201),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x229),'choices':[{'id':0x1,'text':'Methimazole'},{'id':0x2,'text':'Subtotal\x20thyroidectomy'},{'id':0x3,'text':_0x2e8c1b(0x17d)},{'id':0x4,'text':_0x2e8c1b(0x1b9)}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x2ec),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x3c1),'choices':[{'id':0x1,'text':_0x2e8c1b(0x37b)},{'id':0x2,'text':_0x2e8c1b(0x1b1)},{'id':0x3,'text':'Metoclopramide'},{'id':0x4,'text':'Motilin'}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x23e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x1d9),'choices':[{'id':0x1,'text':_0x2e8c1b(0x481)},{'id':0x2,'text':_0x2e8c1b(0x3e2)},{'id':0x3,'text':_0x2e8c1b(0x308)},{'id':0x4,'text':_0x2e8c1b(0x230)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x350),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Oral\x20digoxin\x20is\x20being\x20given\x20to\x20a\x2065-year-old\x20male\x20patient\x20with\x20congestive\x20heart\x20failure\x20as\x20a\x20maintenance\x20dose\x20to\x20gradually\x20digitalize\x20him.\x20A\x20target\x20plasma\x20concentration\x20of\x200.70\x20ng/mL\x20is\x20decided\x20upon.\x20The\x20digoxin\x20clearance\x20for\x20this\x20particular\x20individual\x20is\x20calculated\x20as\x2060\x20mL/min.\x20Knowing\x20that\x20the\x20oral\x20bioavailability\x20of\x20digoxin\x20is\x2070%,\x20what\x20is\x20the\x20dosing\x20rate\x20in\x20this\x20patient?','choices':[{'id':0x1,'text':_0x2e8c1b(0x1ac)},{'id':0x2,'text':_0x2e8c1b(0x189)},{'id':0x3,'text':_0x2e8c1b(0x392)},{'id':0x4,'text':'80\x20ng/min'}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x35a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x394),'choices':[{'id':0x1,'text':'Metformin'},{'id':0x2,'text':_0x2e8c1b(0x379)},{'id':0x3,'text':'Sitagliptin'},{'id':0x4,'text':_0x2e8c1b(0x398)}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x18d),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x25e),'choices':[{'id':0x1,'text':_0x2e8c1b(0x33a)},{'id':0x2,'text':_0x2e8c1b(0x326)},{'id':0x3,'text':_0x2e8c1b(0x3d4)},{'id':0x4,'text':_0x2e8c1b(0x2e3)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x1fb),'explanation_video':'','question_images':[_0x2e8c1b(0x471)],'explanation_images':[_0x2e8c1b(0x1c7)]},{'text':_0x2e8c1b(0x4b8),'choices':[{'id':0x1,'text':'Inhibit\x20funny\x20currents\x20in\x20SA\x20node'},{'id':0x2,'text':_0x2e8c1b(0x1de)},{'id':0x3,'text':_0x2e8c1b(0x172)},{'id':0x4,'text':'K+\x20ATP\x20channel\x20agonist'}],'correct_choice_id':0x2,'solution':'<p><strong>Ranolazine</strong>\x20acts\x20by\u00a0<strong>late\x20sodium\x20current</strong>\u00a0<strong>inhibition\u00a0</strong>in\x20the\x20heart.\u00a0It\x20is\x20used\x20in\x20the\x20prophylaxis\x20of\x20<strong>angina.</strong></p>\x0a<p>Late\x20sodium\x20current\x20(I<sub>Na</sub>)\x20facilitates\x20the\x20entry\x20of\x20calcium\x20via\x20the\x20sodium-calcium\x20exchanger.\x20<strong>Inhibition</strong>\x20of\u00a0<strong>I<sub>Na</sub>,</strong>\x20therefore,\x20reduces\x20the\x20intracellular\x20calcium\x20concentration\x20which\x20in\x20turn\x20reduces\x20the\x20diastolic\x20tension\x20and\x20cardiac\x20contractility.</p>\x0a<p>At\x20higher\x20doses,\x20it\x20may\x20also\x20modify\x20the\x20fatty\x20acid\x20oxidation\x20(<strong>pFOX\x20inhibitor</strong>),\x20which\x20improves\x20the\x20efficiency\x20of\x20cardiac\x20oxygen\x20utilisation\x20but\x20whether\x20this\x20actually\x20occurs\x20at\x20therapeutic\x20doses\x20is\x20still\x20being\x20studied.\x20It\x20also\x20has\x20mild\x20beta-blocking\x20activity.</p>\x0a<p>Ranolazine\x20is\x20the\x20second-line\x20FDA-approved\x20drug\x20for\x20heart\x20failure.\x20Side\x20effects\x20of\x20ranolazine\x20include\x20dizziness,\x20headache,\x20and\x20postural\x20hypotension.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\u00a0<strong>Ivabradine\x20</strong>selectively\x20<strong>blocks\x20the\x20funny\x20current\x20(I<sub>f</sub></strong><strong>)\x20channel\u00a0</strong>involved\x20in\x20the\x20generation\x20of\x20automaticity\x20in\x20the\x20SA\x20node.\x20It\x20reduces\x20heart\x20rate\x20and\x20thereby\x20oxygen\x20demand.\x20It\x20does\x20not\x20have\x20any\x20effect\x20on\x20cardiac\x20contractility.\x20It\x20is\x20an\x20FDA-approved\x20drug\x20for\x20the\x20treatment\x20of\x20<strong>heart\x20failure</strong>.\x20It\x20is\x20also\x20used\x20for\x20treating\x20stable\x20angina.</p>\x0a<p>Option\x20C:\u00a0<strong>Fasudil</strong>\u00a0acts\x20by<strong>\x20inhibiting</strong>\x20smooth\x20muscle\x20<strong>Rho\x20kinase</strong>\x20and\x20reduces\x20coronary\x20vasospasm.</p>\x0a<p>Option\x20D:\u00a0<strong>Nicorandil</strong>\x20acts\x20as\x20an\x20agonist\x20at\x20ATP-sensitive\x20potassium\x20(K<sub>ATP</sub>)\x20channels\x20i.e.\x20<strong>potassium\x20channel\x20opener</strong>.\x20It\x20decreases\x20afterload\x20and\x20preload\x20of\x20the\x20heart\x20by\x20its\x20vasodilatory\x20properties\x20at\x20both\x20arterioles\x20and\x20venules.\x20It\x20is\x20used\x20for\x20the\x20treatment\x20of\x20stable\x20angina.</p>\x0a<p>Note:\x20<strong>Trimetazidine</strong>\x20is\x20a\u00a0<strong>pFOX\x20inhibitor\u00a0</strong>that\x20partially\x20inhibits\x20fatty\x20acid\x20oxidation\x20in\x20the\x20myocardium.\x20Thereby,\x20it\x20decreases\x20the\x20oxygen\x20requirement.\x20It\x20is\x20also\x20used\x20as\x20an\x20anti-anginal\x20agent.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x48f),'choices':[{'id':0x1,'text':_0x2e8c1b(0x30a)},{'id':0x2,'text':_0x2e8c1b(0x18b)},{'id':0x3,'text':_0x2e8c1b(0x2c6)},{'id':0x4,'text':_0x2e8c1b(0x2bf)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x4b2),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x1b3),'choices':[{'id':0x1,'text':_0x2e8c1b(0x497)},{'id':0x2,'text':'Beta-carbolines'},{'id':0x3,'text':_0x2e8c1b(0x217)},{'id':0x4,'text':_0x2e8c1b(0x19a)}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x191),'explanation_video':'','question_images':[_0x2e8c1b(0x20f)],'explanation_images':[_0x2e8c1b(0x213)]},{'text':_0x2e8c1b(0x271),'choices':[{'id':0x1,'text':_0x2e8c1b(0x22f)},{'id':0x2,'text':_0x2e8c1b(0x1a9)},{'id':0x3,'text':'Medullary\x20opioid\x20receptor\x20agonist'},{'id':0x4,'text':_0x2e8c1b(0x3ea)}],'correct_choice_id':0x4,'solution':_0x2e8c1b(0x2db),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x356),'choices':[{'id':0x1,'text':'Rumack\x20matthew'},{'id':0x2,'text':_0x2e8c1b(0x44f)},{'id':0x3,'text':_0x2e8c1b(0x183)},{'id':0x4,'text':_0x2e8c1b(0x215)}],'correct_choice_id':0x1,'solution':'<p><strong>Rumack\x20Matthew</strong>\x20nomogram\x20is\x20used\x20in\x20<strong>paracetamol\x20poisoning</strong>.\x20In\x20this\x20nomogram\x20serum\x20<strong>acetaminophen\x20concentration</strong>\x20is\x20measured\x20for\x20the\x20time\x20after\x20ingestion\x20which\x20is\x20useful\x20in\x20assessing\x20potential\x20<strong>hepatotoxicity</strong>\x20after\x20an\x20acute\x20ingestion\x20of\x20paracetamol.</p>\x0a<p><strong>Acetaminophen\x20toxicity</strong>\x20clinically\x20presents\x20with\x20nausea,\x20vomiting,\x20diarrhea,\x20and\x20abdominal\x20pain.\x20Later,\x20renal\x20failure\x20and\x20myocardial\x20injury\x20may\x20be\x20seen.\x20<strong>Low\x20bilirubin\x20levels</strong>\x20along\x20with\x20<strong>raised\x20aminotransferase</strong>\x20levels\x20are\x20characteristic\x20of\x20the\x20condition.\u00a0</p>\x0a<p><strong>Acetaminophen\x20toxicity</strong>\x20is\x20an\x20important\x20cause\x20of\x20<strong>acute\x20liver\x20failure</strong>.\x20Ingestion\x20of\x20≥25g\x20can\x20be\x20fatal.\x20Cytochrome\x20P450\x20CYP2E1\x20metabolizes\x20acetaminophen\x20to\x20<strong>N-acetyl-p-benzoquinone-imine</strong>\x20(NAPQI).\x20<strong>Glutathione</strong>\x20is\x20responsible\x20for\x20its\x20detoxification,\x20after\x20which\x20it\x20is\x20excreted\x20in\x20the\x20urine.\x20When\x20glutathione\x20reserves\x20are\x20depleted\x20or\x20large\x20amounts\x20of\x20NAPQI\x20are\x20formed,\x20it\x20binds\x20to\x20hepatocyte\x20macromolecules.\x20This\x20can\x20then\x20lead\x20to\x20hepatocyte\x20necrosis.</p>\x0a<p>Initial\x20management\x20includes\x20<strong>gastric\x20lavage</strong>\x20and\x20<strong>oral\x20charcoal</strong>\x20or\x20<strong>cholestyramine</strong>.\x20It\x20should\x20be\x20carried\x20out\x20within\x20thirty\x20minutes\x20of\x20ingestion.\x20If\x20they\x20are\x20used,\x20gastric\x20lavage\x20must\x20be\x20done\x20afterwards\x20before\x20using\x20another\x20agent.\x20Acetaminophen\x20blood\x20levels\x20can\x20be\x20estimated\x20from\x20a\x20nomogram\x20plot.\x20In\x20patients\x20with\x20high\x20acetaminophen\x20levels,\x20<strong>intravenous\x20N-acetylcysteine</strong>\x20administration\x20within\x208\x20hours\x20of\x20ingestion\x20is\x20recommended.\x20It\x20helps\x20in\x20the\x20replenishment\x20of\x20glutathione.\x20It\x20is\x20partially\x20effective\x20even\x20up\x20to\x2036\x20hours.\x20<strong>Liver\x20transplantation</strong>\x20is\x20necessary\x20if\x20signs\x20of\x20hepatic\x20failure\x20continue\x20despite\x20therapy.\u00a0</p>\x0a<p>Other\x20option(s):</p>\x0a<p>Option\x20B:\x20The\x20nomogram\x20used\x20for\x20<strong>vancomycin</strong>\x20dosing\x20is\x20<strong>Matzke</strong>\x20nomogram.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2035-year-old\x20lady\x20came\x20to\x20the\x20OPD\x20with\x20complaints\x20of\x20occasional\x20shock-like\x20sensations\x20down\x20her\x20spine\x20and\x20muscle\x20spasms.\x20T2\x20weighted\x20MRI\x20shows\x20typical\x20Dawson\x20fingers\x20and\x20oligoclonal\x20bands\x20were\x20detected\x20in\x20the\x20CSF\x20study.\x20\x20Which\x20of\x20the\x20following\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20her\x20condition?','choices':[{'id':0x1,'text':_0x2e8c1b(0x3ba)},{'id':0x2,'text':_0x2e8c1b(0x2b1)},{'id':0x3,'text':_0x2e8c1b(0x400)},{'id':0x4,'text':'Infliximab'}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x36e),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'In\x20a\x20patient\x20on\x20lithium\x20therapy\x20for\x20acute\x20mania,\x20what\x20is\x20considered\x20the\x20therapeutic\x20range\x20of\x20serum\x20lithium\x20in\x20mEq/L?','choices':[{'id':0x1,'text':_0x2e8c1b(0x32f)},{'id':0x2,'text':_0x2e8c1b(0x3a0)},{'id':0x3,'text':_0x2e8c1b(0x1d1)},{'id':0x4,'text':_0x2e8c1b(0x2c4)}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x437),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x218),'choices':[{'id':0x1,'text':_0x2e8c1b(0x373)},{'id':0x2,'text':_0x2e8c1b(0x467)},{'id':0x3,'text':_0x2e8c1b(0x4ae)},{'id':0x4,'text':_0x2e8c1b(0x47b)}],'correct_choice_id':0x4,'solution':_0x2e8c1b(0x168),'explanation_video':'','question_images':[_0x2e8c1b(0x46b)],'explanation_images':[_0x2e8c1b(0x3c2)]},{'text':_0x2e8c1b(0x4a0),'choices':[{'id':0x1,'text':_0x2e8c1b(0x224)},{'id':0x2,'text':_0x2e8c1b(0x180)},{'id':0x3,'text':_0x2e8c1b(0x327)},{'id':0x4,'text':_0x2e8c1b(0x25a)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x3a4),'explanation_video':'','question_images':[_0x2e8c1b(0x1f1)],'explanation_images':[_0x2e8c1b(0x2c9)]},{'text':'A\x2060-year-old\x20female\x20patient\x20presented\x20with\x20the\x20following\x20finding.\x20Her\x20medical\x20history\x20includes\x20hypertension\x20for\x20which\x20she\x20has\x20been\x20taking\x20amlodipine\x20for\x20the\x20past\x203\x20months.\x20Which\x20of\x20the\x20following\x20mechanisms\x20is\x20most\x20likely\x20to\x20be\x20responsible?','choices':[{'id':0x1,'text':_0x2e8c1b(0x48b)},{'id':0x2,'text':_0x2e8c1b(0x30e)},{'id':0x3,'text':'Precapillary\x20dilation\x20and\x20reflex\x20post\x20capillary\x20constriction'},{'id':0x4,'text':_0x2e8c1b(0x338)}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x357),'explanation_video':'','question_images':[_0x2e8c1b(0x470)],'explanation_images':[]},{'text':'A\x2066-year-old\x20male\x20presents\x20with\x20fatigue,\x20weight\x20loss\x20and\x20anorexia.\x20On\x20examination,\x20generalised\x20lymphadenopathy\x20is\x20seen.\x20Peripheral\x20smear\x20showed\x20smudge\x20cells\x20and\x20increased\x20lymphocytes.\x20Which\x20of\x20the\x20following\x20antimetabolites\x20is\x20preferred\x20in\x20treating\x20this\x20condition?','choices':[{'id':0x1,'text':'5-Fluorouracil'},{'id':0x2,'text':'Fludarabine'},{'id':0x3,'text':_0x2e8c1b(0x280)},{'id':0x4,'text':_0x2e8c1b(0x16e)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x1f5),'explanation_video':'','question_images':[],'explanation_images':[_0x2e8c1b(0x30f)]},{'text':_0x2e8c1b(0x315),'choices':[{'id':0x1,'text':_0x2e8c1b(0x3e6)},{'id':0x2,'text':_0x2e8c1b(0x1e9)},{'id':0x3,'text':_0x2e8c1b(0x459)},{'id':0x4,'text':'Intramuscular\x20iron\x20dextran'}],'correct_choice_id':0x2,'solution':'<p>The\x20preferred\x20form\x20of<strong>\x20iron</strong>\x20in\x20a\x20patient\x20with\x20<strong>chronic\x20kidney\x20disease\x20</strong>(CKD)\x20already\x20being\x20treated\x20with\x20<strong>darbepoetin</strong>\x20is\x20<strong>intravenous\x20iron\x20sucrose</strong>.</p>\x0a<p>Patients\x20with\x20CKD,\x20particularly\x20those\x20receiving\x20erythropoiesis-stimulating\x20agents\x20like\x20darbepoetin,\x20often\x20have\x20i<strong>mpaired\x20gastrointestinal\x20absorption\x20of\x20iron</strong>\x20and\x20increased\x20iron\x20requirements.\x20<strong>Intravenous</strong>\x20<strong>iron</strong>,\x20such\x20as\x20iron\x20sucrose,\x20is\x20<strong>preferred</strong>\x20because\x20it\x20<strong>bypasses</strong>\x20the\x20<strong>gastrointestinal</strong>\x20<strong>tract</strong>,\x20has\x20better\x20bioavailability,\x20and\x20replenishes\x20iron\x20stores\x20more\x20efficiently\x20in\x20CKD\x20patients.</p>\x0a<p><strong>Oral\x20</strong>iron,\x20like\x20<strong>ferrous\x20sulfate</strong>,\x20is\x20generally\x20<strong>less\x20effective\x20</strong>in\x20CKD\x20patients,\x20and\x20<strong>subcutaneous\x20</strong>or<strong>\x20intramuscular</strong>\x20forms,\x20like<strong>\x20iron\x20dextran</strong>,\x20are\x20<strong>less</strong>\x20commonly\x20used\x20due\x20to\x20risks\x20of\x20<strong>adverse\x20reactions</strong>\x20and\x20<strong>poor\x20absorption</strong>.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x428),'choices':[{'id':0x1,'text':_0x2e8c1b(0x1db)},{'id':0x2,'text':_0x2e8c1b(0x417)},{'id':0x3,'text':'64\x20mg'},{'id':0x4,'text':'28\x20mg'}],'correct_choice_id':0x2,'solution':'<p>The\x20amount\x20of\x20drug\x20remaining\x20in\x20the\x20body\x20after\x206\x20hours\x20following\x20an\x20initial\x20administration\x20of\x20300mg\x20of\x20the\x20drug\x20is\x20<strong>38mg</strong>.</p>\x0a<p>In\x20first-order\x20kinetics,<strong>\u00a0a\x20constant\x20fraction\x20of\x20the\x20drug\x20is\x20excreted\x20in\x20a\x20given\x20time.</strong>\u00a0</p>\x0a<p>120\x20mg\x20of\x20300\x20mg\x20is\x20excreted\x20in\x2090\x20minutes\x20---&gt;\x20120/300\x20=\u00a0<strong>0.40</strong>\u00a0is\x20eliminated\u00a0</p>\x0a<p>After\x2090\x20minutes;\x20300\x20mg-120\x20mg\x20=\x20180\x20mg\x20remains\u00a0</p>\x0a<p>The\x20next\x2090\x20minutes\x20(after\x20180\x20minutes)\x20=\x20180\x20*\u00a00.4\x20=\x2072\x20mg\x20is\x20eliminated\x20and\x20180-72\x20=\x20108\x20mg\x20remains\u00a0</p>\x0a<p>The\x20next\x2090\x20minutes\x20(after\x20270\x20minutes)\x20=\x20108\x20*\u00a00.4\x20=\x2043.2\x20mg\x20is\x20eliminated\x20and\x20108-43.2\x20=\x2064.8\x20remains\u00a0</p>\x0a<p>The\x20next\x2090\x20minutes\x20(after\x20360\x20minutes)\x20=\x2064.8\x20*\u00a00.4\x20=\x2025.92\x20mg\x20is\x20eliminated\x20and\x2064.80-25.92\x20=\u00a0<strong>38.88\x20mg\x20remains\x20after\x206\x20hours.\u00a0</strong></p>\x0a<p><strong>A\x20simpler\x20way\x20to\x20calculate\u00a0</strong></p>\x0a<ul>\x0a<li>2/5\x20fraction\x20is\x20excreted\x20in\x2090\x20minutes\u00a0→\x203/5\x20remains\x20after\x2090\x20minutes.</li>\x0a<li>6\x20hours\x20(360\x20min)\x20is\x204\x20times\x20of\x2090\x20minutes.</li>\x0a<li>So\x20300\x20*\x20(3/5)(3/5)(3/5)(3/5)\x20=\x2038.88\x20mg\x20remains\x20after\x20360\x20minutes\u00a0</li>\x0a</ul>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x1d4),'choices':[{'id':0x1,'text':_0x2e8c1b(0x49b)},{'id':0x2,'text':_0x2e8c1b(0x1ab)},{'id':0x3,'text':_0x2e8c1b(0x42f)},{'id':0x4,'text':_0x2e8c1b(0x2d9)}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x41c),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Match\x20the\x20following\x20pairs\x20of\x20drugs\x20with\x20their\x20antidotes.','choices':[{'id':0x1,'text':_0x2e8c1b(0x24e)},{'id':0x2,'text':_0x2e8c1b(0x1ba)},{'id':0x3,'text':_0x2e8c1b(0x197)},{'id':0x4,'text':_0x2e8c1b(0x276)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x1f4),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x1ef),'choices':[{'id':0x1,'text':_0x2e8c1b(0x1c4)},{'id':0x2,'text':'Tacrolimus'},{'id':0x3,'text':_0x2e8c1b(0x351)},{'id':0x4,'text':_0x2e8c1b(0x4aa)}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x3c8),'explanation_video':'','question_images':[_0x2e8c1b(0x206)],'explanation_images':[]},{'text':_0x2e8c1b(0x4b3),'choices':[{'id':0x1,'text':'Inhibition\x20of\x20calcineurin'},{'id':0x2,'text':_0x2e8c1b(0x34e)},{'id':0x3,'text':_0x2e8c1b(0x36c)},{'id':0x4,'text':_0x2e8c1b(0x2ae)}],'correct_choice_id':0x4,'solution':_0x2e8c1b(0x450),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x1b8),'choices':[{'id':0x1,'text':_0x2e8c1b(0x323)},{'id':0x2,'text':_0x2e8c1b(0x1a1)},{'id':0x3,'text':_0x2e8c1b(0x3b2)},{'id':0x4,'text':_0x2e8c1b(0x349)}],'correct_choice_id':0x1,'solution':_0x2e8c1b(0x419),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x2d6),'choices':[{'id':0x1,'text':'Celecoxib'},{'id':0x2,'text':_0x2e8c1b(0x23c)},{'id':0x3,'text':_0x2e8c1b(0x2ca)},{'id':0x4,'text':_0x2e8c1b(0x1f6)}],'correct_choice_id':0x4,'solution':'<p><strong>Parecoxib\x20</strong>is\x20chosen\x20as\x20it\x20is\x20the\x20only\x20<strong>injectable\x20COX-2\x20selective\x20drug\u00a0</strong>among\x20the\x20given\x20options.</p>\x0a<p>It\x20is\x20a\u00a0<strong>water-soluble</strong>\u00a0<strong>prodrug</strong>\x20of\x20<strong>valdecoxib</strong>.\x20It\x20is\x20effective\x20in\x20the\x20perioperative\x20period\x20when\x20oral\x20medications\x20are\x20not\x20indicated.</p>','explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x3a3),'choices':[{'id':0x1,'text':_0x2e8c1b(0x33b)},{'id':0x2,'text':_0x2e8c1b(0x185)},{'id':0x3,'text':_0x2e8c1b(0x1f9)},{'id':0x4,'text':_0x2e8c1b(0x226)}],'correct_choice_id':0x4,'solution':_0x2e8c1b(0x31a),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x380),'choices':[{'id':0x1,'text':_0x2e8c1b(0x28a)},{'id':0x2,'text':'Bosentan'},{'id':0x3,'text':_0x2e8c1b(0x1a6)},{'id':0x4,'text':_0x2e8c1b(0x16d)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x194),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x47e),'choices':[{'id':0x1,'text':'Lipid-soluble\x20reversible\x20inhibitor\x20of\x20acetylcholinesterase'},{'id':0x2,'text':_0x2e8c1b(0x31e)},{'id':0x3,'text':_0x2e8c1b(0x410)},{'id':0x4,'text':_0x2e8c1b(0x24d)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x38f),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'A\x2024-year-old\x20man\x20presents\x20at\x20your\x20outpatient\x20department\x20with\x20a\x20productive\x20cough.\x20You\x20have\x20decided\x20to\x20prescribe\x20him\x20expectorants.\x20Which\x20of\x20the\x20following\x20is\x20an\x20expectorant?','choices':[{'id':0x1,'text':_0x2e8c1b(0x395)},{'id':0x2,'text':_0x2e8c1b(0x317)},{'id':0x3,'text':_0x2e8c1b(0x1e7)},{'id':0x4,'text':_0x2e8c1b(0x44e)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x328),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':_0x2e8c1b(0x1cf),'choices':[{'id':0x1,'text':_0x2e8c1b(0x378)},{'id':0x2,'text':'Physostigmine'},{'id':0x3,'text':_0x2e8c1b(0x42d)},{'id':0x4,'text':'Atropine'}],'correct_choice_id':0x4,'solution':'<p>On\x20instillation\x20of\x20the\x20drug,\x20there\x20is\x20<strong>mydriasis</strong>\x20in\x20the\x20eye\x20and\x20<strong>loss\x20of\x20light\x20reflex</strong>.\x20The\x20drug\x20is\x20likely\x20to\x20be\x20<strong>atropine</strong>.\x20It\x20is\x20an\x20anticholinergic\x20agent.\x20It\x20causes\x20mydriasis,\x20cycloplegia,\x20loss\x20of\x20light\x20reflex,\x20and\x20impaired\x20accommodation.</p>\x0a<p>Autonomic\x20supply\x20of\x20the\x20eye:</p>\x0a<p>The\x20<strong>radial\x20muscle</strong>\x20of\x20the\x20iris\x20is\x20controlled\x20by\u00a0<strong>α</strong><span\x20class=\x22s1\x22><strong>1\x20adrenergic\x20receptor</strong>.\x20Stimulation\x20of\x20this\x20receptor\x20causes\x20<strong>mydriasis.\u00a0</strong></span></p>\x0a<p><span\x20class=\x22s1\x22>The<strong>\x20sphincter\x20muscle\x20</strong>of\x20the\x20iris\x20is\x20controlled\x20by\x20the\u00a0</span><strong>M<span\x20class=\x22s1\x22>3\x20and</span>\u00a0M</strong><span\x20class=\x22s1\x22><strong>2\x20cholinergic\x20receptors.</strong>\x20Stimulation\x20of\x20these\x20receptors\x20causes\x20<strong>miosis.</strong></span></p>\x0a<p><span\x20class=\x22s1\x22><strong>The\x20ciliary\x20muscle\x20</strong>is\x20supplied\x20by\x20the\u00a0</span><strong>β</strong><span\x20class=\x22s1\x22><strong>2</strong>\x20adrenergic\x20receptors\x20as\x20well\x20as\u00a0</span><strong>M<span\x20class=\x22s1\x22>3\x20and</span>\u00a0M</strong><span\x20class=\x22s1\x22><strong>2</strong>\x20cholinergic\x20receptors.\x20The\u00a0<strong>β2</strong>\u00a0receptors\x20cause\x20relaxation\x20of\x20the\x20ciliary\x20muscle,\x20which\x20helps\x20in\x20<strong>far\x20vision,</strong>\x20while\u00a0<strong>M3\x20and\x20M2\u00a0</strong>receptors\x20cause\x20contraction\x20of\x20the\x20ciliary\x20muscle,\x20which\x20helps\x20in\u00a0<strong>near\x20vision.</strong></span></p>\x0a<p><span\x20class=\x22s1\x22><strong>Lacrimal\x20glands\x20are\x20supplied\x20by\x20the\u00a0</strong></span>α\x20receptors\x20and\x20M3\x20and\x20M2\x20receptors.\x20They\x20increase\x20lacrimal\x20secretion.</p>\x0a<p>Effects\x20of\x20various\x20drugs\x20on\x20the\x20eye</p>\x0a<table\x20style=\x22height:\x20217px;\x20width:\x20733px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x20text-align:\x20center;\x22><strong>Class</strong></td>\x0a<td\x20style=\x22width:\x20134px;\x20text-align:\x20center;\x22><strong>Muscarinic\x20receptor\x20antagonist</strong></td>\x0a<td\x20style=\x22width:\x20134px;\x20text-align:\x20center;\x22><strong>Cholinesterase\x20inhibitors</strong></td>\x0a<td\x20style=\x22width:\x20135px;\x20text-align:\x20center;\x22><strong>Muscarinic\x20receptor\x20agonist</strong></td>\x0a<td\x20style=\x22width:\x20135px;\x20text-align:\x20center;\x22><strong>Adrenergic\x20agonist</strong></td>\x0a<td\x20style=\x22width:\x20162px;\x20text-align:\x20center;\x22><strong>Local\x20anesthetic</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x22>Drugs</td>\x0a<td\x20style=\x22width:\x20134px;\x22><strong>Atropine</strong>,\x20homatropine,\x20Scopalamine,\x20Tropicamide</td>\x0a<td\x20style=\x22width:\x20134px;\x22><strong>Physostigmine</strong>,\x20neostigmine,\x20pyridostigmine,\x20organophosphorus\x20compounds,\x20etc</td>\x0a<td\x20style=\x22width:\x20135px;\x22><strong>Pilocarpine</strong></td>\x0a<td\x20style=\x22width:\x20135px;\x22>Epinephrine</td>\x0a<td\x20style=\x22width:\x20162px;\x22><strong>Cocaine</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x22>Mechanism\x20of\x20action\x20in\x20the\x20eye</td>\x0a<td\x20style=\x22width:\x20134px;\x22><strong>Blocks\x20M3\x20and\x20M2</strong>\x20receptors</td>\x0a<td\x20style=\x22width:\x20134px;\x22><strong>Stimulates\x20M3\x20and\x20M2</strong>\x20receptors</td>\x0a<td\x20style=\x22width:\x20135px;\x22><strong>Stimulates\x20M3\x20and\x20M2</strong>\x20receptors\x20in\x20the\x20eye</td>\x0a<td\x20style=\x22width:\x20135px;\x22><strong>Stimulates\u00a0α</strong><span\x20class=\x22s1\x22><strong>1\x20</strong>receptor\u00a0\x20in\x20the\x20eye</span></td>\x0a<td\x20style=\x22width:\x20162px;\x22><strong>Blocks\x20sodium\x20channel</strong>\x20and\x20blocks\x20<strong>norepinephrine\x20transporter</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x22>Effect\x20on\x20iris</td>\x0a<td\x20style=\x22width:\x20134px;\x22>Mydriasis</td>\x0a<td\x20style=\x22width:\x20134px;\x22>Miosis</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Miosis</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Mydriasis</td>\x0a<td\x20style=\x22width:\x20162px;\x22>Mydriasis</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x22>Corneal\x20reflex</td>\x0a<td\x20style=\x22width:\x20134px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20134px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20162px;\x22>Absent</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x22>Light\x20reflex</td>\x0a<td\x20style=\x22width:\x20134px;\x22><strong>Absent</strong></td>\x0a<td\x20style=\x22width:\x20134px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Present</td>\x0a<td\x20style=\x22width:\x20162px;\x22>Present</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20134px;\x22>Lacrimal\x20secretions</td>\x0a<td\x20style=\x22width:\x20134px;\x22>Decreased</td>\x0a<td\x20style=\x22width:\x20134px;\x22>Increased</td>\x0a<td\x20style=\x22width:\x20135px;\x22>Increased</td>\x0a<td\x20style=\x22width:\x20135px;\x22>\u00a0Increased</td>\x0a<td\x20style=\x22width:\x20162px;\x22>---</td>\x0a</tr>\x0a</tbody>\x0a</table>','explanation_video':'','question_images':[_0x2e8c1b(0x18e)],'explanation_images':[]},{'text':'A\x2060-year-old\x20male\x20patient\x20who\x20is\x20a\x20known\x20case\x20of\x20familial\x20hypercholesterolemia\x20was\x20prescribed\x20alirocumab.\x20It\x20helps\x20in\x20lowering\x20lipid\x20by\x20__________.','choices':[{'id':0x1,'text':_0x2e8c1b(0x3e8)},{'id':0x2,'text':'PCSK-9\x20inhibition'},{'id':0x3,'text':_0x2e8c1b(0x2e6)},{'id':0x4,'text':_0x2e8c1b(0x1a2)}],'correct_choice_id':0x2,'solution':_0x2e8c1b(0x473),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'The\x20urine\x20of\x20the\x20patient\x20taking\x20indapamide\x20will\x20have:','choices':[{'id':0x1,'text':'1'},{'id':0x2,'text':'2'},{'id':0x3,'text':'3'},{'id':0x4,'text':'4'}],'correct_choice_id':0x3,'solution':_0x2e8c1b(0x3cd),'explanation_video':'','question_images':[],'explanation_images':[]},{'text':'Which\x20of\x20the\x20following\x20is\x20incorrect\x20regarding\x20chlorpheniramine?','choices':[{'id':0x1,'text':_0x2e8c1b(0x2a3)},{'id':0x2,'text':_0x2e8c1b(0x17a)},{'id':0x3,'text':'It\x20has\x20anticholinergic\x20action'},{'id':0x4,'text':_0x2e8c1b(0x42c)}],'correct_choice_id':0x2,'solution':'<p><strong>Chlorpheniramine</strong>\x20<strong>crosses\x20</strong>the\x20<strong>blood-brain\x20barrier</strong>.\x20Hence,\x20<strong>option\x20B</strong>\x20is\x20<strong>incorrect.</strong></p>\x0a<p>Chlorpheniramine\x20is\x20a\x20<strong>first-generation\x20antihistamine</strong>.\x20First-generation\x20antihistamines\x20are\x20<strong>lipophilic</strong>\x20and\x20hence\x20are\x20<strong>sedative</strong>\x20because\x20of\x20their\x20ability\x20to\x20cross\x20the\x20blood-brain\x20barrier.\x20It\x20also\x20has\x20<strong>anticholinergic\x20action</strong>,\x20which\x20can\x20cause\x20side\x20effects\x20like\x20dry\x20mouth\x20and\x20blurred\x20vision.\u00a0</p>\x0a<p><strong>First-generation\x20antihistamines</strong>\x20such\x20as\x20<strong>chlorpheniramine,</strong>\x20promethazine,\x20dimenhydrinate\x20diphenhydramine,\x20cyclizine,\x20and\x20meclizine\x20are\x20effective\x20in\x20controlling\x20nausea\x20and\x20vomiting\x20in<strong>\x20motion\x20sickness</strong>.\x20<strong>First</strong>-<strong>generation</strong>\x20<strong>antihistamines</strong>\x20have\x20a\x20strong\x20<strong>sedative</strong>\x20property\x20and\x20also\x20have\x20an\x20<strong>antimuscarinic</strong>\x20function.\x20Whereas\x20<strong>second</strong>-<strong>generation</strong>\x20antihistamines\x20like\x20cetirizine\x20and\x20fexofenadine\x20are\x20<strong>ineffective</strong>\x20in\x20the\x20treatment\x20of\x20<strong>motion</strong>\x20<strong>sickness</strong>.\x20Second-generation\x20antihistamines\x20are\x20<strong>less\x20sedative</strong>\x20because\x20of\x20less\x20central\x20nervous\x20system\x20penetration\x20and\x20do\x20not\x20block\x20autonomic\x20receptors.</p>','explanation_video':'','question_images':[],'explanation_images':[]}],quizName=_0x2e8c1b(0x451);const quizFilename='pharmacology-test-d52ece43.html';let hierarchy=[_0x2e8c1b(0x3b6),_0x2e8c1b(0x3ce),'Year\x202024\x20-\x2025'];if(window[_0x2e8c1b(0x352)][_0x2e8c1b(0x430)]['endsWith'](_0x2e8c1b(0x2d4))){const customData=JSON[_0x2e8c1b(0x4a8)](localStorage[_0x2e8c1b(0x1cd)](_0x2e8c1b(0x3e0)));if(customData){const yJPgKy='1|5|2|3|4|0'[_0x2e8c1b(0x1a0)]('|');let eVxljA=0x0;while(!![]){switch(yJPgKy[eVxljA++]){case'0':document[_0x2e8c1b(0x2e5)]('quizHierarchy')[_0x2e8c1b(0x2a5)]=hierarchy[_0x2e8c1b(0x2f3)](_0x2e8c1b(0x1c5));continue;case'1':questionsData=customData['questions'];continue;case'2':hierarchy=customData[_0x2e8c1b(0x391)];continue;case'3':document['title']=quizName+'\x20-\x20Brain\x20And\x20Scalpel';continue;case'4':document[_0x2e8c1b(0x2e5)](_0x2e8c1b(0x369))[_0x2e8c1b(0x2a5)]=questionsData['length'];continue;case'5':quizName=customData[_0x2e8c1b(0x413)];continue;}break;}}}let currentQuestionIndex=0x0,selectedOption=null,currentMode=_0x2e8c1b(0x38b),timer=null,timeRemaining=0x0,questionStartTime=Date[_0x2e8c1b(0x389)](),quizStartTime=Date[_0x2e8c1b(0x389)](),isQuizCompleted=![],questionStates=new Array(questionsData[_0x2e8c1b(0x3af)])['fill'](null)[_0x2e8c1b(0x1e8)](()=>({'status':_0x2e8c1b(0x45b),'bookmarked':![],'markedForReview':![],'selectedAnswer':null,'timeSpent':0x0})),stats={'correctAnswers':0x0,'incorrectAnswers':0x0,'totalAttempted':0x0,'totalTime':0x0,'notAttempted':questionsData[_0x2e8c1b(0x3af)]};function saveProgress(){const _0x1122b4=_0x2e8c1b,_0x17e50b={'FFzem':'incomplete'};if(isQuizCompleted)return;const _0x27da09=JSON[_0x1122b4(0x4a8)](localStorage[_0x1122b4(0x1cd)](_0x1122b4(0x26b)))||{};_0x27da09[quizFilename]={'questionStates':questionStates,'stats':stats,'currentQuestionIndex':currentQuestionIndex,'currentMode':currentMode,'status':_0x17e50b[_0x1122b4(0x1b6)],'lastSeen':new Date()[_0x1122b4(0x409)]()},localStorage[_0x1122b4(0x34a)]('userHistory',JSON[_0x1122b4(0x182)](_0x27da09));}function loadProgress(){const _0x55b3d1=_0x2e8c1b,_0x539775={'HgaLy':_0x55b3d1(0x2a8),'IicNj':function(_0xae852e,_0xa5c14a){return _0xae852e!==_0xa5c14a;},'KzspF':_0x55b3d1(0x3f0)},_0x540ce2=JSON[_0x55b3d1(0x4a8)](localStorage[_0x55b3d1(0x1cd)](_0x55b3d1(0x26b)))||{},_0x1f3f66=_0x540ce2[quizFilename];if(_0x1f3f66){if(_0x539775[_0x55b3d1(0x2a7)](_0x55b3d1(0x3fa),_0x55b3d1(0x2f8))){const _0x5d1cc1=_0x539775['KzspF'][_0x55b3d1(0x1a0)]('|');let _0xf4cf71=0x0;while(!![]){switch(_0x5d1cc1[_0xf4cf71++]){case'0':questionStates=_0x1f3f66['questionStates'];continue;case'1':currentQuestionIndex=_0x1f3f66[_0x55b3d1(0x28c)];continue;case'2':return!![];case'3':currentMode=_0x1f3f66[_0x55b3d1(0x440)];continue;case'4':console[_0x55b3d1(0x465)]('Progress\x20loaded.');continue;case'5':stats=_0x1f3f66[_0x55b3d1(0x305)];continue;}break;}}else{const _0x5c138b=_0x35cecb['parse'](_0x6c9fc0['getItem']('userHistory'))||{};_0x5c138b[_0x393570]&&(delete _0x5c138b[_0x48846b],_0x11280d[_0x55b3d1(0x34a)]('userHistory',_0x56c813[_0x55b3d1(0x182)](_0x5c138b)),_0x4b2190[_0x55b3d1(0x465)](_0x539775[_0x55b3d1(0x396)]));}}return![];}function clearProgress(){const _0x74af7d=_0x2e8c1b,_0x1fac76={'UMSEt':function(_0x3eb258,_0x294b77){return _0x3eb258===_0x294b77;},'qKBGU':'correct','AJdVc':'Correct','bDPNf':_0x74af7d(0x18c),'UDzGz':_0x74af7d(0x26b),'zwGmk':function(_0xdd8153,_0x4f3573){return _0xdd8153!==_0x4f3573;},'ohIDu':'EJJnX'},_0x3ce1c5=JSON[_0x74af7d(0x4a8)](localStorage[_0x74af7d(0x1cd)](_0x1fac76['UDzGz']))||{};if(_0x3ce1c5[quizFilename]){if(_0x1fac76['zwGmk'](_0x1fac76[_0x74af7d(0x3b8)],_0x1fac76[_0x74af7d(0x3b8)])){const _0x57b3bb=_0x56a8bd['choices'][_0x3e4c6b[_0x74af7d(0x2fb)]];_0x1fac76[_0x74af7d(0x1fe)](_0x57b3bb['id'],_0x169f2c)?(_0x51d78b=_0x1fac76[_0x74af7d(0x2fc)],_0x503de9=_0x1fac76[_0x74af7d(0x284)]):(_0x3ab868=_0x1fac76[_0x74af7d(0x436)],_0x5d1d09=_0x74af7d(0x303));}else delete _0x3ce1c5[quizFilename],localStorage['setItem'](_0x1fac76[_0x74af7d(0x388)],JSON[_0x74af7d(0x182)](_0x3ce1c5)),console[_0x74af7d(0x465)](_0x74af7d(0x2a8));}}function markQuizAsCompleted(){const _0x5a190c=_0x2e8c1b,_0x220bb2={'QrUQd':'completed'},_0x52a28a=JSON[_0x5a190c(0x4a8)](localStorage[_0x5a190c(0x1cd)]('userHistory'))||{},_0x4d97bc=questionsData[_0x5a190c(0x3af)],_0x3cbb03=stats[_0x5a190c(0x49e)]||0x0;_0x52a28a[quizFilename]={'score':_0x3cbb03,'total':_0x4d97bc,'status':_0x220bb2['QrUQd'],'completedOn':new Date()[_0x5a190c(0x409)]()},localStorage[_0x5a190c(0x34a)](_0x5a190c(0x26b),JSON[_0x5a190c(0x182)](_0x52a28a));}const urlParams=new URLSearchParams(window[_0x2e8c1b(0x352)][_0x2e8c1b(0x47a)]),startAt=parseInt(urlParams[_0x2e8c1b(0x363)]('startAt')),resume=urlParams[_0x2e8c1b(0x363)](_0x2e8c1b(0x456))===_0x2e8c1b(0x300);function goBack(){const _0x5f59a1=_0x2e8c1b,_0x409aa2={'zbrcF':function(_0x367020){return _0x367020();},'Tscjb':_0x5f59a1(0x412)};if(!isQuizCompleted)_0x409aa2['zbrcF'](saveProgress);window['location']['href']=document[_0x5f59a1(0x29c)]||_0x409aa2[_0x5f59a1(0x27d)];}function selectMode(_0x450289){const _0x29bd92=_0x2e8c1b,_0x3a9df3={'rvdAN':_0x29bd92(0x228),'ujxIj':_0x29bd92(0x1c8),'doimF':function(_0x325255){return _0x325255();}};currentMode=_0x450289,document[_0x29bd92(0x2e5)](_0x3a9df3[_0x29bd92(0x43a)])[_0x29bd92(0x454)][_0x29bd92(0x272)]=_0x3a9df3[_0x29bd92(0x348)],_0x3a9df3[_0x29bd92(0x1c9)](initializeQuiz);}function initializeQuiz(){const _0x30625c=_0x2e8c1b,_0x39c90b={'dQmpl':function(_0x14e56c,_0x13b25c){return _0x14e56c(_0x13b25c);},'dZbQo':function(_0x1571fa){return _0x1571fa();},'USxvR':_0x30625c(0x2f9),'pblSQ':_0x30625c(0x167),'tgIUn':_0x30625c(0x240),'bDvmx':function(_0x4095d7,_0x10dee4){return _0x4095d7===_0x10dee4;},'UqqJQ':'test','LrzzW':'timed_exam','pOlET':_0x30625c(0x35d),'zIZrm':_0x30625c(0x1c8),'Ndcjy':_0x30625c(0x480),'XUolu':'studyModeLegend','FxOWj':_0x30625c(0x261),'iJniV':'flex','dQQoP':function(_0x349bfe,_0x352287){return _0x349bfe===_0x352287;},'VRLEV':'timed_study','IpzNO':_0x30625c(0x41d),'IQkjD':_0x30625c(0x21a),'LdecM':function(_0x5e8b09,_0x35499a){return _0x5e8b09(_0x35499a);},'OuiIF':function(_0x5cd258,_0x5cc9eb){return _0x5cd258>=_0x5cc9eb;},'SulfF':function(_0x49abf9,_0x38fc44){return _0x49abf9<_0x38fc44;},'HMCIW':function(_0xa2a76e,_0x5e50a6){return _0xa2a76e!==_0x5e50a6;},'nKejz':_0x30625c(0x44b),'gAibH':function(_0x5894d5){return _0x5894d5();}};quizStartTime=Date[_0x30625c(0x389)]();const _0x41ddd6=document['getElementById'](_0x39c90b[_0x30625c(0x3c6)]),_0x231fb0=document['getElementById'](_0x39c90b[_0x30625c(0x445)]),_0x4ff7aa=document[_0x30625c(0x2e5)](_0x39c90b['tgIUn']),_0xad8c73=_0x39c90b[_0x30625c(0x424)](currentMode,_0x39c90b[_0x30625c(0x290)])||currentMode===_0x39c90b[_0x30625c(0x18f)];document[_0x30625c(0x2e5)](_0x39c90b[_0x30625c(0x264)])[_0x30625c(0x454)][_0x30625c(0x272)]=_0xad8c73?_0x39c90b[_0x30625c(0x403)]:_0x39c90b['Ndcjy'],document[_0x30625c(0x2e5)](_0x39c90b[_0x30625c(0x36b)])[_0x30625c(0x454)]['display']=_0xad8c73?_0x39c90b[_0x30625c(0x403)]:_0x30625c(0x480),document[_0x30625c(0x2e5)](_0x30625c(0x25f))[_0x30625c(0x454)][_0x30625c(0x272)]=_0xad8c73?_0x39c90b[_0x30625c(0x17c)]:_0x39c90b[_0x30625c(0x403)],document[_0x30625c(0x2e5)](_0x39c90b['FxOWj'])['style'][_0x30625c(0x272)]=_0xad8c73?_0x39c90b['Ndcjy']:_0x30625c(0x1c8),_0x41ddd6['style'][_0x30625c(0x272)]=_0xad8c73?_0x30625c(0x1c8):_0x39c90b['iJniV'],_0x231fb0['style'][_0x30625c(0x272)]=_0xad8c73?_0x39c90b[_0x30625c(0x2c8)]:_0x39c90b[_0x30625c(0x403)],_0x4ff7aa[_0x30625c(0x454)][_0x30625c(0x272)]=_0xad8c73?_0x39c90b['iJniV']:'none',(_0x39c90b[_0x30625c(0x242)](currentMode,_0x39c90b['VRLEV'])||currentMode===_0x39c90b[_0x30625c(0x18f)])&&document['getElementById'](_0x39c90b[_0x30625c(0x342)])[_0x30625c(0x464)][_0x30625c(0x1da)](_0x39c90b[_0x30625c(0x210)]),!_0x39c90b['LdecM'](isNaN,startAt)&&_0x39c90b[_0x30625c(0x3f6)](startAt,0x0)&&_0x39c90b[_0x30625c(0x330)](startAt,questionsData[_0x30625c(0x3af)])&&(_0x39c90b['HMCIW'](_0x39c90b['nKejz'],_0x39c90b['nKejz'])?_0x39c90b[_0x30625c(0x311)](_0x40de62,'You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?')&&(_0x166fea=0x0,_0x39c90b[_0x30625c(0x34f)](_0x51d024),_0x223708()):currentQuestionIndex=startAt),_0x39c90b[_0x30625c(0x298)](loadBookmarkedQuestions),_0x39c90b[_0x30625c(0x34f)](generateQuestionNav),_0x39c90b[_0x30625c(0x298)](updateStats),displayQuestion();}function _0x3678(_0x57cdf3,_0x4011f9){const _0x2c9eb7=_0x53f1();return _0x3678=function(_0x2465cd,_0x100e65){_0x2465cd=_0x2465cd-0x166;let _0x175084=_0x2c9eb7[_0x2465cd];return _0x175084;},_0x3678(_0x57cdf3,_0x4011f9);}function generateQuestionNav(){const _0x2f87f0=_0x2e8c1b,_0x4ee052={'eZXfT':_0x2f87f0(0x472),'jQEvD':function(_0x2caead,_0x48b12c){return _0x2caead(_0x48b12c);},'HZsid':_0x2f87f0(0x235),'bkxAW':function(_0x141411,_0x56e666){return _0x141411+_0x56e666;},'LbRHx':function(_0x42c26a,_0x415dda){return _0x42c26a+_0x415dda;},'mSnzo':_0x2f87f0(0x1a7),'zGNEw':function(_0x134c3e,_0x2bd667){return _0x134c3e+_0x2bd667;},'RzraE':_0x2f87f0(0x345),'tSBdK':_0x2f87f0(0x2e9),'cbCVm':function(_0x1de96d,_0x21b995){return _0x1de96d<_0x21b995;},'WErIo':function(_0x15c3fc,_0x4bf2ec){return _0x15c3fc!==_0x4bf2ec;},'QLOCk':_0x2f87f0(0x178),'qCnuE':_0x2f87f0(0x3d1),'qdyHU':'button','wYSQv':_0x2f87f0(0x3f8),'ALFnR':function(_0x1edcc9){return _0x1edcc9();}},_0x267b1b=document[_0x2f87f0(0x2e5)](_0x4ee052[_0x2f87f0(0x249)]);_0x267b1b['innerHTML']='';for(let _0x259f62=0x0;_0x4ee052[_0x2f87f0(0x187)](_0x259f62,questionsData[_0x2f87f0(0x3af)]);_0x259f62++){if(_0x4ee052[_0x2f87f0(0x291)](_0x4ee052[_0x2f87f0(0x3ac)],_0x4ee052[_0x2f87f0(0x374)])){const _0x786772=document['createElement'](_0x4ee052[_0x2f87f0(0x366)]);_0x786772[_0x2f87f0(0x2a5)]=_0x259f62+0x1,_0x786772[_0x2f87f0(0x334)]=_0x4ee052['wYSQv'],_0x786772[_0x2f87f0(0x397)]=()=>jumpToQuestion(_0x259f62),_0x786772['id']=_0x2f87f0(0x463)+_0x259f62,_0x267b1b['appendChild'](_0x786772);}else{const _0x38b590={'voutI':function(_0x314cb0,_0x501bb0){const _0x2d7c91=_0x2f87f0;return _0x4ee052[_0x2d7c91(0x21f)](_0x314cb0,_0x501bb0);},'QZtmU':_0x2f87f0(0x416),'vOyhj':function(_0x2135bd,_0x40ee0f){return _0x4ee052['LbRHx'](_0x2135bd,_0x40ee0f);},'UsWYd':_0x4ee052[_0x2f87f0(0x29e)],'FddYP':function(_0x4b1ee2,_0x2e1df1){return _0x4ee052['zGNEw'](_0x4b1ee2,_0x2e1df1);}};_0x48a736['choices'][_0x2f87f0(0x40c)]((_0x34160e,_0x4c14c9)=>{const _0x274049=_0x2f87f0,_0x3bc7a8=_0x35f618[_0x274049(0x257)](_0x38b590[_0x274049(0x19e)](0x41,_0x4c14c9)),_0x2f4b15=_0x5aab44===_0x4c14c9,_0x2cf429=_0x5b55dd[_0x274049(0x253)](_0x274049(0x3d7));_0x2cf429[_0x274049(0x3a7)]=_0x274049(0x26d)+(_0x2f4b15?_0x38b590[_0x274049(0x41b)]:'')+_0x274049(0x16f)+_0x4c14c9+_0x274049(0x1a4)+_0x3bc7a8+_0x274049(0x29f)+(_0x34160e[_0x274049(0x232)]||_0x38b590[_0x274049(0x20b)](_0x38b590[_0x274049(0x49c)],_0x38b590[_0x274049(0x2c7)](_0x4c14c9,0x1)))+_0x274049(0x34b),_0x2629d6[_0x274049(0x22e)](_0x2cf429);}),_0x32ad56[_0x2f87f0(0x2c5)](_0x4ee052['RzraE'],function(_0x1d036e){const _0x5e407d=_0x2f87f0,_0x4061db=_0x1d036e[_0x5e407d(0x3e1)][_0x5e407d(0x3c0)](_0x4ee052['eZXfT']);if(_0x4061db){const _0x361965=_0x4ee052['jQEvD'](_0x5dc03a,_0x4061db['getAttribute'](_0x4ee052[_0x5e407d(0x40f)]));_0x2406cc(_0x361965);}});}}_0x4ee052[_0x2f87f0(0x1aa)](updateQuestionNav);}function updateQuestionNav(){const _0x182889=_0x2e8c1b,_0x4581f4={'JMDzu':_0x182889(0x21a),'mXFdb':function(_0x9febd1,_0xfca437){return _0x9febd1<_0xfca437;},'cMmZW':function(_0x414daa,_0x5affa8){return _0x414daa===_0x5affa8;},'soyKn':_0x182889(0x28e),'ugNsZ':_0x182889(0x2d5),'gZUvo':function(_0x3708a6,_0x3c8c72){return _0x3708a6!==_0x3c8c72;},'zQqPM':_0x182889(0x444),'ejlFD':_0x182889(0x198),'sryrs':_0x182889(0x3d6),'KXxDh':function(_0x278a28,_0x5dbc4c){return _0x278a28===_0x5dbc4c;},'seGYf':'EEcIl','TEyAP':_0x182889(0x362),'NnPPi':_0x182889(0x18c),'ZWyaq':_0x182889(0x468),'KqrzT':_0x182889(0x377),'rTDcI':_0x182889(0x1be)};for(let _0x4d211c=0x0;_0x4581f4['mXFdb'](_0x4d211c,questionsData[_0x182889(0x3af)]);_0x4d211c++){const _0x3925d7=document[_0x182889(0x2e5)](_0x182889(0x463)+_0x4d211c),_0x165062=questionStates[_0x4d211c];let _0x27c682='';if(_0x4581f4[_0x182889(0x2bd)](_0x4d211c,currentQuestionIndex))_0x182889(0x2dc)!==_0x4581f4['soyKn']?_0x27c682=_0x4581f4[_0x182889(0x1a8)]:_0x4c69cf[_0x182889(0x2e5)](_0x182889(0x41d))[_0x182889(0x464)][_0x182889(0x1da)](_0x4581f4[_0x182889(0x29b)]);else{if(_0x165062['bookmarked'])_0x27c682=_0x182889(0x24c);else{if(_0x165062[_0x182889(0x385)])_0x4581f4['gZUvo'](_0x4581f4[_0x182889(0x2ff)],_0x4581f4['ejlFD'])?_0x27c682=_0x4581f4[_0x182889(0x487)]:_0x4cf58f['explanation_images'][_0x182889(0x40c)](_0x5a0d00=>{const _0x133f0b=_0x182889;if(_0x5a0d00)_0x49a093['innerHTML']+=_0x133f0b(0x381)+_0x5a0d00+'\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>';});else{if(_0x4581f4['KXxDh'](currentMode,'study')||_0x4581f4[_0x182889(0x2bd)](currentMode,_0x182889(0x401))){if('EEcIl'===_0x4581f4[_0x182889(0x2d3)]){if(_0x4581f4[_0x182889(0x2bd)](_0x165062[_0x182889(0x2b9)],_0x4581f4[_0x182889(0x299)]))_0x27c682=_0x182889(0x3c5);else{if(_0x4581f4[_0x182889(0x2bd)](_0x165062[_0x182889(0x2b9)],_0x4581f4[_0x182889(0x442)]))_0x27c682=_0x4581f4['ZWyaq'];else _0x27c682=_0x4581f4['KqrzT'];}}else _0x42ca8a[_0x40b8dd[_0x182889(0x1b5)]][_0x182889(0x493)]=!![];}else{if(_0x165062[_0x182889(0x2fb)]!==null)_0x27c682=_0x4581f4['rTDcI'];else _0x27c682=_0x4581f4[_0x182889(0x20c)];}}}}_0x3925d7['className']=_0x182889(0x20d)+_0x27c682;}}function jumpToQuestion(_0x40e930){const _0x22edce=_0x2e8c1b,_0x2fbef0={'FKvsB':function(_0x310c1b,_0x5d7b10){return _0x310c1b===_0x5d7b10;},'umtjJ':function(_0x414871,_0x27b929){return _0x414871===_0x27b929;},'RXmKf':'border-gray-600','hXVHD':_0x22edce(0x1b7),'NvxCw':function(_0x8867d7,_0x32dbc0){return _0x8867d7+_0x32dbc0;},'uFHjm':function(_0x4fa17f,_0x1f7537){return _0x4fa17f>=_0x1f7537;},'rhlFF':function(_0xbda633,_0x259ac7){return _0xbda633===_0x259ac7;},'gTiPP':_0x22edce(0x475),'TzEmV':function(_0x14f0b2,_0x4760bd){return _0x14f0b2-_0x4760bd;},'FrjlJ':function(_0x908371){return _0x908371();}};if(_0x2fbef0[_0x22edce(0x36f)](_0x40e930,0x0)&&_0x40e930<questionsData[_0x22edce(0x3af)]){if(_0x2fbef0['rhlFF'](_0x2fbef0['gTiPP'],_0x2fbef0['gTiPP']))questionStartTime&&(questionStates[currentQuestionIndex][_0x22edce(0x3ae)]+=_0x2fbef0[_0x22edce(0x320)](Date[_0x22edce(0x389)](),questionStartTime)),currentQuestionIndex=_0x40e930,displayQuestion(),_0x2fbef0['FrjlJ'](saveProgress);else{const _0x1bc5ce=_0x2fbef0[_0x22edce(0x43d)](_0x51f2ea[_0x22edce(0x2fb)],_0x5f55be),_0xd43af9=_0x2fbef0[_0x22edce(0x207)](_0xa1a642['id'],_0x262a08);let _0xecdc89=_0x2fbef0[_0x22edce(0x353)];if(_0xd43af9)_0xecdc89=_0x2fbef0[_0x22edce(0x49f)];else{if(_0x1bc5ce)_0xecdc89='border-red-500';}return _0x22edce(0x4af)+_0xecdc89+_0x22edce(0x236)+_0x2c0a75[_0x22edce(0x257)](_0x2fbef0[_0x22edce(0x40b)](0x41,_0x465a53))+_0x22edce(0x245)+_0x1748b6['text']+'</span></div>';}}}function updateStats(){const _0x1953f5=_0x2e8c1b,_0x1925dc={'bdDmP':function(_0x6e82f8,_0x1760ba){return _0x6e82f8===_0x1760ba;},'zqMwn':_0x1953f5(0x401),'sbyuS':'correctCount','nRWoG':_0x1953f5(0x2eb),'ekbgn':_0x1953f5(0x307),'DsxvK':function(_0xa938f7,_0x4839aa){return _0xa938f7>_0x4839aa;},'pVCDN':function(_0x432ee0,_0x166b78){return _0x432ee0*_0x166b78;},'IjXBr':function(_0x560c7f,_0x421e82){return _0x560c7f/_0x421e82;},'hzMYW':_0x1953f5(0x43c),'fGnPL':function(_0x31fdca,_0x1352fc){return _0x31fdca%_0x1352fc;},'YnAuW':function(_0x3ffd54,_0x5434e2){return _0x3ffd54+_0x5434e2;}};if(currentMode===_0x1953f5(0x38b)||_0x1925dc['bdDmP'](currentMode,_0x1925dc[_0x1953f5(0x1f2)])){document[_0x1953f5(0x2e5)](_0x1925dc['sbyuS'])['textContent']=stats[_0x1953f5(0x49e)],document[_0x1953f5(0x2e5)](_0x1925dc[_0x1953f5(0x1e1)])['textContent']=stats[_0x1953f5(0x174)],document['getElementById'](_0x1925dc[_0x1953f5(0x1f8)])[_0x1953f5(0x2a5)]=stats['totalAttempted'];const _0x29ee81=_0x1925dc[_0x1953f5(0x1d7)](stats['totalAttempted'],0x0)?Math[_0x1953f5(0x22a)](_0x1925dc[_0x1953f5(0x3d9)](_0x1925dc['IjXBr'](stats['correctAnswers'],stats['totalAttempted']),0x64)):0x0;document['getElementById'](_0x1925dc[_0x1953f5(0x301)])['textContent']=_0x29ee81+'%',stats[_0x1953f5(0x3ca)]=questionStates[_0x1953f5(0x333)]((_0xd4dd05,_0x2a9396)=>_0xd4dd05+_0x2a9396['timeSpent'],0x0);const _0x2e0464=Math[_0x1953f5(0x469)](_0x1925dc['IjXBr'](stats[_0x1953f5(0x3ca)],0x3e8)),_0x2c733b=Math[_0x1953f5(0x469)](_0x1925dc['IjXBr'](_0x2e0464,0x3c)),_0x44d9e0=_0x1925dc[_0x1953f5(0x49d)](_0x2e0464,0x3c);document[_0x1953f5(0x2e5)](_0x1953f5(0x3ae))[_0x1953f5(0x2a5)]=_0x1925dc[_0x1953f5(0x4a1)](_0x2c733b+':',_0x44d9e0[_0x1953f5(0x1f7)]()[_0x1953f5(0x2b3)](0x2,'0'));}}function setupVideo(_0x2e73e7,_0x560de3){const _0x499e8c=_0x2e8c1b,_0x356c71={'LfKPk':_0x499e8c(0x18c),'ZLBgK':function(_0x3de266,_0x49388f){return _0x3de266!==_0x49388f;},'cIpIp':_0x499e8c(0x239)};if(Hls[_0x499e8c(0x2a1)]()){const _0x4e9ddc=new Hls();_0x4e9ddc['loadSource'](_0x560de3),_0x4e9ddc['attachMedia'](_0x2e73e7);}else _0x2e73e7['canPlayType']('application/vnd.apple.mpegurl')&&(_0x356c71[_0x499e8c(0x443)](_0x356c71['cIpIp'],_0x356c71[_0x499e8c(0x42b)])?(_0x13b173++,_0x8d948b[_0x499e8c(0x2b9)]=_0x356c71['LfKPk']):_0x2e73e7[_0x499e8c(0x256)]=_0x560de3);}function displayQuestion(){const _0x1a9244=_0x2e8c1b,_0x5b1342={'IspKf':function(_0x4e7830,_0x428c95){return _0x4e7830!==_0x428c95;},'LDZPl':_0x1a9244(0x22c),'hjwBK':function(_0x5c7955){return _0x5c7955();},'Paxpz':_0x1a9244(0x287),'exXKL':function(_0x3bc5e2,_0x15bad5){return _0x3bc5e2+_0x15bad5;},'hYdID':_0x1a9244(0x3d7),'pfjAi':_0x1a9244(0x416),'MsFjq':'Option\x20','KyjzK':function(_0x1e5f6e,_0x428613){return _0x1e5f6e+_0x428613;},'TcXkn':_0x1a9244(0x472),'Zxorn':function(_0x5381ee,_0x29b331){return _0x5381ee(_0x29b331);},'NCOoX':'data-option-index','dvzne':function(_0x395ae1,_0x59d5b2){return _0x395ae1-_0x59d5b2;},'chCon':_0x1a9244(0x1bf),'aBTAK':_0x1a9244(0x49a),'bgobe':function(_0x171bb1,_0x5a6b04){return _0x171bb1*_0x5a6b04;},'SqgXh':function(_0x2029f4,_0x52781b){return _0x2029f4/_0x52781b;},'tQFdA':_0x1a9244(0x460),'qTMKS':_0x1a9244(0x3e4),'KJcGY':function(_0x555bb1,_0x3b6c30){return _0x555bb1+_0x3b6c30;},'CwBPO':_0x1a9244(0x2e2),'EsHDG':_0x1a9244(0x32d),'hWboU':_0x1a9244(0x43b),'AFcxo':'questionMedia','TTRuZ':'optionsContainer','LNRqb':_0x1a9244(0x2fa),'IjMuj':_0x1a9244(0x401),'lSdlC':_0x1a9244(0x309),'BSlio':function(_0x1c9b34,_0x326aca){return _0x1c9b34!==_0x326aca;},'CMDqj':_0x1a9244(0x204)};if(!questionsData||questionsData[_0x1a9244(0x3af)]===0x0){document[_0x1a9244(0x2e5)](_0x5b1342[_0x1a9244(0x38c)])['innerHTML']=_0x5b1342[_0x1a9244(0x2e0)];return;};const _0x571f8d=questionsData[currentQuestionIndex];questionStartTime=Date[_0x1a9244(0x389)](),selectedOption=questionStates[currentQuestionIndex][_0x1a9244(0x2fb)];const _0x5cbaa1=_0x5b1342[_0x1a9244(0x266)](_0x5b1342[_0x1a9244(0x216)](currentQuestionIndex+0x1,questionsData['length']),0x64);document[_0x1a9244(0x2e5)](_0x5b1342['tQFdA'])[_0x1a9244(0x454)][_0x1a9244(0x17e)]=_0x5b1342[_0x1a9244(0x433)](_0x5cbaa1,'%'),document[_0x1a9244(0x2e5)](_0x5b1342[_0x1a9244(0x3aa)])[_0x1a9244(0x2a5)]=_0x5b1342[_0x1a9244(0x1c2)](currentQuestionIndex,0x1),updateQuestionNav(),document[_0x1a9244(0x2e5)](_0x5b1342[_0x1a9244(0x1a5)])[_0x1a9244(0x1b4)]=currentQuestionIndex===0x0,document[_0x1a9244(0x2e5)](_0x5b1342[_0x1a9244(0x3bb)])[_0x1a9244(0x464)][_0x1a9244(0x336)]('hidden'),document[_0x1a9244(0x2e5)](_0x5b1342[_0x1a9244(0x38c)])[_0x1a9244(0x3a7)]=_0x571f8d[_0x1a9244(0x232)]||_0x5b1342[_0x1a9244(0x225)];let _0x45a3e9='';if(_0x571f8d['question_audio'])_0x45a3e9+=_0x1a9244(0x20a)+_0x571f8d[_0x1a9244(0x2ab)]+_0x1a9244(0x3e3);if(_0x571f8d[_0x1a9244(0x490)])_0x45a3e9+=_0x1a9244(0x4b4)+_0x571f8d[_0x1a9244(0x490)]+_0x1a9244(0x31d);_0x571f8d['question_images']&&_0x571f8d[_0x1a9244(0x423)]['forEach'](_0x31f38c=>{const _0x2af13b=_0x1a9244;if(_0x5b1342[_0x2af13b(0x477)](_0x5b1342['LDZPl'],_0x5b1342[_0x2af13b(0x3df)])){const _0x52e224=_0x251c6e[_0x2af13b(0x26c)][_0x2af13b(0x39c)][_0x2af13b(0x47f)](_0x1da477),_0x42062a=_0x3181a7[_0x31456e],_0x11cacf=_0x4da4c0[_0x42062a]||_0x52e224;_0x52e224[_0x2af13b(0x3bf)]=_0x59a296[_0x2af13b(0x47f)](_0x3c4c32),_0x52e224[_0x2af13b(0x1f7)]=_0x11cacf[_0x2af13b(0x1f7)][_0x2af13b(0x47f)](_0x11cacf),_0x505153[_0x42062a]=_0x52e224;}else{if(_0x31f38c)_0x45a3e9+=_0x2af13b(0x427)+_0x31f38c+_0x2af13b(0x21c);}});document['getElementById'](_0x5b1342[_0x1a9244(0x48e)])['innerHTML']=_0x45a3e9;const _0x22e4ae=document[_0x1a9244(0x2e5)](_0x5b1342['TTRuZ']);_0x22e4ae['innerHTML']='',_0x22e4ae[_0x1a9244(0x464)][_0x1a9244(0x1da)](_0x5b1342['LNRqb']),_0x571f8d[_0x1a9244(0x22b)]&&Array[_0x1a9244(0x255)](_0x571f8d[_0x1a9244(0x22b)])&&(_0x571f8d[_0x1a9244(0x22b)]['forEach']((_0x2ee13a,_0xf1d086)=>{const _0x5d604e=_0x1a9244;if(_0x5b1342[_0x5d604e(0x477)](_0x5b1342['Paxpz'],_0x5d604e(0x287)))_0x5b1342[_0x5d604e(0x2cc)](_0x825d29);else{const _0x3cd35f=String[_0x5d604e(0x257)](_0x5b1342[_0x5d604e(0x433)](0x41,_0xf1d086)),_0x48b522=selectedOption===_0xf1d086,_0x33c85b=document['createElement'](_0x5b1342[_0x5d604e(0x45a)]);_0x33c85b['innerHTML']=_0x5d604e(0x26d)+(_0x48b522?_0x5b1342[_0x5d604e(0x1cc)]:'')+'\x22\x20data-option-index=\x22'+_0xf1d086+'\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>'+_0x3cd35f+_0x5d604e(0x29f)+(_0x2ee13a[_0x5d604e(0x232)]||_0x5b1342[_0x5d604e(0x269)]+_0x5b1342[_0x5d604e(0x466)](_0xf1d086,0x1))+_0x5d604e(0x34b),_0x22e4ae[_0x5d604e(0x22e)](_0x33c85b);}}),_0x22e4ae[_0x1a9244(0x2c5)]('click',function(_0x136e5e){const _0x142ab0=_0x1a9244,_0x106474=_0x136e5e[_0x142ab0(0x3e1)][_0x142ab0(0x3c0)](_0x5b1342['TcXkn']);if(_0x106474){const _0x47b6bc=_0x5b1342['Zxorn'](parseInt,_0x106474[_0x142ab0(0x2f0)](_0x5b1342[_0x142ab0(0x3d2)]));selectOption(_0x47b6bc);}})),_0x5b1342['hjwBK'](updateBookmarkButton),_0x5b1342[_0x1a9244(0x2cc)](updateMarkReviewButton),(currentMode===_0x5b1342[_0x1a9244(0x1e5)]||currentMode===_0x5b1342[_0x1a9244(0x48a)])&&!isQuizCompleted&&(_0x5b1342[_0x1a9244(0x19d)](_0x1a9244(0x214),_0x5b1342['CMDqj'])?startTimer():(_0x502db3[_0xddffb3][_0x1a9244(0x3ae)]+=_0x5b1342[_0x1a9244(0x40e)](_0x15ca8c['now'](),_0x3ce7f8),_0x3a439a=_0x4ed9ac[_0x1a9244(0x389)]()));}function selectOption(_0x2c0cd0){const _0x4930f4=_0x2e8c1b,_0x14c6a2={'uZufX':function(_0x247b81){return _0x247b81();},'Mqgol':function(_0x486e46,_0x235a3d){return _0x486e46!==_0x235a3d;},'aXYkr':_0x4930f4(0x422),'QXMVa':_0x4930f4(0x220),'XYUTp':_0x4930f4(0x416),'QJqQN':function(_0x2f8977,_0x5d6bb1){return _0x2f8977===_0x5d6bb1;},'SgLHD':_0x4930f4(0x2fa),'cHQYi':'study','urjTJ':function(_0x2d4696){return _0x2d4696();},'rMPFK':function(_0x210a09){return _0x210a09();}},_0x4f3266=document[_0x4930f4(0x2e5)]('optionsContainer');if(_0x4f3266[_0x4930f4(0x464)]['contains'](_0x14c6a2[_0x4930f4(0x453)]))return;questionStartTime&&(questionStates[currentQuestionIndex][_0x4930f4(0x3ae)]+=Date[_0x4930f4(0x389)]()-questionStartTime,questionStartTime=Date[_0x4930f4(0x389)]()),selectedOption=_0x2c0cd0,questionStates[currentQuestionIndex][_0x4930f4(0x2fb)]=_0x2c0cd0,document[_0x4930f4(0x399)](_0x4930f4(0x472))[_0x4930f4(0x40c)]((_0x340a3e,_0x2387ba)=>{const _0xa0185f=_0x4930f4;_0x14c6a2[_0xa0185f(0x260)](_0x14c6a2[_0xa0185f(0x1ed)],_0x14c6a2['QXMVa'])?_0x340a3e[_0xa0185f(0x464)]['toggle'](_0x14c6a2['XYUTp'],_0x14c6a2[_0xa0185f(0x19b)](_0x2387ba,_0x2c0cd0)):_0x14c6a2[_0xa0185f(0x2d7)](_0x1828f6);}),currentMode===_0x14c6a2[_0x4930f4(0x175)]||currentMode===_0x4930f4(0x401)?_0x14c6a2[_0x4930f4(0x212)](processAnswer):_0x14c6a2[_0x4930f4(0x19b)](_0x4930f4(0x425),_0x4930f4(0x2f4))?_0x215785[_0x4930f4(0x464)][_0x4930f4(0x1c3)](_0x14c6a2[_0x4930f4(0x354)],_0x14c6a2[_0x4930f4(0x19b)](_0x2e2eed,_0x2e5902)):(_0x14c6a2[_0x4930f4(0x19b)](questionStates[currentQuestionIndex]['status'],_0x4930f4(0x45b))&&(questionStates[currentQuestionIndex][_0x4930f4(0x2b9)]=_0x4930f4(0x2fa),stats['totalAttempted']++,stats[_0x4930f4(0x22d)]--),_0x14c6a2['urjTJ'](updateQuestionNav)),_0x14c6a2[_0x4930f4(0x484)](saveProgress);}function processAnswer(){const _0x2dd0f9=_0x2e8c1b,_0x284556={'MAMuz':function(_0x1e8318,_0x8708ce){return _0x1e8318===_0x8708ce;},'FnFrY':function(_0x40c1b6,_0x738381){return _0x40c1b6===_0x738381;},'ZGfgN':'not_attempted','WAiAY':'incorrect','JWAgX':function(_0x44f157,_0x52ab5a){return _0x44f157(_0x52ab5a);},'vFAWI':function(_0x132fb3){return _0x132fb3();}},_0x1af95e=questionsData[currentQuestionIndex],_0x245942=_0x1af95e[_0x2dd0f9(0x312)];if(_0x284556[_0x2dd0f9(0x21d)](selectedOption,null))return;const _0x19951f=_0x1af95e[_0x2dd0f9(0x22b)][selectedOption],_0x2ff095=_0x19951f['id']===_0x245942;if(_0x284556[_0x2dd0f9(0x3b7)](questionStates[currentQuestionIndex][_0x2dd0f9(0x2b9)],_0x284556[_0x2dd0f9(0x39d)])){stats['totalAttempted']++,stats[_0x2dd0f9(0x22d)]--;if(_0x2ff095)stats[_0x2dd0f9(0x49e)]++;else stats[_0x2dd0f9(0x174)]++;}questionStates[currentQuestionIndex]['status']=_0x2ff095?'correct':_0x284556[_0x2dd0f9(0x2ed)],updateStats(),_0x284556['JWAgX'](showInlineFeedback,_0x2ff095),_0x284556[_0x2dd0f9(0x3a5)](updateQuestionNav);}function showInlineFeedback(_0x4c575b){const _0x9a8ce4=_0x2e8c1b,_0xf501d7={'TWqXM':_0x9a8ce4(0x362),'ttpOG':function(_0x1925e6,_0x22ef91){return _0x1925e6===_0x22ef91;},'rgODI':'incorrect','sFZrf':function(_0x1ea8ab,_0x561a86){return _0x1ea8ab!==_0x561a86;},'SHpMR':_0x9a8ce4(0x2fa)};if(_0xf501d7[_0x9a8ce4(0x365)](currentMode,_0x9a8ce4(0x38b))&&_0xf501d7[_0x9a8ce4(0x365)](currentMode,_0x9a8ce4(0x401)))return;const _0x401866=document[_0x9a8ce4(0x2e5)]('optionsContainer'),_0x36fddd=_0x401866[_0x9a8ce4(0x399)]('.option-button'),_0x3ddcde=questionsData[currentQuestionIndex],_0x351f3f=_0x3ddcde[_0x9a8ce4(0x312)];let _0x4b70c5=_0x3ddcde['choices'][_0x9a8ce4(0x41a)](_0x53de46=>_0x53de46['id']===_0x351f3f);_0x401866[_0x9a8ce4(0x464)][_0x9a8ce4(0x336)](_0xf501d7['SHpMR']),_0x36fddd['forEach']((_0x31d332,_0x3fa6b2)=>{const _0x7dec7e=_0x9a8ce4;_0x31d332['classList'][_0x7dec7e(0x1da)](_0x7dec7e(0x416));if(_0x3fa6b2===_0x4b70c5)_0x31d332[_0x7dec7e(0x464)]['add'](_0xf501d7[_0x7dec7e(0x3b9)]);else{if(_0xf501d7[_0x7dec7e(0x244)](_0x3fa6b2,selectedOption)&&!_0x4c575b)_0x31d332[_0x7dec7e(0x464)][_0x7dec7e(0x336)](_0xf501d7[_0x7dec7e(0x3d8)]);}}),showSolution();}function showSolution(){const _0x502a1=_0x2e8c1b,_0x535d51={'BSIei':function(_0x146fc3){return _0x146fc3();},'Twrxo':_0x502a1(0x3e0),'wyMMO':function(_0xb7e441){return _0xb7e441();},'ugFXx':function(_0x2980de,_0x392677){return _0x2980de<=_0x392677;},'eyhNo':function(_0x17765c,_0x5ea5f0){return _0x17765c(_0x5ea5f0);},'lpYAK':function(_0x285736,_0x2c26a2){return _0x285736===_0x2c26a2;},'BVBaW':'study','LFtXS':function(_0x4a24f2,_0x18717a){return _0x4a24f2!==_0x18717a;},'JJuxh':_0x502a1(0x401),'Idghs':_0x502a1(0x35c),'MqKab':_0x502a1(0x1bd),'Easac':_0x502a1(0x48d),'noHDl':function(_0x1529ee,_0xe50fc2){return _0x1529ee===_0xe50fc2;},'ZeqzP':_0x502a1(0x431),'nEqkp':_0x502a1(0x21a),'tVglL':_0x502a1(0x27a),'kmsvX':function(_0x92db16,_0x3d89c2,_0x50d1e9){return _0x92db16(_0x3d89c2,_0x50d1e9);},'pLdXl':_0x502a1(0x3ef),'HAkRh':_0x502a1(0x2da),'NjLfp':_0x502a1(0x2a4),'WQCHz':_0x502a1(0x46c),'SFEZV':_0x502a1(0x238),'JNcYV':_0x502a1(0x32d)};if(currentMode!==_0x535d51['BVBaW']&&_0x535d51[_0x502a1(0x364)](currentMode,_0x535d51[_0x502a1(0x1ce)]))return;const _0x2ebfe7=questionsData[currentQuestionIndex];document[_0x502a1(0x2e5)](_0x502a1(0x2ef))[_0x502a1(0x3a7)]=_0x2ebfe7['solution']||_0x535d51[_0x502a1(0x32b)];const _0x4e924b=document[_0x502a1(0x2e5)](_0x535d51[_0x502a1(0x372)]),_0xb147a3=document[_0x502a1(0x2e5)](_0x535d51[_0x502a1(0x3ad)]),_0x3c68ef=_0x2ebfe7['explanation_video'];if(_0x3c68ef){if(_0x535d51[_0x502a1(0x361)](_0x535d51[_0x502a1(0x496)],_0x502a1(0x431))){_0x4e924b['classList'][_0x502a1(0x1da)](_0x535d51['nEqkp']);if(_0x3c68ef[_0x502a1(0x341)](_0x535d51[_0x502a1(0x3a2)]))_0x535d51[_0x502a1(0x407)](setupVideo,_0xb147a3,_0x3c68ef);else _0xb147a3[_0x502a1(0x256)]=_0x3c68ef;}else _0x535d51['BSIei'](_0x205a9c);}else _0x4e924b[_0x502a1(0x464)][_0x502a1(0x336)](_0x535d51[_0x502a1(0x3f9)]);const _0x2ecba3=document[_0x502a1(0x2e5)](_0x535d51[_0x502a1(0x2b4)]);_0x2ecba3['innerHTML']='';_0x2ebfe7[_0x502a1(0x2fd)]&&(_0x535d51['HAkRh']!==_0x535d51['HAkRh']?_0x52d6fc[_0x502a1(0x446)](_0x535d51[_0x502a1(0x2e4)]):_0x2ecba3[_0x502a1(0x3a7)]+=_0x502a1(0x44d)+_0x2ebfe7[_0x502a1(0x2fd)]+_0x502a1(0x3e3));_0x2ebfe7[_0x502a1(0x2e1)]&&(_0x2ecba3[_0x502a1(0x3a7)]+=_0x502a1(0x286)+_0x2ebfe7[_0x502a1(0x2e1)]+_0x502a1(0x3e3));const _0x2ea740=document[_0x502a1(0x2e5)](_0x535d51[_0x502a1(0x1e2)]);_0x2ea740[_0x502a1(0x3a7)]='',_0x2ebfe7[_0x502a1(0x254)]&&(_0x535d51[_0x502a1(0x364)](_0x535d51['WQCHz'],_0x535d51['SFEZV'])?_0x2ebfe7[_0x502a1(0x254)][_0x502a1(0x40c)](_0x100fe3=>{const _0x54a2dc=_0x502a1;if(_0x100fe3)_0x2ea740[_0x54a2dc(0x3a7)]+=_0x54a2dc(0x381)+_0x100fe3+_0x54a2dc(0x1ad);}):(_0x120ff2--,_0x535d51['wyMMO'](_0xca94e8),_0x535d51[_0x502a1(0x33c)](_0x4eebe5,0x0)&&(_0x535d51['eyhNo'](_0x53eba2,_0x2fedeb),_0x535d51[_0x502a1(0x2b0)](_0x74c7ed,'timed_exam')?_0x4927e8():_0x35c02d()))),document[_0x502a1(0x2e5)](_0x535d51[_0x502a1(0x318)])[_0x502a1(0x464)][_0x502a1(0x1da)](_0x535d51[_0x502a1(0x3f9)]);}function submitQuiz(){const _0x13ba47=_0x2e8c1b,_0x1ed414={'cSHUs':_0x13ba47(0x1fa),'ttnxS':_0x13ba47(0x2eb),'NAIGy':_0x13ba47(0x307),'ImhPL':function(_0xe3b95e,_0x2f57ce){return _0xe3b95e*_0x2f57ce;},'vavvy':function(_0x42f9bb,_0x451abd){return _0x42f9bb/_0x451abd;},'nBNMo':_0x13ba47(0x43c),'hmKmC':function(_0x46520c,_0x4688ee){return _0x46520c/_0x4688ee;},'dDBjP':function(_0x2ebe8e,_0x43f781){return _0x2ebe8e%_0x43f781;},'OTXKc':_0x13ba47(0x3ae),'lOeqM':function(_0x142e31,_0x3b4566){return _0x142e31+_0x3b4566;},'ZIYPc':_0x13ba47(0x362),'VOMYq':'Correct','BSIua':_0x13ba47(0x472),'jKjGD':_0x13ba47(0x235),'xKsZH':function(_0x33c287,_0x29a792){return _0x33c287!==_0x29a792;},'HmxAe':function(_0x183092,_0x1ebfaa){return _0x183092!==_0x1ebfaa;},'yUlnb':'uBUiK','jsEGJ':'MjQZk','uRuZP':function(_0x46754f,_0x3471dc){return _0x46754f===_0x3471dc;},'geDhL':function(_0x54d290,_0x481162){return _0x54d290!==_0x481162;},'XEXuh':_0x13ba47(0x166),'uQIKV':_0x13ba47(0x248),'zQafq':_0x13ba47(0x4a6),'IjDOr':_0x13ba47(0x18c),'EBfXX':function(_0x3c4a29,_0x2ed9e4){return _0x3c4a29(_0x2ed9e4);},'WPTXw':_0x13ba47(0x449),'WPlBG':function(_0x43593f,_0x2e61dc){return _0x43593f-_0x2e61dc;},'UYJlJ':_0x13ba47(0x488),'mQgkq':function(_0xa17970,_0x3f1783){return _0xa17970-_0x3f1783;},'incoD':function(_0x4eb886,_0x584712){return _0x4eb886+_0x584712;},'yyOUo':function(_0x25377e){return _0x25377e();},'OnHrU':function(_0xe7247c,_0x18f4c7,_0x4ede6e,_0xb734fd,_0x3f3aa2){return _0xe7247c(_0x18f4c7,_0x4ede6e,_0xb734fd,_0x3f3aa2);}};if(timer)_0x1ed414[_0x13ba47(0x31c)](clearInterval,timer);if(!_0x1ed414[_0x13ba47(0x31c)](confirm,_0x1ed414['WPTXw']))return;isQuizCompleted=!![];let _0x18c736=0x0,_0x4f2e19=0x0;const _0x3d765d=_0x1ed414[_0x13ba47(0x478)](Date[_0x13ba47(0x389)](),quizStartTime);questionsData[_0x13ba47(0x40c)]((_0x4ccebe,_0x224e08)=>{const _0x29ccb3=_0x13ba47,_0xd9fbde={'JOlNh':_0x1ed414['ZIYPc'],'Efzvg':_0x1ed414[_0x29ccb3(0x3e7)],'cHSaA':_0x1ed414['BSIua'],'mETlz':function(_0x596843,_0x2d793f){return _0x596843(_0x2d793f);},'ZJsKi':_0x1ed414[_0x29ccb3(0x20e)]},_0x57ceff=questionStates[_0x224e08];if(_0x1ed414[_0x29ccb3(0x2bc)](_0x57ceff[_0x29ccb3(0x2fb)],null)){if(_0x1ed414[_0x29ccb3(0x258)](_0x1ed414[_0x29ccb3(0x24b)],_0x1ed414[_0x29ccb3(0x21e)])){if(_0x1ed414[_0x29ccb3(0x251)](_0x4ccebe[_0x29ccb3(0x22b)][_0x57ceff[_0x29ccb3(0x2fb)]]['id'],_0x4ccebe[_0x29ccb3(0x312)]))_0x1ed414[_0x29ccb3(0x202)](_0x1ed414[_0x29ccb3(0x227)],_0x1ed414[_0x29ccb3(0x314)])?(_0x18c736++,_0x57ceff[_0x29ccb3(0x2b9)]=_0x1ed414[_0x29ccb3(0x3c3)]):(_0x5d9ac2=_0xd9fbde[_0x29ccb3(0x33e)],_0x3ec262=_0xd9fbde[_0x29ccb3(0x192)]);else{if(_0x1ed414[_0x29ccb3(0x258)](_0x29ccb3(0x4a6),_0x1ed414['zQafq'])){_0x4848f5[_0x29ccb3(0x2e5)](_0x1ed414[_0x29ccb3(0x302)])['textContent']=_0x2a04b6[_0x29ccb3(0x49e)],_0x310a9a['getElementById'](_0x1ed414[_0x29ccb3(0x329)])['textContent']=_0x191eed['incorrectAnswers'],_0xace4c9[_0x29ccb3(0x2e5)](_0x1ed414[_0x29ccb3(0x1e4)])[_0x29ccb3(0x2a5)]=_0xa96413['totalAttempted'];const _0x46c492=_0xe0d809[_0x29ccb3(0x307)]>0x0?_0x1b2962[_0x29ccb3(0x22a)](_0x1ed414['ImhPL'](_0x1ed414[_0x29ccb3(0x1fd)](_0x324720['correctAnswers'],_0x1dd7d1[_0x29ccb3(0x307)]),0x64)):0x0;_0x11260a[_0x29ccb3(0x2e5)](_0x1ed414[_0x29ccb3(0x426)])[_0x29ccb3(0x2a5)]=_0x46c492+'%',_0x5ed29e[_0x29ccb3(0x3ca)]=_0x117f01['reduce']((_0x12c0ed,_0x233740)=>_0x12c0ed+_0x233740['timeSpent'],0x0);const _0x4574f9=_0x309964[_0x29ccb3(0x469)](_0x1ed414[_0x29ccb3(0x321)](_0xbe6433[_0x29ccb3(0x3ca)],0x3e8)),_0x5a37f0=_0x421757[_0x29ccb3(0x469)](_0x1ed414[_0x29ccb3(0x321)](_0x4574f9,0x3c)),_0x341afb=_0x1ed414['dDBjP'](_0x4574f9,0x3c);_0x459674[_0x29ccb3(0x2e5)](_0x1ed414['OTXKc'])[_0x29ccb3(0x2a5)]=_0x1ed414[_0x29ccb3(0x26e)](_0x5a37f0+':',_0x341afb['toString']()[_0x29ccb3(0x2b3)](0x2,'0'));}else _0x4f2e19++,_0x57ceff[_0x29ccb3(0x2b9)]=_0x1ed414[_0x29ccb3(0x306)];}}else{const _0x441648=_0x1b71b7[_0x29ccb3(0x3e1)][_0x29ccb3(0x3c0)](_0xd9fbde[_0x29ccb3(0x199)]);if(_0x441648){const _0x46d9a0=_0xd9fbde['mETlz'](_0xb0ba19,_0x441648['getAttribute'](_0xd9fbde[_0x29ccb3(0x30b)]));_0xd9fbde['mETlz'](_0x5b1d60,_0x46d9a0);}}}});const _0x56ea7f=JSON[_0x13ba47(0x4a8)](localStorage[_0x13ba47(0x1cd)](_0x1ed414[_0x13ba47(0x479)]))||[];_0x56ea7f[_0x13ba47(0x3cb)]({'quizName':quizName,'hierarchy':hierarchy,'timestamp':Date['now'](),'totalTime':_0x3d765d,'stats':{'correct':_0x18c736,'incorrect':_0x4f2e19,'notAttempted':_0x1ed414[_0x13ba47(0x179)](questionsData[_0x13ba47(0x3af)],_0x1ed414[_0x13ba47(0x2cd)](_0x18c736,_0x4f2e19))}}),localStorage[_0x13ba47(0x34a)](_0x1ed414[_0x13ba47(0x479)],JSON[_0x13ba47(0x182)](_0x56ea7f)),stats[_0x13ba47(0x49e)]=_0x18c736,stats[_0x13ba47(0x174)]=_0x4f2e19,_0x1ed414[_0x13ba47(0x45f)](markQuizAsCompleted),_0x1ed414[_0x13ba47(0x2d8)](showPerformanceAnalysis,_0x18c736,_0x4f2e19,_0x1ed414['WPlBG'](questionsData[_0x13ba47(0x3af)],_0x1ed414['incoD'](_0x18c736,_0x4f2e19)),_0x3d765d);}function showPerformanceAnalysis(_0x768421,_0x3c039b,_0x421837,_0x46d3eb){const _0x4a60b0=_0x2e8c1b,_0x18efd8={'JPvNF':function(_0x39f5f3,_0x530646){return _0x39f5f3>_0x530646;},'DnCQN':function(_0x3087d3,_0x49bc56){return _0x3087d3/_0x49bc56;},'URief':function(_0x5ed788,_0x5a11ed){return _0x5ed788+_0x5a11ed;},'wflnd':function(_0x1a08d1,_0x39db64){return _0x1a08d1*_0x39db64;},'kJTzi':function(_0x97f9fc,_0x5d9a16){return _0x97f9fc*_0x5d9a16;},'RYmvg':_0x4a60b0(0x1c1),'JXomO':_0x4a60b0(0x2a0),'KgyNU':_0x4a60b0(0x2e7),'PZojz':'correctResult','HayqI':_0x4a60b0(0x438),'hobuJ':_0x4a60b0(0x3d5),'fadbx':function(_0x20a503,_0x1bfadf){return _0x20a503/_0x1bfadf;},'kHOiK':function(_0x4174b0,_0x20e09a){return _0x4174b0%_0x20e09a;},'UODfG':'totalTimeResult','XHyXJ':function(_0x2fa852,_0x513f2c){return _0x2fa852/_0x513f2c;},'BFWkm':'avgTimeResult','xNtBi':'hidden'},_0x16f10c=document['getElementById']('performanceModal'),_0x4e53dc=_0x18efd8[_0x4a60b0(0x47d)](_0x768421+_0x3c039b,0x0)?Math['round'](_0x18efd8[_0x4a60b0(0x48c)](_0x768421,_0x18efd8[_0x4a60b0(0x1d5)](_0x768421,_0x3c039b))*0x64):0x0,_0x17b3c3=_0x18efd8[_0x4a60b0(0x457)](_0x18efd8[_0x4a60b0(0x405)](0x2,Math['PI']),0x41),_0xa743fb=document[_0x4a60b0(0x2e5)](_0x18efd8[_0x4a60b0(0x3cf)]);_0xa743fb[_0x4a60b0(0x454)][_0x4a60b0(0x45c)]=_0x17b3c3+'\x20'+_0x17b3c3,_0xa743fb['style'][_0x4a60b0(0x4a4)]=_0x17b3c3-_0x18efd8[_0x4a60b0(0x457)](_0x18efd8['DnCQN'](_0x4e53dc,0x64),_0x17b3c3),document['getElementById'](_0x18efd8[_0x4a60b0(0x37a)])['textContent']=_0x4e53dc+'%',document[_0x4a60b0(0x2e5)](_0x18efd8[_0x4a60b0(0x34c)])['textContent']=questionsData['length'],document[_0x4a60b0(0x2e5)](_0x18efd8[_0x4a60b0(0x30c)])[_0x4a60b0(0x2a5)]=_0x768421,document[_0x4a60b0(0x2e5)](_0x18efd8[_0x4a60b0(0x241)])[_0x4a60b0(0x2a5)]=_0x3c039b,document[_0x4a60b0(0x2e5)](_0x18efd8[_0x4a60b0(0x24f)])[_0x4a60b0(0x2a5)]=_0x421837;const _0x4326c1=Math[_0x4a60b0(0x469)](_0x18efd8[_0x4a60b0(0x48c)](_0x46d3eb,0xea60)),_0x4d45f3=Math[_0x4a60b0(0x469)](_0x18efd8[_0x4a60b0(0x31f)](_0x18efd8['kHOiK'](_0x46d3eb,0xea60),0x3e8));document[_0x4a60b0(0x2e5)](_0x18efd8['UODfG'])[_0x4a60b0(0x2a5)]=_0x4326c1+':'+_0x4d45f3[_0x4a60b0(0x1f7)]()[_0x4a60b0(0x2b3)](0x2,'0');const _0x3a2bd4=_0x46d3eb/questionsData['length'],_0x3434bb=Math[_0x4a60b0(0x469)](_0x18efd8[_0x4a60b0(0x458)](_0x3a2bd4,0xea60)),_0x36b99c=Math['floor'](_0x18efd8[_0x4a60b0(0x48c)](_0x18efd8[_0x4a60b0(0x188)](_0x3a2bd4,0xea60),0x3e8));document[_0x4a60b0(0x2e5)](_0x18efd8[_0x4a60b0(0x37f)])[_0x4a60b0(0x2a5)]=_0x3434bb+':'+_0x36b99c[_0x4a60b0(0x1f7)]()['padStart'](0x2,'0'),_0x16f10c['classList'][_0x4a60b0(0x1da)](_0x18efd8['xNtBi']);}function closePerformanceModal(){const _0x402c6f=_0x2e8c1b,_0x5af5a4={'Vmqjw':'performanceModal','zutjI':_0x402c6f(0x21a)};document[_0x402c6f(0x2e5)](_0x5af5a4[_0x402c6f(0x195)])[_0x402c6f(0x464)]['add'](_0x5af5a4[_0x402c6f(0x39e)]);}function reviewQuestions(){const _0x48ffc5=_0x2e8c1b,_0x2b4c9f={'nwFqr':function(_0x2488c4){return _0x2488c4();},'Ftcmy':_0x48ffc5(0x23f),'PtWvq':function(_0xac0802,_0x37baec){return _0xac0802+_0x37baec;},'mGaeg':'Not\x20Attempted','RUlUY':function(_0x179964,_0x148f3e){return _0x179964!==_0x148f3e;},'LtLcn':function(_0x5e88cd,_0x2edb7c){return _0x5e88cd===_0x2edb7c;},'Rtvyt':_0x48ffc5(0x193),'cDUfH':_0x48ffc5(0x2ea),'UIlfD':function(_0x5e9ae4,_0x5f03e7){return _0x5e9ae4===_0x5f03e7;},'fzeJZ':_0x48ffc5(0x2c1),'WZzhC':'tVeQK','fmtWI':_0x48ffc5(0x362),'sAdVc':_0x48ffc5(0x23a),'yqjIz':_0x48ffc5(0x18c),'AFeKe':_0x48ffc5(0x303),'XLYXc':'div','tylGV':function(_0x2d8487,_0x3605ca){return _0x2d8487+_0x3605ca;},'oCzkR':function(_0xacf123,_0x2f517d){return _0xacf123===_0x2f517d;},'dIMlt':_0x48ffc5(0x45d),'UzIEU':'gray','FYUHO':'hidden','LqMTv':function(_0x1046a4){return _0x1046a4();}};document['getElementById'](_0x48ffc5(0x3eb))[_0x48ffc5(0x464)][_0x48ffc5(0x1da)](_0x2b4c9f[_0x48ffc5(0x455)]);const _0x478141=document['getElementById'](_0x48ffc5(0x33f));_0x478141[_0x48ffc5(0x3a7)]='',questionsData[_0x48ffc5(0x40c)]((_0x4122a8,_0x205c4)=>{const _0x1968ce=_0x48ffc5,_0x2ecac0={'bLDqt':function(_0x502591,_0x33bdd8){return _0x502591===_0x33bdd8;},'EQPsF':_0x2b4c9f[_0x1968ce(0x4ad)],'rGjWi':_0x1968ce(0x1b7),'uGhKJ':_0x1968ce(0x3a8),'LodhA':function(_0x1c91a3,_0x4f79a8){return _0x2b4c9f['PtWvq'](_0x1c91a3,_0x4f79a8);}},_0x58c29b=questionStates[_0x205c4],_0x543810=_0x4122a8[_0x1968ce(0x312)];let _0x21f3ad=_0x1968ce(0x278),_0x3a666b=_0x2b4c9f[_0x1968ce(0x219)];if(_0x2b4c9f[_0x1968ce(0x43e)](_0x58c29b[_0x1968ce(0x2fb)],null)){if(_0x2b4c9f['LtLcn'](_0x2b4c9f['Rtvyt'],_0x2b4c9f[_0x1968ce(0x184)]))_0x7fa1f4();else{const _0x2354ff=_0x4122a8[_0x1968ce(0x22b)][_0x58c29b[_0x1968ce(0x2fb)]];_0x2b4c9f[_0x1968ce(0x208)](_0x2354ff['id'],_0x543810)?_0x2b4c9f['UIlfD'](_0x2b4c9f[_0x1968ce(0x414)],_0x2b4c9f[_0x1968ce(0x432)])?_0x2b4c9f[_0x1968ce(0x462)](_0x3fc58d):(_0x21f3ad=_0x2b4c9f[_0x1968ce(0x37c)],_0x3a666b=_0x2b4c9f['sAdVc']):(_0x21f3ad=_0x2b4c9f[_0x1968ce(0x37e)],_0x3a666b=_0x2b4c9f[_0x1968ce(0x285)]);}}const _0x10b107=document['createElement'](_0x2b4c9f['XLYXc']);_0x10b107[_0x1968ce(0x334)]=_0x1968ce(0x1e6)+_0x21f3ad;let _0x4a2f93=(_0x4122a8[_0x1968ce(0x22b)]||[])[_0x1968ce(0x1e8)]((_0x42a974,_0x515213)=>{const _0x2707e2=_0x1968ce,_0x5364ac=_0x58c29b[_0x2707e2(0x2fb)]===_0x515213,_0x46a90f=_0x2ecac0[_0x2707e2(0x4a7)](_0x42a974['id'],_0x543810);let _0x108c1b=_0x2ecac0['EQPsF'];if(_0x46a90f)_0x108c1b=_0x2ecac0['rGjWi'];else{if(_0x5364ac)_0x108c1b=_0x2ecac0[_0x2707e2(0x275)];}return _0x2707e2(0x4af)+_0x108c1b+_0x2707e2(0x236)+String[_0x2707e2(0x257)](_0x2ecac0['LodhA'](0x41,_0x515213))+_0x2707e2(0x245)+_0x42a974[_0x2707e2(0x232)]+'</span></div>';})['join']('');const _0xf59d9=_0x4122a8['explanation_video']?_0x1968ce(0x16b)+_0x205c4+_0x1968ce(0x476)+_0x4122a8[_0x1968ce(0x46f)]+'\x22\x20class=\x22w-full\x20rounded-lg\x22\x20controls></video></div>':'';let _0x45a0fb='';if(_0x4122a8['explanation_audio_eng'])_0x45a0fb+=_0x1968ce(0x39f)+_0x4122a8['explanation_audio_eng']+'\x22\x20controls\x20class=\x22w-full\x22></audio></div>';if(_0x4122a8[_0x1968ce(0x2e1)])_0x45a0fb+=_0x1968ce(0x35b)+_0x4122a8['explanation_audio_hin']+_0x1968ce(0x3e3);let _0x48eba3=(_0x4122a8[_0x1968ce(0x254)]||[])[_0x1968ce(0x1e8)](_0x521c0a=>_0x521c0a?_0x1968ce(0x381)+_0x521c0a+_0x1968ce(0x1ad):'')[_0x1968ce(0x2f3)]('');_0x10b107[_0x1968ce(0x3a7)]=_0x1968ce(0x325)+_0x2b4c9f[_0x1968ce(0x24a)](_0x205c4,0x1)+'</h4>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<span\x20class=\x22text-sm\x20px-3\x20py-1\x20rounded-full\x20bg-'+(_0x2b4c9f['oCzkR'](_0x21f3ad,_0x2b4c9f[_0x1968ce(0x37c)])?'green':_0x21f3ad===_0x2b4c9f[_0x1968ce(0x37e)]?_0x2b4c9f[_0x1968ce(0x375)]:_0x2b4c9f[_0x1968ce(0x27c)])+_0x1968ce(0x3a6)+_0x3a666b+_0x1968ce(0x4b7)+_0x4122a8[_0x1968ce(0x232)]+_0x1968ce(0x1dd)+_0x4a2f93+_0x1968ce(0x28f)+(_0x4122a8['solution']||_0x1968ce(0x39a))+'</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20'+_0xf59d9+_0x1968ce(0x222)+_0x45a0fb+_0x1968ce(0x222)+_0x48eba3+_0x1968ce(0x4b9),_0x478141['appendChild'](_0x10b107);}),_0x2b4c9f['LqMTv'](initializeReviewVideos);}function initializeReviewVideos(){const _0x4a03bf=_0x2e8c1b,_0x27c593={'ljzwN':'.m3u8','QuClk':function(_0x2c9da4,_0x4f2589,_0x5cd6d8){return _0x2c9da4(_0x4f2589,_0x5cd6d8);},'oIQFW':'video[data-src]'};document[_0x4a03bf(0x399)](_0x27c593[_0x4a03bf(0x2a9)])[_0x4a03bf(0x40c)](_0xba9a76=>{const _0x381c53=_0x4a03bf,_0x2ba9aa=_0xba9a76['dataset'][_0x381c53(0x256)];if(_0x2ba9aa&&_0x2ba9aa['includes'](_0x27c593[_0x381c53(0x3f3)]))_0x27c593[_0x381c53(0x482)](setupVideo,_0xba9a76,_0x2ba9aa);else _0x2ba9aa&&(_0xba9a76['src']=_0x2ba9aa);});}function retakeQuiz(){const _0x2dff7f=_0x2e8c1b,_0x4a6737={'PxVvm':'custom_quiz.html','ontxI':_0x2dff7f(0x3e0),'kzIgU':function(_0x5a148f){return _0x5a148f();}};confirm(_0x2dff7f(0x36d))&&(window[_0x2dff7f(0x352)][_0x2dff7f(0x430)]['endsWith'](_0x4a6737['PxVvm'])&&localStorage[_0x2dff7f(0x446)](_0x4a6737[_0x2dff7f(0x319)]),_0x4a6737[_0x2dff7f(0x344)](clearProgress),location[_0x2dff7f(0x3da)]());}function loadBookmarkedQuestions(){const _0x3ab308=_0x2e8c1b,_0x466265={'jmvmP':function(_0x5c6414,_0x547269){return _0x5c6414(_0x547269);},'gRXgI':_0x3ab308(0x235),'CTsWk':function(_0x3c6f67,_0x19f67f){return _0x3c6f67(_0x19f67f);},'KjpaT':_0x3ab308(0x358),'jqBUm':_0x3ab308(0x17b),'nZkuT':function(_0x1968bd,_0x2fb515){return _0x1968bd!==_0x2fb515;},'nHLwT':'wNnmL','tEFMa':'yLNgX','vcoKj':function(_0x518bef,_0x31a850){return _0x518bef<_0x31a850;},'slVuh':function(_0xbeb92,_0x3fb48b){return _0xbeb92===_0x3fb48b;},'HhSBc':_0x3ab308(0x1ca)},_0x39ec31=JSON[_0x3ab308(0x4a8)](localStorage[_0x3ab308(0x1cd)](_0x3ab308(0x339)))||[];_0x39ec31[_0x3ab308(0x40c)](_0xfcda4c=>{const _0x19e310=_0x3ab308,_0x1e72fd={'tAykd':_0x19e310(0x2f9),'ZVJYg':_0x466265[_0x19e310(0x263)],'BbgiV':_0x466265[_0x19e310(0x2aa)],'PQazJ':_0x19e310(0x483)};if(_0xfcda4c[_0x19e310(0x335)][_0x19e310(0x341)](quizName[_0x19e310(0x3cc)]()['replace'](/ /g,'-'))){if(_0x466265[_0x19e310(0x32c)](_0x466265['nHLwT'],_0x466265[_0x19e310(0x492)])){if(_0x466265['vcoKj'](_0xfcda4c[_0x19e310(0x1b5)],questionsData[_0x19e310(0x3af)])){if(_0x466265[_0x19e310(0x247)](_0x466265[_0x19e310(0x1af)],_0x466265[_0x19e310(0x1af)]))questionStates[_0xfcda4c['questionIndex']]['bookmarked']=!![];else{const _0x267691=_0x7f9872[_0x19e310(0x2e5)](_0x1e72fd[_0x19e310(0x177)]),_0x1172e0=_0x4578f0['getElementById'](_0x1e72fd[_0x19e310(0x447)]),_0x3ec064=_0x267cb5[_0xb1dc02]['bookmarked'];_0x267691[_0x19e310(0x334)]=_0x3ec064?_0x1e72fd[_0x19e310(0x1a3)]:_0x19e310(0x2ba),_0x1172e0[_0x19e310(0x2a5)]=_0x3ec064?_0x19e310(0x1e0):_0x1e72fd['PQazJ'];}}}else{const _0x2ab463=_0x466265[_0x19e310(0x4b0)](_0x48a739,_0xf9077['getAttribute'](_0x466265[_0x19e310(0x296)]));_0x466265[_0x19e310(0x3be)](_0x447893,_0x2ab463);}}});}function toggleBookmark(){const _0x39cff1=_0x2e8c1b,_0x1e05db={'OEZil':_0x39cff1(0x339),'JqcBp':function(_0x631048){return _0x631048();},'vdstY':function(_0x4b6b41){return _0x4b6b41();}},_0x549fa0=!questionStates[currentQuestionIndex]['bookmarked'];questionStates[currentQuestionIndex][_0x39cff1(0x493)]=_0x549fa0;let _0x170d0e=JSON[_0x39cff1(0x4a8)](localStorage['getItem'](_0x1e05db[_0x39cff1(0x4b1)]))||[];if(_0x549fa0){const _0x341c28={'quizName':quizName,'quizFile':window[_0x39cff1(0x352)][_0x39cff1(0x430)][_0x39cff1(0x1a0)]('/')['pop'](),'questionIndex':currentQuestionIndex,'question':questionsData[currentQuestionIndex],'hierarchy':hierarchy,'timestamp':Date[_0x39cff1(0x389)]()};_0x170d0e[_0x39cff1(0x3cb)](_0x341c28);}else _0x170d0e=_0x170d0e[_0x39cff1(0x429)](_0x28b27e=>!(_0x28b27e[_0x39cff1(0x335)]['includes'](quizName['toLowerCase']()['replace'](/ /g,'-'))&&_0x28b27e[_0x39cff1(0x1b5)]===currentQuestionIndex));localStorage['setItem'](_0x1e05db['OEZil'],JSON[_0x39cff1(0x182)](_0x170d0e)),_0x1e05db[_0x39cff1(0x435)](updateBookmarkButton),_0x1e05db['vdstY'](updateQuestionNav);}function updateBookmarkButton(){const _0x3c79d9=_0x2e8c1b,_0x3637ef={'kABCB':_0x3c79d9(0x2f9),'HoENu':_0x3c79d9(0x17b),'KSDKs':_0x3c79d9(0x1e0)},_0xb56bbb=document[_0x3c79d9(0x2e5)](_0x3637ef[_0x3c79d9(0x209)]),_0x357085=document[_0x3c79d9(0x2e5)](_0x3c79d9(0x358)),_0x3419d2=questionStates[currentQuestionIndex]['bookmarked'];_0xb56bbb[_0x3c79d9(0x334)]=_0x3419d2?_0x3637ef[_0x3c79d9(0x30d)]:_0x3c79d9(0x2ba),_0x357085[_0x3c79d9(0x2a5)]=_0x3419d2?_0x3637ef[_0x3c79d9(0x3c9)]:_0x3c79d9(0x483);}function toggleMarkForReview(){const _0xcc16e9=_0x2e8c1b,_0x476a6f={'JFmvt':function(_0x351f0e){return _0x351f0e();},'KSsUg':function(_0x22809c){return _0x22809c();}};questionStates[currentQuestionIndex][_0xcc16e9(0x385)]=!questionStates[currentQuestionIndex]['markedForReview'],_0x476a6f[_0xcc16e9(0x289)](updateMarkReviewButton),_0x476a6f[_0xcc16e9(0x346)](updateQuestionNav);}function updateMarkReviewButton(){const _0xf9972e=_0x2e8c1b,_0x4d8c2b={'JYpzh':'markReviewBtn','nbQGf':_0xf9972e(0x29a),'hykPL':_0xf9972e(0x3e9),'gHzOo':_0xf9972e(0x3f7)},_0x3926e6=document[_0xf9972e(0x2e5)](_0x4d8c2b[_0xf9972e(0x2bb)]),_0x53a96a=document[_0xf9972e(0x2e5)](_0x4d8c2b[_0xf9972e(0x3c7)]),_0x4bea11=questionStates[currentQuestionIndex]['markedForReview'];_0x3926e6['className']=_0x4bea11?_0x4d8c2b['hykPL']:'glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-purple-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center',_0x53a96a['textContent']=_0x4bea11?_0x4d8c2b[_0xf9972e(0x181)]:'Mark\x20for\x20Review';}function previousQuestion(){const _0x621de8=_0x2e8c1b,_0x6ac5fd={'aAwaM':function(_0x4d65f2,_0x3724f0,_0xcc0ec4){return _0x4d65f2(_0x3724f0,_0xcc0ec4);},'rPReC':'completed','SOubn':'userHistory','AfqjG':function(_0x365a3b,_0x500357){return _0x365a3b>_0x500357;},'lWpoC':function(_0x40d3b3,_0x3bed45){return _0x40d3b3===_0x3bed45;},'hnqtF':'pXtqn','iQKRy':function(_0x431bda,_0x1a17bd){return _0x431bda!==_0x1a17bd;},'ExgfD':'HkHwO','pbcKG':_0x621de8(0x3b5),'DeLvp':function(_0x27ccb2,_0x1e8791){return _0x27ccb2-_0x1e8791;},'wskyD':function(_0x4def74){return _0x4def74();}};if(_0x6ac5fd['AfqjG'](currentQuestionIndex,0x0)){if(_0x6ac5fd[_0x621de8(0x1df)](_0x6ac5fd[_0x621de8(0x489)],_0x6ac5fd[_0x621de8(0x489)])){if(questionStartTime){if(_0x6ac5fd[_0x621de8(0x376)](_0x6ac5fd[_0x621de8(0x4ac)],_0x6ac5fd[_0x621de8(0x2cf)]))questionStates[currentQuestionIndex][_0x621de8(0x3ae)]+=_0x6ac5fd[_0x621de8(0x408)](Date[_0x621de8(0x389)](),questionStartTime);else{const _0x2ad9c3=_0xad2f7d[_0x621de8(0x2b7)]['src'];if(_0x2ad9c3&&_0x2ad9c3[_0x621de8(0x341)]('.m3u8'))_0x6ac5fd[_0x621de8(0x1bb)](_0x1c33e0,_0x5b9e42,_0x2ad9c3);else _0x2ad9c3&&(_0x45de1c['src']=_0x2ad9c3);}}currentQuestionIndex--,displayQuestion(),_0x6ac5fd[_0x621de8(0x494)](saveProgress);}else{const _0x41a294=_0x3b6302['parse'](_0x3349a6['getItem'](_0x621de8(0x26b)))||{},_0x633108=_0x589fc5[_0x621de8(0x3af)],_0x75ce81=_0x477f92[_0x621de8(0x49e)]||0x0;_0x41a294[_0x495e08]={'score':_0x75ce81,'total':_0x633108,'status':_0x6ac5fd[_0x621de8(0x277)],'completedOn':new _0x2081ea()[_0x621de8(0x409)]()},_0xb1d138[_0x621de8(0x34a)](_0x6ac5fd['SOubn'],_0x305167[_0x621de8(0x182)](_0x41a294));}}}function nextQuestion(){const _0x4eb069=_0x2e8c1b,_0x10b7bd={'QNkCi':'5|0|3|2|4|1','WhVph':'quizHierarchy','EzdiH':'\x20>\x20','HqvJv':function(_0x1138d0,_0x1f76c3){return _0x1138d0+_0x1f76c3;},'RpsDh':'totalQuestions','ilQhZ':function(_0x3ec0fe){return _0x3ec0fe();},'ydsSY':function(_0x622721,_0x305128){return _0x622721(_0x305128);},'NAiKp':_0x4eb069(0x1d0),'ugZbv':function(_0x335f4b){return _0x335f4b();},'nPHVl':_0x4eb069(0x465),'dYZYB':_0x4eb069(0x23d),'GXDJr':_0x4eb069(0x3dd),'qbzVp':_0x4eb069(0x295),'veuDc':function(_0x367c43,_0x356c01){return _0x367c43-_0x356c01;},'IWYhr':function(_0x5f33c0,_0x5671d4){return _0x5f33c0-_0x5671d4;},'VTLwr':function(_0x206d0f){return _0x206d0f();},'TImZN':function(_0x5846ab){return _0x5846ab();},'QPmOA':'timed_exam','fAAjA':function(_0x4f0419,_0x3e7e8e){return _0x4f0419(_0x3e7e8e);},'ZfCBG':function(_0x108b4e,_0x503ddc){return _0x108b4e===_0x503ddc;},'kgWBv':_0x4eb069(0x38d),'tQZbh':function(_0x530d3d){return _0x530d3d();},'oMywW':function(_0x3e715f,_0xe31370){return _0x3e715f===_0xe31370;},'Zsxzz':_0x4eb069(0x273),'AmxUr':function(_0x2571f6,_0x323b80){return _0x2571f6!==_0x323b80;},'VijuJ':'RKPOY','uoZxC':_0x4eb069(0x3db)};questionStartTime&&(questionStates[currentQuestionIndex][_0x4eb069(0x3ae)]+=_0x10b7bd[_0x4eb069(0x29d)](Date['now'](),questionStartTime));if(currentQuestionIndex<_0x10b7bd[_0x4eb069(0x2d1)](questionsData[_0x4eb069(0x3af)],0x1))currentQuestionIndex++,_0x10b7bd[_0x4eb069(0x38e)](displayQuestion),_0x10b7bd[_0x4eb069(0x1d2)](saveProgress);else{if(currentMode==='test'||currentMode===_0x10b7bd['QPmOA']){if(_0x10b7bd[_0x4eb069(0x31b)](confirm,_0x4eb069(0x411))){if(_0x10b7bd['ZfCBG'](_0x10b7bd[_0x4eb069(0x491)],_0x10b7bd[_0x4eb069(0x491)]))_0x10b7bd[_0x4eb069(0x281)](submitQuiz);else{const _0x15f208=_0x10b7bd['QNkCi']['split']('|');let _0x3d91a3=0x0;while(!![]){switch(_0x15f208[_0x3d91a3++]){case'0':_0x56fb35=_0x1610ca[_0x4eb069(0x413)];continue;case'1':_0xe3aa03[_0x4eb069(0x2e5)](_0x10b7bd[_0x4eb069(0x3b4)])[_0x4eb069(0x2a5)]=_0x218278[_0x4eb069(0x2f3)](_0x10b7bd[_0x4eb069(0x205)]);continue;case'2':_0xfa2605[_0x4eb069(0x41f)]=_0x10b7bd['HqvJv'](_0x5070cd,_0x4eb069(0x2fe));continue;case'3':_0x3f57cc=_0x4c1643[_0x4eb069(0x391)];continue;case'4':_0x318315[_0x4eb069(0x2e5)](_0x10b7bd[_0x4eb069(0x1cb)])[_0x4eb069(0x2a5)]=_0x2ff5eb['length'];continue;case'5':_0x50490f=_0x365b75[_0x4eb069(0x2a2)];continue;}break;}}}}else{if(_0x10b7bd[_0x4eb069(0x169)](_0x4eb069(0x370),_0x4eb069(0x370)))_0x10b7bd[_0x4eb069(0x2df)](confirm,_0x10b7bd[_0x4eb069(0x4a3)])&&(_0x10b7bd['AmxUr'](_0x10b7bd[_0x4eb069(0x2a6)],_0x10b7bd[_0x4eb069(0x3bd)])?(currentQuestionIndex=0x0,_0x10b7bd['TImZN'](displayQuestion),saveProgress()):(_0x5ca99a++,_0x10b7bd['ilQhZ'](_0x452248),_0x10b7bd[_0x4eb069(0x1ea)](_0x3676a5)));else{let _0x55516d;try{const _0x3a1583=UqvAqu[_0x4eb069(0x2df)](_0x40633b,UqvAqu[_0x4eb069(0x297)](UqvAqu[_0x4eb069(0x297)]('return\x20(function()\x20',UqvAqu[_0x4eb069(0x3ec)]),');'));_0x55516d=UqvAqu['ugZbv'](_0x3a1583);}catch(_0x421caa){_0x55516d=_0x4c714a;}const _0x3add37=_0x55516d['console']=_0x55516d[_0x4eb069(0x3fc)]||{},_0x4fe92d=[UqvAqu[_0x4eb069(0x3de)],UqvAqu[_0x4eb069(0x252)],UqvAqu[_0x4eb069(0x418)],_0x4eb069(0x39b),UqvAqu[_0x4eb069(0x18a)],'table','trace'];for(let _0x2a3577=0x0;_0x2a3577<_0x4fe92d[_0x4eb069(0x3af)];_0x2a3577++){const _0x52a710=_0xe94e02[_0x4eb069(0x26c)]['prototype'][_0x4eb069(0x47f)](_0x3c5e93),_0x2b380f=_0x4fe92d[_0x2a3577],_0x3af839=_0x3add37[_0x2b380f]||_0x52a710;_0x52a710[_0x4eb069(0x3bf)]=_0x333ceb[_0x4eb069(0x47f)](_0x487ef6),_0x52a710[_0x4eb069(0x1f7)]=_0x3af839['toString'][_0x4eb069(0x47f)](_0x3af839),_0x3add37[_0x2b380f]=_0x52a710;}}}}}function startTimer(){const _0x586890=_0x2e8c1b,_0x16c4f3={'sQCvm':_0x586890(0x2e9),'PloIk':function(_0x336107,_0x45eb1d){return _0x336107<_0x45eb1d;},'HSTAQ':_0x586890(0x173),'bPWqL':function(_0x1a44e1,_0x1557b4){return _0x1a44e1+_0x1557b4;},'bmGTM':_0x586890(0x3f8),'rzuIx':function(_0x1adc5f){return _0x1adc5f();},'JSofN':_0x586890(0x486),'edEQd':_0x586890(0x43f),'mFOXw':function(_0x36a622,_0x2861df){return _0x36a622<=_0x2861df;},'EuUSt':function(_0x318e2f,_0x1dbe44){return _0x318e2f(_0x1dbe44);},'TeaCw':function(_0xc0307d,_0x18f7d3){return _0xc0307d===_0x18f7d3;},'WoHFd':_0x586890(0x309),'sBjvI':function(_0x34c10c,_0x106a86){return _0x34c10c!==_0x106a86;},'lyGRT':_0x586890(0x274),'SxhVe':function(_0x76c585,_0x19027a,_0x383144){return _0x76c585(_0x19027a,_0x383144);}};if(timer)clearInterval(timer);timeRemaining=0x78,_0x16c4f3[_0x586890(0x3bc)](updateTimerDisplay),timer=_0x16c4f3['SxhVe'](setInterval,()=>{const _0x2c399a=_0x586890,_0x3ba7f0={'bZftZ':_0x2c399a(0x26b),'PknLv':_0x16c4f3[_0x2c399a(0x21b)]};if(_0x16c4f3[_0x2c399a(0x420)]===_0x16c4f3[_0x2c399a(0x420)]){timeRemaining--,updateTimerDisplay();if(_0x16c4f3[_0x2c399a(0x1d6)](timeRemaining,0x0)){_0x16c4f3[_0x2c399a(0x25c)](clearInterval,timer);if(_0x16c4f3[_0x2c399a(0x485)](currentMode,_0x16c4f3[_0x2c399a(0x203)]))_0x16c4f3[_0x2c399a(0x3bc)](submitQuiz);else{if(_0x16c4f3[_0x2c399a(0x1fc)](_0x2c399a(0x1ee),_0x16c4f3[_0x2c399a(0x3d0)]))nextQuestion();else{if(_0x19302f)return;const _0x1031ad=_0x3d7667[_0x2c399a(0x4a8)](_0x55812b[_0x2c399a(0x1cd)](_0x3ba7f0['bZftZ']))||{};_0x1031ad[_0xdc269a]={'questionStates':_0x416da8,'stats':_0x305331,'currentQuestionIndex':_0x467cea,'currentMode':_0x2cb94a,'status':_0x3ba7f0['PknLv'],'lastSeen':new _0x416df6()['toISOString']()},_0x211291['setItem'](_0x2c399a(0x26b),_0x1df0fa['stringify'](_0x1031ad));}}}}else{const _0x547001=_0x16f424[_0x2c399a(0x2e5)](_0x16c4f3['sQCvm']);_0x547001['innerHTML']='';for(let _0x520345=0x0;_0x16c4f3['PloIk'](_0x520345,_0x57e2ab[_0x2c399a(0x3af)]);_0x520345++){const _0x2c21a9=_0x24e10b[_0x2c399a(0x253)](_0x16c4f3['HSTAQ']);_0x2c21a9[_0x2c399a(0x2a5)]=_0x16c4f3['bPWqL'](_0x520345,0x1),_0x2c21a9[_0x2c399a(0x334)]=_0x16c4f3['bmGTM'],_0x2c21a9[_0x2c399a(0x397)]=()=>_0x1eb5d6(_0x520345),_0x2c21a9['id']=_0x2c399a(0x463)+_0x520345,_0x547001[_0x2c399a(0x22e)](_0x2c21a9);}_0x16c4f3[_0x2c399a(0x3bc)](_0xd2b865);}},0x3e8);}function updateTimerDisplay(){const _0x561292=_0x2e8c1b,_0x206e75={'dkdLP':function(_0xa50733,_0xeacc08){return _0xa50733/_0xeacc08;},'jYjUm':function(_0x17f87a,_0x1a9541){return _0x17f87a%_0x1a9541;},'jOFJH':function(_0x42cdcb,_0x3892dd){return _0x42cdcb+_0x3892dd;}},_0x1d1ee1=Math[_0x561292(0x469)](_0x206e75[_0x561292(0x171)](timeRemaining,0x3c)),_0x123036=_0x206e75[_0x561292(0x324)](timeRemaining,0x3c);document[_0x561292(0x2e5)]('timeDisplay')[_0x561292(0x2a5)]=_0x206e75[_0x561292(0x1d3)](_0x1d1ee1,':')+_0x123036[_0x561292(0x1f7)]()[_0x561292(0x2b3)](0x2,'0');}function _0x53f1(){const _0x707631=['JNcYV','ontxI','<p><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22><strong>Acetazolamide\x20</strong>is\x20used\x20in\x20all\x20the\x20above\x20conditions<strong>\x20except\x20chronic\x20kidney\x20disease</strong>\x20(CKD).</span></p>\x0a<p><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22>Acetazolamide\x20is\x20not\x20typically\x20used\x20in\x20patients\x20with\x20chronic\x20kidney\x20disease\x20(CKD),\x20especially\x20those\x20with\x20advanced\x20kidney\x20disease.\x20Since\x20acetazolamide\x20relies\x20on\x20<strong>renal\x20excretion</strong>,\x20impaired\x20kidney\x20function\x20can\x20lead\x20to\x20drug\x20accumulation\x20and\x20increase\x20the\x20risk\x20of\x20metabolic\x20acidosis,\x20which\x20is\x20already\x20a\x20concern\x20in\x20CKD\x20patients.\x20Additionally,\x20its\x20diuretic\x20effect\x20is\x20weak\x20compared\x20to\x20other\x20diuretics\x20and\x20is\x20generally\x20not\x20helpful\x20in\x20managing\x20CKD-related\x20issues.\x20Thus,\x20acetazolamide\x20is\x20generally\x20avoided\x20in\x20CKD\x20patients\x20due\x20to\x20potential\x20complications\x20and\x20limited\x20benefit.</span></p>\x0a<p><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22>Therapeutic\x20uses\x20of\x20acetazolamide:</span></p>\x0a<ul>\x0a<li><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22>Glaucoma</span></li>\x0a<li><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22><strong>Epilepsy</strong></span></li>\x0a<li><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22>Altitude\x20sickness</span></li>\x0a<li><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22><strong>Diuretic\x20resistance</strong></span></li>\x0a<li><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22>Metabolic\x20alkalosis</span></li>\x0a<li><span\x20style=\x22font-family:\x20arial,\x20helvetica,\x20sans-serif;\x22><strong>Familial\x20periodic\x20paralysis</strong></span></li>\x0a</ul>','fAAjA','EBfXX','\x22\x20controls\x20class=\x22w-full\x20rounded-lg\x22></video></div>','Water-soluble\x20reversible\x20inhibitor\x20of\x20acetylcholinesterase','fadbx','TzEmV','hmKmC','MfyQV','Phenylephrine','jYjUm','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22mb-4\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22flex\x20justify-between\x20items-center\x20mb-3\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h4\x20class=\x22text-lg\x20font-bold\x20text-white\x22>Question\x20','Linezolid','Dantrolene','<p>Among\x20the\x20given\x20drugs,\x20<strong>guaifenesin</strong>\x20is\x20an\x20<strong>expectorant\u00a0</strong>used\x20in\x20productive\x20cough.</p>\x0a<p><strong>Guaifenesin</strong>\x20is\x20an\x20<strong>expectorant</strong>\x20that\x20helps\x20to\x20<strong>thin\x20</strong>and<strong>\x20loosen\x20mucus</strong>,\x20making\x20it\x20<strong>easier\x20to\x20clear</strong>\x20from\x20the\x20airways\x20through\x20coughing.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Acetylcysteine</strong>\x20is\x20a\x20<strong>mucolytic\x20</strong>agent\x20that\x20reduces\x20the\x20viscosity\x20of\x20mucus,\x20but\x20is\x20not\x20an\x20expectorant.</p>\x0a<p>Option\x20C:\x20<strong>Bromhexine</strong>\x20is\x20also\x20a\x20<strong>mucolytic\x20</strong>agent<strong>\x20</strong>and<strong>\x20</strong>is<strong>\x20</strong>not\x20an\x20expectorant.</p>\x0a<p>Option\x20D:\x20<strong>Dornase\x20alfa</strong>\x20is\x20used\x20to\x20<strong>break\x20down\x20DNA\x20in\x20mucus</strong>,\x20primarily\x20for\x20patients\x20with\x20cystic\x20fibrosis,\x20and\x20is\x20not\x20classified\x20as\x20an\x20expectorant.</p>','ttnxS','tVPIZ','Idghs','nZkuT','solutionContainer','It\x20increases\x20risk\x20of\x20urinary\x20tract\x20infections','0.4\x20-\x200.8','SulfF','StBBy','1-c,\x202-d,\x203-a,\x204-b','reduce','className','quizFile','add','lvrTb','Precapillary\x20constriction\x20and\x20reflex\x20post\x20capillary\x20dilation','bookmarkedQuestions','Chloramphenicol','Epilepsy','ugFXx','A\x2040-year-old\x20male\x20patient\x20has\x20been\x20prescribed\x20a\x20drug\x20that\x20catalyzes\x20the\x20enzymatic\x20oxidation\x20of\x20uric\x20acid\x20into\x20allantoin\x20for\x20the\x20treatment\x20of\x20his\x20chronic\x20gout.\x20What\x20is\x20this\x20drug?','JOlNh','reviewQuestionsContainer','Ustekinumab','includes','IpzNO','Dolutegravir','kzIgU','click','KSsUg','endsWith','ujxIj','Papaverine','setItem','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</button>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','KgyNU','viqiz','Inhibition\x20of\x20mTOR','dZbQo','<p><strong>Cycloserine</strong>\x20is\x20likely\x20to\x20have\x20caused\x20features\x20of\x20<strong>frank\x20psychosis</strong>.</p>\x0a<p>It\x20is\x20an\x20<strong>oral</strong>\u00a0<strong>second-line\x20antitubercular\x20drug</strong>\x20that\x20inhibits\x20<em>M.\x20tuberculosis</em>\u00a0and,\x20according\x20to\x20RNTCP\x20guidelines,\x20is\x20given\x20during\x20the\x20<strong>intensive\x20phase</strong>\x20of\x20treating\x20<strong>multi-drug\x20resistant\x20TB</strong>.</p>\x0a<p>This\x20drug\x20has\x20the\x20nickname,\x20<strong>pych-serine</strong>,\x20due\x20to\x20its\x20strong\x20association\x20with\x20<strong>neuropsychiatric</strong>\x20adverse\x20effects.\x20Symptoms\x20range\x20from\x20headache\x20and\x20somnolence\x20to\x20severe\x20<strong>psychosis,</strong>\x20seizures,\x20and\x20suicidal\x20ideas.\u00a0Therefore,\x20it\x20is\x20contraindicated\x20in\x20epilepsy\x20and\x20given\x20with\x20caution\x20in\x20patients\x20with\x20depression.\x20<strong>Pyridoxine\x20100\x20mg/day</strong>\x20should\x20be\x20given\x20to\x20<strong>reduce\x20neuropsychiatric</strong>\x20symptoms.</p>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Options\x20A\x20and\x20C:\x20<strong>Amikacin</strong>\x20(aminoglycoside)\x20and\x20<strong>capreomycin</strong>\x20(cyclic\x20peptide\x20analogue)\x20are<strong>\x20injectables</strong>\x20that\x20are\x20also\x20used\x20as\x20<strong>second-line\x20antitubercular\x20drugs</strong>.\x20They\x20cause\x20ototoxicity\x20and\x20nephrotoxicity.\u00a0</p>\x0a<p>Option\x20D:\x20<strong>Rifampicin</strong>\x20is\x20a\x20<strong>first-line\x20anti-TB\x20drug</strong>\x20that\x20is\x20used\x20to\x20treat\x20<strong>drug-sensitive</strong>\x20TB.\x20Other\x20first-line\x20drugs\x20include\x20<strong>isoniazid</strong>,\x20<strong>pyrazinamide</strong>,\x20and\x20<strong>ethambutol</strong>.\u00a0</p>','Cyclosporine','location','RXmKf','XYUTp','eAwuH','Which\x20of\x20the\x20following\x20nomograms\x20is\x20used\x20for\x20paracetamol\x20poisoning\x20?','<p>The\x20image\x20shows<strong>\x20pitting\x20pedal\x20edema</strong>\x20in\x20a\x20hypertensive\x20patient.\x20<strong>Calcium\x20channel\x20blockers\x20(CCBs)</strong>\x20like\x20<strong>amlodipine</strong>\x20are\x20most\x20likely\x20to\x20be\x20associated\x20with\x20peripheral\x20edema.\u00a0CCB-induced\x20peripheral\x20edema\x20occurs\x20due\x20to\x20a\x20disproportionate\x20decrease\x20in\x20the\u00a0arteriolar\x20resistance\x20than\x20in\x20the\x20venous\x20circulation,\x20resulting\x20in\x20increased\u00a0hydrostatic\x20pressure\x20in\x20the\x20precapillary\x20circulation.\x20This\x20leads\x20to\x20a\x20fluid\x20shift\u00a0into\x20the\x20interstitial\x20compartment\x20causing\x20edema.</p>\x0a<p>The\x20frequency\x20of\x20CCB-induced\x20peripheral\x20edema\x20is\x20both\x20<strong>drug-specific</strong>\x20(i.e\x20more\x20potent\x20drugs\x20like\x20amlodipine\x20will\x20be\x20associated\x20with\x20higher\x20rates\x20of\x20developing\x20edema)\x20and\x20<strong>dose-dependent</strong>\x20(i.e\x20incidence\x20of\x20edema\x20increases\x20with\x20an\x20increase\x20in\x20drug\x20dosage\x20and\x20chronicity\x20of\x20its\x20usage).\x20It\x20is\x20more\x20common\x20among\x20<strong>females.</strong></p>\x0a<p>Treatment:</p>\x0a<ul>\x0a<li>Dose\x20reduction</li>\x0a<li>Interclass\x20switching\x20of\x20CCB\x20-\x20switch\x20to\x20non-dihydropyridines\x20like\x20verapamil,\x20and\x20diltiazem</li>\x0a<li>Addition\x20of\x20a\x20venodilator\x20-\x20ACE\x20inhibitor,\x20ARBs,\x20Nitrates</li>\x0a<li>Others\x20-\x20compression\x20stockings,\x20avoiding\x20prolonged\x20upright\x20position</li>\x0a<li>Definitive\x20treatment\x20would\x20be\x20discontinuation\x20of\x20the\x20CCB\x20and\x20switching\x20to\x20another\x20class\x20of\x20antihypertensives</li>\x0a</ul>','bookmarkText','5wlcHgM','<p>The\x20dosing\x20rate\x20in\x20this\x20patient\x20is\u00a0<strong>60\x20ng/min.</strong></p>\x0a<p>The\x20<strong>oral\x20bioavailability\x20of\x20digoxin\x20is\x2070%\x20(F\x20=\x200.7)</strong>\x20and\x20the\x20required\x20target\x20plasma\x20concentration\x20(Cp)\x20is\x20<strong>0.70\x20ng/mL</strong>.\x20<strong>CL</strong>\x20is\x20the\x20clearance\x20of\x20digoxin\x20which\x20is\u00a060\x20mL/min.</p>\x0a<p>Hence,\x20the\x20appropriate\x20dose\x20rate\x20for\x20this\x20patient\x20can\x20be\x20calculated\x20as:</p>\x0a<p><strong>Dosing\x20rate\x20=\x20Target\x20Cp\x20x\x20CL/F</strong></p>\x0a<p>=\x20[0.70\x20ng/mL\x20×\x2060\x20mL/min]\x20÷\x20[0.7]</p>\x0a<p>=\x20<strong>60\x20ng/min</strong></p>','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish:</p><audio\x20src=\x22','No\x20solution\x20provided','statsBar','Inhalation','https://dhmbxeygs57ff.cloudfront.net/uploads/c1c5288ebe8f4f18af77726317f3d045x856x672.PNG','It\x20acts\x20by\x20inhibiting\x20SGLT-2\x20transporter\x20on\x20distal\x20convoluted\x20tubule','noHDl','correct','get','LFtXS','sFZrf','qdyHU','XpNEE','<p>The\x20anticoagulant\x20of\x20choice\x20for\x20the\x20management\x20of<strong>\x20cancer-associated\x20thromboembolism</strong>\x20is\x20<strong>l</strong><strong>ow-molecular-weight\x20heparin\x20</strong>(LMWH).\x20It\x20is\x20the\x20preferred\x20agent\x20because\x20of\x20more\x20<strong>bioavailability,\x20lack</strong>\x20of\x20<strong>need</strong>\x20for\x20<strong>anticoagulant\x20monitoring,</strong>\x20and\x20a\x20<strong>long\x20t1/2.\u00a0</strong></p>\x0a<p>Venous\x20thromboembolism\x20(including\x20deep\x20vein\x20thrombosis,\x20pulmonary\x20embolism,\x20and\x20splanchnic\x20vein\x20thrombosis),\x20is\x20a\x20frequent\x20complication\x20of\x20cancer\x20and\x20is\x20the\x20second-leading\x20cause\x20of\x20death\x20in\x20cancer\x20patients\x20receiving\x20chemotherapy.</p>\x0a<p>Based\x20on\x20the\x20results\x20from\x20the\u00a0<strong>C</strong>omparison\x20of\x20<strong>L</strong>ow-molecular-weight\u00a0heparin\x20vs.\u00a0<strong>O</strong>ral\x20anticoagulants\x20for\x20long-term\x20anticoagulation\x20in\x20cancer\x20patients\x20with\x20venous\x20<strong>T</strong>hromboembolism\x20(<strong>CLOT</strong>)\x20Trial,\x20all\x20recent\x20guidelines\x20now\x20advise\x20LMWH\x20for\x20cancer-associated\x20thromboembolism.\u00a0</p>\x0a<p>However,\x20unfractionated\x20heparin\x20<strong>(UFH)</strong>\x20can\x20be\x20used\x20in\x20patients\x20with\x20<strong>renal\x20failure</strong>,\x20and\x20<strong>fondaparinux</strong>\x20can\x20be\x20considered\x20in\x20patients\x20with\x20heparin-induced\x20thrombocytopenia\x20(<strong>HIT</strong>).</p>','totalQuestions','Lansoprazole','XUolu','Inhibition\x20of\x20TNF-α','Are\x20you\x20sure\x20you\x20want\x20to\x20retake\x20the\x20quiz?\x20This\x20will\x20reset\x20all\x20your\x20answers.','<p>The\x20given\x20scenario\x20is\x20suggestive\x20of\x20<strong>multiple\x20sclerosis.&nbsp;</strong><strong>Interferon\x20beta</strong>\x20is\x20approved\x20for\x20use\x20in\x20this\x20condition.\x20It\x20reduces\x20the\x20frequency\x20of\x20attacks\x20in\x20relapsing-remitting\x20multiple\x20sclerosis.</p>\x0a<p>The\x20probable\x20mechanisms\x20of\x20action\x20of\x20interferon-beta\x20are:</p>\x0a<ul>\x0a<li>Immune\x20modulation\x20and\x20a\x20decrease\x20in\x20T\x20cell\x20proliferation.</li>\x0a<li>Limiting\x20the\x20entry\x20of\x20T\x20cells\x20into\x20CNS.</li>\x0a<li>Reducing\x20pro-inflammatory\x20and\x20increasing\x20regulatory\x20cytokines.</li>\x0a</ul>','uFHjm','tPznT','yXVJP','MqKab','Quinidine','qCnuE','dIMlt','iQKRy','nav-btn-not-attempted\x20hover:bg-white\x20hover:bg-opacity-20','Cocaine','Dapagliflozin','JXomO','Cisapride','fmtWI','PoNWe','yqjIz','BFWkm','A\x2050-year-old\x20male\x20patient\x20was\x20diagnosed\x20with\x20pulmonary\x20artery\x20hypertension.\x20He\x20was\x20prescribed\x20an\x20endothelin\x20receptor\x20antagonist\x20for\x20the\x20management\x20of\x20the\x20same.\x20After\x20starting\x20the\x20drug,\x20he\x20developed\x20nasal\x20congestion\x20and\x20pharyngitis.\x20Which\x20of\x20the\x20following\x20drugs\x20was\x20prescribed?','<div\x20class=\x22mt-4\x22><img\x20src=\x22','A\x20patient\x20with\x20endometrial\x20cancer\x20comes\x20with\x20pain\x20in\x20her\x20right\x20calf\x20which\x20is\x20confirmed\x20to\x20be\x20a\x20thrombus\x20by\x20USG.\x20Which\x20of\x20the\x20following\x20is\x20preferred\x20to\x20be\x20used\x20in\x20her\x20to\x20prevent\x20propagation\x20of\x20the\x20clot\x20and\x20why?','ZcqmT','Match\x20the\x20following\x20chemotherapeutic\x20agents\x20with\x20their\x20adverse\x20effects.','markedForReview','QJQgJ','TDujx','UDzGz','now','Anastrozole','study','chCon','QcftM','VTLwr','<p><strong>Neostigmine\x20</strong>is\x20the\x20drug\x20given\x20postoperatively\x20to\x20recover\x20from\x20muscle\x20weakness,\x20which\x20is\x20a\x20<strong>water-soluble\x20reversible\x20inhibitor\x20of\x20acetylcholinesterase</strong>.</p>\x0a<p><strong>Non-depolarizing\x20muscle\x20relaxants</strong>\x20(NDMRs)\x20act\x20mainly\x20by\x20the\x20<strong>competitive\x20antagonism</strong>\x20of\x20nicotinic\x20(Nm)\x20receptors.\x20<strong>Neostigmine</strong>\x20inhibits\x20acetylcholinesterase\x20and\x20inhibits\x20the\x20degradation\x20of\x20acetylcholine.\x20The\x20increased\x20accumulation\x20of\x20undegraded\x20acetylcholine\x20can\x20effectively\x20compete\x20with\x20NDMRs,\x20thereby\x20displacing\x20them\x20from\x20the\x20site\x20and\x20antagonising\x20their\x20effects.</p>\x0a<p>Neostigmine\x20is\x20a\x20<strong>quaternary\x20ammonium\x20compound</strong>\x20that\x20results\x20in\x20a\x20permanently\x20charged\x20molecule\x20that\x20<strong>cannot\x20cross\x20the\x20blood-brain\x20barrier</strong>,\x20so\x20its\x20effects\x20are\x20limited\x20to\x20peripheral\x20tissues.\u00a0</p>\x0a<p>Neostigmine\x20is\x20most\x20commonly\x20used\x20in\x20the\x20management\x20of\x20myasthenia\x20gravis.\u00a0</p>\x0a<p>Other\x20therapeutic\x20uses\x20of\x20neostigmine:\u00a0</p>\x0a<ul>\x0a<li>Postoperative\x20decurarization</li>\x0a<li>Cobra\x20bite</li>\x0a<li>Belladonna\x20poisoning</li>\x0a<li>Postoperative\x20paralytic\x20ileus</li>\x0a</ul>','It\x20also\x20has\x20anti-epileptic\x20activity','hierarchy','70\x20ng/min','VpXZH','A\x2045-year-old\x20woman\x20with\x20type\x202\x20diabetes\x20mellitus\x20is\x20being\x20treated\x20with\x20oral\x20antidiabetic\x20drugs.\x20She\x20has\x20a\x20history\x20of\x20hypothyroidism\x20and\x20is\x20on\x20levothyroxine\x20therapy.\x20Routine\x20blood\x20tests\x20reveal\x20low\x20TSH\x20levels\x20and\x20normal\x20free\x20T4\x20and\x20T3\x20levels.\x20Which\x20of\x20the\x20following\x20drugs\x20may\x20be\x20responsible\x20for\x20this\x20patient\x27s\x20blood\x20test\x20results?','Acetylcysteine','HgaLy','onclick','Glibenclamide','querySelectorAll','No\x20solution\x20available.','error','prototype','ZGfgN','zutjI','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English:</p><audio\x20src=\x22','0.6\x20-\x201.0','aqJAa','tVglL','Acetazolamide\x20is\x20used\x20in\x20all\x20the\x20following\x20conditions\x20except','<p><span\x20data-preserver-spaces=\x22true\x22>The\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>DAT</span></strong>(Dopamine\x20active\x20transporter)<strong><span\x20data-preserver-spaces=\x22true\x22>scan</span></strong><span\x20data-preserver-spaces=\x22true\x22>\x20image\x20shows\x20a\x20normal\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>comma-shaped</span></strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0pattern\x20of\x20the\x20striatal\x20nuclei,\x20which\x20rules\x20out\x20degenerative\x20parkinsonism,\x20suggesting\x20secondary\x20parkinsonism\x20such\x20as\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>drug</span></strong><span\x20data-preserver-spaces=\x22true\x22>-</span><strong><span\x20data-preserver-spaces=\x22true\x22>induced</span></strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>parkinsonism</span></strong><span\x20data-preserver-spaces=\x22true\x22>.\x20Among\x20the\x20given\x20options,\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>Benztropine</span></strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0can\x20be\x20used\x20for\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>drug-induced\x20parkinsonism\x20</span></strong><span\x20data-preserver-spaces=\x22true\x22>and\x20it\x20</span><span\x20data-preserver-spaces=\x22true\x22>is\x20an\x20</span><strong><span\x20data-preserver-spaces=\x22true\x22>anticholinergic.</span></strong></p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22><strong>Drug-induced\x20parkinsonism</strong>\x20is\x20a\x20condition\x20caused\x20by\x20certain\x20drugs\x20having\x20D2\x20antagonistic\x20action\x20(typical\x20antipsychotics).\x20The\x20decrease\x20in\x20dopaminergic\x20activity\x20results\x20in\x20an\u00a0</span><strong><span\x20data-preserver-spaces=\x22true\x22>unbalanced\x20cholinergic\x20activity</span></strong><span\x20data-preserver-spaces=\x22true\x22>.\x20Anticholinergics\x20act\x20by\x20restoring\x20balance.</span></p>\x0a<p><strong><span\x20data-preserver-spaces=\x22true\x22>Management\x20of\x20Drug-induced\x20Parkinsonism</span></strong></p>\x0a<p><span\x20data-preserver-spaces=\x22true\x22>There\x20are\x20two\x20approaches\x20to\x20managing\x20drug-induced\x20parkinsonism:\x20avoidance\x20or\x20discontinuation\x20of\x20known\x20causative\x20medications\x20and\x20symptomatic\x20treatment\x20of\x20parkinsonism.</span></p>\x0a<ol>\x0a<li><strong><span\x20data-preserver-spaces=\x22true\x22>Avoidance\x20or\x20discontinuation\x20of\x20the\x20drug</span></strong><span\x20data-preserver-spaces=\x22true\x22>-\x20The\x20best\x20way\x20to\x20treat\x20drug-induced\x20parkinsonism\x20is\x20to\x20avoid\x20using\x20causative\x20agents,\x20especially\x20in\x20high-risk\x20populations\x20such\x20as\x20older\x20adults.\x20Unfortunately,\x20this\x20is\x20not\x20always\x20possible,\x20as\x20some\x20patients\x20with\x20psychosis\x20need\x20to\x20be\x20treated\x20with\x20antipsychotic\x20agents.</span></li>\x0a<li><strong><span\x20data-preserver-spaces=\x22true\x22>Symptomatic\x20treatment-</span></strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0When\x20the\x20causative\x20agent\x20cannot\x20be\x20discontinued,\x20lowered,\x20or\x20switched\x20to\x20an\x20alternative\x20drug,\x20symptomatic\x20treatment\x20of\x20parkinsonism\x20may\x20be\x20considered\x20like:</span></li>\x0a</ol>\x0a<ul>\x0a<li><strong><span\x20data-preserver-spaces=\x22true\x22>Anticholinergic\x20-</span></strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0Benztropine</span></li>\x0a<li><span\x20data-preserver-spaces=\x22true\x22>Amantadine</span></li>\x0a<li><span\x20data-preserver-spaces=\x22true\x22>Levodopa</span></li>\x0a</ul>','vFAWI','-600\x20text-white\x22>','innerHTML','border-red-500','RJChz','qTMKS','An\x20HIV-positive\x20patient\x20was\x20started\x20on\x20antiretroviral\x20therapy.\x20These\x20drugs\x20belong\x20to\x20which\x20category?','QLOCk','Easac','timeSpent','length','A\x2035-year-old\x20woman\x20presents\x20with\x20persistent\x20loss\x20of\x20interest\x20in\x20going\x20to\x20work,\x20insomnia,\x20fatigue,\x20and\x20reduced\x20concentration\x20at\x20work\x20for\x20the\x20past\x203\x20weeks.\x20She\x20also\x20had\x20a\x20history\x20of\x20myocardial\x20infarction\x20a\x20year\x20ago.\x20Which\x20drug\x20is\x20preferred\x20for\x20the\x20management\x20of\x20this\x20patient?','wkWOq','Alprostadil','bQuVX','WhVph','InqGB','Marrow','FnFrY','ohIDu','TWqXM','Interferon\x20alpha','EsHDG','rzuIx','uoZxC','CTsWk','__proto__','closest','A\x20patient\x20is\x20diagnosed\x20with\x20gastroparesis.\x20Which\x20of\x20the\x20following\x20drugs\x20cannot\x20be\x20used\x20to\x20treat\x20this\x20condition?','https://dhmbxeygs57ff.cloudfront.net/uploads/b2b1e13fe6134e12b1862511d5f653abx1280x1424.JPEG','ZIYPc','JRtjT','nav-btn-correct','USxvR','nbQGf','<p>The\x20given\x20image\x20shows\x20<strong>gum\x20hyperplasia</strong>,\x20which\x20is\x20an\x20adverse\x20effect\x20most\x20likely\x20produced\x20by\x20<strong>cyclosporine</strong>.</p>\x0a<p>Other\x20drugs\x20that\x20cause\x20gum\x20hyperplasia\x20are:</p>\x0a<ul>\x0a<li><strong>Phenytoin</strong></li>\x0a<li><strong>Calcium\x20channel\x20blockers</strong></li>\x0a</ul>\x0a<p>Cyclosporine\x20is\x20an\x20<strong>immunomodulator</strong>\x20that\x20binds\x20with\x20the\x20<strong>cyclophilin</strong>\x20protein,\x20and\x20this\x20complex\x20<strong>inhibits</strong>\x20the\x20<strong>calcineurin</strong>\x20activity.\x20It\x20decreases\x20T-cell\x20activation\x20and\x20is\x20useful\x20in\x20T-cell-mediated\x20transplant\x20rejection.\x20It\x20is\x20useful\x20in\x20autoimmune\x20conditions\x20like\x20rheumatoid\x20arthritis,\x20psoriasis,\x20uveitis,\x20Behcet\x27s\x20disease,\x20atopic\x20dermatitis,\x20inflammatory\x20bowel\x20disease,\x20nephrotic\x20syndrome,\x20etc.\x20The\x20major\x20adverse\x20effects\x20are\x20as\x20follows:</p>\x0a<ul>\x0a<li><strong>Hirsutism</strong></li>\x0a<li><strong>Gum\x20hyperplasia</strong></li>\x0a<li><strong>Nephrotoxicity</strong></li>\x0a<li><strong>Hepatotoxicity</strong></li>\x0a<li><strong>Hypertension</strong></li>\x0a<li>Hyperlipidemia</li>\x0a<li>Hyperglycemia</li>\x0a<li>Hyperuricemia</li>\x0a<li>Altered\x20mental\x20status,\x20seizures</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:\x20<strong>Carbamazepine</strong>\x20is\x20an\x20antiepileptic\x20agent\x20used\x20in\x20the\x20treatment\x20of\x20generalised\x20tonic-clonic\x20seizures,\x20focal\x20seizures,\x20trigeminal\x20and\x20glossopharyngeal\x20neuralgias,\x20bipolar\x20disorder,\x20and\x20nephrogenic\x20diabetes\x20insipidus.\x20The\x20main\x20adverse\x20events\x20are\x20<strong>hepatotoxicity,</strong>\x20<strong>dilutional\x20hyponatremia,\x20</strong>hypersensitivity\x20reactions,\x20aplastic\x20anaemia,\x20and\x20agranulocytosis.</p>\x0a<p>Option\x20B:\x20<strong>Tacrolimus</strong>\x20is\x20a\x20macrolide\x20antibiotic\x20that\x20binds\x20to\x20<strong>FKBP-12</strong>\x20protein\x20(similar\x20to\x20cyclophilin)\x20and\x20<strong>inhibits\x20calcineurin</strong>\x20activity.\x20It\x20is\x20indicated\x20in\x20the\x20prophylaxis\x20of\x20solid-organ\x20allograft\x20rejection.\x20Some\x20of\x20the\x20adverse\x20effects\x20include\x20<strong>nephrotoxicity,\x20neurotoxicity</strong>,\x20hypertension,\x20and\x20hyperglycemia.</p>\x0a<p>Option\x20D:\x20<strong>Lamotrigine</strong>\x20is\x20an\x20antiepileptic\x20agent\x20used\x20in\x20focal\x20and\x20generalised\x20tonic-clonic\x20seizures\x20and\x20Lennox\x20Gestaut\x20syndrome.\x20The\x20adverse\x20effects\x20include\x20<strong>Stevens-Johnson\x20syndrome</strong>,\x20dizziness,\x20ataxia,\x20and\x20double\x20vision.</p>','KSDKs','totalTime','push','toLowerCase','<p>The\x20correct\x20option\x20is\x20option\x20C\x20i.e.\x20the\x20urine\x20will\x20have<strong>\x20increased</strong>\x20levels\x20of\x20<strong>chloride,\x20magnesium</strong>,\x20and\x20<strong>potassium</strong>\x20and\x20<strong>decreased</strong>\x20levels\x20of\x20<strong>urea</strong>.\u00a0</p>\x0a<p><strong>Indapamide</strong>\x20is\x20a<strong>\x20thiazide</strong>\x20diuretic\x20that\x20can\x20cause\x20increased\x20loss\x20of\x20chloride,\x20potassium,\x20and\x20magnesium\x20and\x20decreased\x20excretion\x20of\x20urea\x20in\x20urine.\x20Thus\x20resulting\x20in\x20<strong>hypokalemia,\x20hyperuricemia,\x20hypomagnesemia</strong>,\x20and\x20<strong>hypercalcemia</strong>\u00a0as\x20adverse\x20effects.</p>\x0a<p><strong>Thiazides</strong>\x20act\x20on\x20the\x20<strong>distal\x20convoluted\x20tubule</strong>\x20(DCT).\x20They\x20block\x20the\x20<strong>Na<sup>+</sup>/Cl<sup>-</sup>\x20co-transporter</strong>\x20in\x20the\x20DCT.\x20This\x20results\x20in\x20the\x20loss\x20of\x20sodium,\x20chloride,\x20and\x20water\x20contributing\x20to\x20the\x20diuretic\x20effect.</p>\x0a<p>The\x20diuretic\x20effect\x20of\x20thiazide\x20leads\x20to\x20<strong>decreased\x20osmotic\x20pressure</strong>\x20due\x20to\x20the\x20loss\x20of\x20Na<sup>+</sup>,\x20Cl<sup>-</sup>,\x20and\x20water\x20leading\x20to\x20compensatory\x20reabsorption\x20of\x20uric\x20acid\x20thus\x20resulting\x20in\x20<strong>hyperuricemia.</strong></p>\x0a<p>The\x20intracytoplasmic\x20Na<sup>+</sup>\x20concentration\x20also\x20decreases\x20due\x20to\x20the\x20blockade\x20of\x20the\x20co-transporter.\x20To\x20compensate,\x20the\x20<strong>Na<sup>+</sup>/Ca<sup>2+</sup>\x20exchanger</strong>\x20pumps\x20sodium\x20from\x20the\x20systemic\x20circulation\x20into\x20the\x20epithelial\x20cells\x20in\x20exchange\x20for\x20calcium.\x20The\x20declining\x20calcium\x20levels\x20inside\x20the\x20cell\x20will\x20draw\x20more\x20calcium\x20from\x20the\x20lumen\x20into\x20the\x20systemic\x20circulation.\x20This\x20results\x20in\x20<strong>hypercalcemia.</strong>\x20There\x20is\x20also\x20<strong>increased\x20loss</strong>\x20of\x20<strong>Mg<sup>2+</sup></strong>,\x20<strong>K<sup>+</sup></strong>,\x20and<strong>\x20H<sup>+</sup></strong>.</p>\x0a<p>Thiazides\x20are\x20the\x20diuretic\x20of\x20choice\x20for\x20<strong>uncomplicated\x20hypertension</strong>.</p>\x0a<p>The\x20advantages\x20of\x20thiazide\x20as\x20an\x20antihypertensive\x20are:</p>\x0a<ul>\x0a<li>It\x20can\x20be\x20given\x20as\x20once\x20a\x20day\x20dose\x20and\x20has\x20a\x20flat\x20dose-response\x20curve</li>\x0a<li>Decreased\x20incidence\x20of\x20postural\x20hypotension\x20and\x20relative\x20freedom\x20from\x20CNS\x20side\x20effects</li>\x0a<li>No\x20tolerance</li>\x0a<li>No\x20fluid\x20retention</li>\x0a<li>Decreased\x20risk\x20of\x20<strong>osteoporotic\x20fractures</strong>\x20due\x20to\x20its\x20<strong>hypocalciuric</strong>\x20action</li>\x0a<li>Low\x20cost</li>\x0a<li>Effectiveness\x20in\x20<strong>isolated\x20systolic\x20hypertension</strong></li>\x0a</ul>\x0a<p>Thiazides\x20are\x20ineffective\x20both\x20as\x20antihypertensive\x20and\x20diuretic\x20in\x20patients\x20with\x20chronic\x20renal\x20failure.</p>','NEET\x20PG\x20Test\x20Series\x20Subject\x20Wise','RYmvg','lyGRT','jvbxv','NCOoX','1331028Zprtct','Vancomycin','notAttemptedResult','nav-btn-marked-review','div','rgODI','pVCDN','reload','rQwFF','qZmkF','info','nPHVl','LDZPl','customQuizData','target','Cycloserine','\x22\x20controls\x20class=\x22w-full\x22></audio></div>','currentQuestion','It\x20can\x20cause\x20transient\x20leukopenia','Oral\x20ferrous\x20sulphate','VOMYq','PCSK-7\x20inhibition','gradient-purple\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','NMDA\x20receptor\x20antagonist','questionReviewSection','NAiKp','It\x20can\x20lead\x20to\x20hyponatremia\x20in\x20the\x20elderly','Colchicine','solutionAudio','0|5|1|3|4|2','Schedule\x20X\x20drugs','Efavirenz','ljzwN','A\x20diabetic\x20woman\x20who\x20did\x20not\x20respond\x20well\x20to\x20metformin\x20therapy\x20was\x20started\x20on\x20dapagliflozin.\x20Which\x20of\x20the\x20following\x20is\x20not\x20true\x20about\x20this\x20drug?','trace','OuiIF','Marked','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20transition-all\x20duration-200','nEqkp','ongnW','6649080oNkNVq','console','Low\x20molecular\x20weight\x20heparin,\x20more\x20bioavailability','<p><strong>Dapagliflozin\x20</strong>acts\x20by\x20<strong>inhibiting\x20</strong>the\x20<strong>SGLT2\x20transporter\x20</strong>present\x20on\x20the\x20<strong>proximal\x20segment\x20</strong>of\x20the\x20<strong>renal\x20tubule</strong>.\x20SGLT2\x20transporter\x20is\x20present\x20on\x20the\x20proximal\x20segment\x20of\x20the\x20renal\x20tubule\x20and\x20not\x20in\x20the\x20distal\x20convoluted\x20tubule.</p>\x0a<p>The\x20<strong>SGLT2\x20transporter</strong>\x20present\x20in\x20the\x20proximal\x20segment\x20of\x20the\x20renal\x20tubule\x20is\x20responsible\x20for\x20the\x20<strong>reabsorption</strong>\x20of\x20<strong>80-90%</strong>\x20of\x20<strong>filtered\x20glucose</strong>.\x20Dapagliflozin\x20acts\x20by\x20inhibiting\x20this\x20transporter\x20resulting\x20in\x20<strong>glycosuria</strong>\x20and\x20decreasing\x20the\x20blood\x20glucose\x20level.\x20This\x20drug\x20is\x20effective\x20<strong>orally</strong>.\x20This\x20drug\x20also\x20results\x20in\x20<strong>weight\x20loss</strong>.<br\x20/><br\x20/>Dapagliflozin\x20has\x20been\x20approved\x20by\x20the\x20FDA\x20for\x20the\x20treatment\x20of\x20heart\x20failure\x20in\x20both\x20diabetic\x20and\x20non-diabetic\x20patients.</p>\x0a<p>The\x20common\x20side\x20effects\x20of\x20dapagliflozin\x20include\x20<strong>urinary\x20tract\x20infections</strong>,\x20genital\x20mycotic\x20infections\x20due\x20to\x20the\x20high\x20glucose\x20content\x20of\x20the\x20urine,\x20and\x20also\x20<strong>increased</strong>\u00a0<strong>risk\x20</strong>of\x20<strong>fractures</strong>.</p>\x0a<p>Other\x20SGLT2\x20inhibitors\x20include\x20<strong>empagliflozin</strong>,\x20canagliflozin,\x20and\x20ertugliflozin.</p>\x0a<p>Empagliflozin\x20has\x20been\x20found\x20to\x20decrease\x20the\x20risk\x20of\x20mortality\x20from\x20cardiovascular\x20causes\x20in\x20diabetic\x20patients.</p>','1497722QeGyQC','Interferon\x20gamma','timed_study','A\x2066-year-old\x20man\x20presented\x20with\x20difficulty\x20in\x20urination\x20and\x20back\x20pain.\x20His\x20PSA\x20levels\x20were\x20found\x20to\x20be\x20elevated\x20and\x20the\x20x-ray\x20pelvis\x20revealed\x20two\x20osteoblastic\x20lesions\x20in\x20the\x20bony\x20pelvis.\x20Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20used\x20to\x20treat\x20the\x20given\x20condition?','zIZrm','<p>In\x20the\x20given\x20clinical\x20scenario,\x20the\x20presentations\x20of\x20loss\x20of\x20interest\x20in\x20going\x20to\x20work,\x20insomnia,\x20fatigue,\x20and\x20reduced\x20concentration\x20at\x20work\x20for\x203\x20weeks(&gt;\x202\x20weeks)\x20suggest\x20that\x20the\x20patient\x20is\x20suffering\x20from\x20<strong>depression</strong>.\x20<strong>Sertraline</strong>\u00a0is\x20the\x20preferred\x20drug\x20in\x20treating\x20<strong>depression</strong>\x20in\x20this\x20patient\x20with\x20a\x20<strong>history\x20of\x20myocardial\x20infarction</strong>\x20(MI),\x20as\x20it\x20is\x20<strong>cardio-safe</strong>.</p>\x0a<p><strong>Sertraline</strong>\x20is\x20a\x20<strong>selective\x20serotonin\x20reuptake\x20inhibitor</strong>\x20(SSRI).\x20SSRIs\x20are\x20generally\x20considered\x20<strong>safer</strong>\x20in\x20patients\x20with\x20a\x20history\x20of\x20cardiovascular\x20disease,\x20as\x20they\x20have\x20a\x20relatively\x20low\x20risk\x20of\x20cardiotoxicity.</p>\x0a<p><strong>Non-selective\x20serotonin\x20reuptake\x20inhibitors\x20</strong>are\x20usually\x20<strong>cardiotoxic</strong>.\u00a0</p>\x0a<p>\u00a0The\x20various\x20drug\x20classes\x20used\x20in\x20depression\x20and\x20anxiety\x20are\x20listed\x20below:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2046.1716%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Class\x20of\x20drugs</td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>Examples</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Selective\x20serotonin\x20reuptake\x20inhibitors\x20(SSRI)<br\x20/><br\x20/></td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>\x0a<ul>\x0a<li>Fluoxetine</li>\x0a<li>Fluvoxamine</li>\x0a<li>Paroxetine</li>\x0a<li><strong>Sertraline</strong></li>\x0a<li>Citalopram</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Serotonin-norepinephrine\x20reuptake\x20inhibitors<br\x20/>(non-selective)</td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>\x0a<ul>\x0a<li>Venlafaxine,\x20desvenlafaxine</li>\x0a<li><strong>Duloxetine</strong></li>\x0a<li>Milnacipran</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Tricyclic\x20antidepressants<br\x20/>(non-selective)</td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>\x0a<ul>\x0a<li><strong>Amitriptyline</strong></li>\x0a<li><strong>Imipramine</strong></li>\x0a<li>Nortriptyline</li>\x0a<li>Desipramine</li>\x0a<li>Amoxapine</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Atypical\x20antipsychotics<br\x20/><br\x20/></td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>\x0a<ul>\x0a<li>Aripiprazole</li>\x0a<li>Olanzapine</li>\x0a<li>Quetiapine</li>\x0a<li>Risperidone</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Monoamine\x20oxidase\x20inhibitors\x20(MAO)<br\x20/><br\x20/></td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>\x0a<ul>\x0a<li>Isocarboxazid</li>\x0a<li>Selegiline</li>\x0a<li>Phenelzine</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2029.96%;\x22>Atypical\x20antidepressants<br\x20/><br\x20/></td>\x0a<td\x20style=\x22width:\x2070.0416%;\x22>\x0a<ul>\x0a<li>Bupropion</li>\x0a<li>Trazodone</li>\x0a<li>Mirtazapine</li>\x0a<li>Mianserin</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Depression</strong>\x20or\x20major\x20depressive\x20disorder\x20is\x20a\x20mood\x20disorder\x20in\x20which\x20the\x20individual\x20experiences\x20<strong>at\x20least\x205</strong>\x20of\x20the\x20following\x20symptoms\x20during\x20<strong>2\x20weeks</strong>\x20and\x20is\x20a\x20change\x20from\x20previous\x20functioning\x20along\x20with\x20either\x20a\x20depressed\x20mood\x20or\x20a\x20loss\x20of\x20interest\x20or\x20pleasure.</p>\x0a<ul>\x0a<li><strong>Depressed\x20mood\x20</strong>most\x20of\x20the\x20day,\x20nearly\x20every\x20day\x20(feeling\x20sad,\x20empty,\x20hopeless)\x20or\x20as\x20an\x20observa­tion\x20made\x20by\x20others</li>\x0a<li>Markedly\x20<strong>diminished\x20interest</strong>\x20or\x20pleasure\x20in\x20all\x20or\x20almost\x20all\x20activities</li>\x0a<li>Significant\x20weight\x20loss/weight\x20gain\x20or\x20change\x20in\x20appetite</li>\x0a<li><strong>Insomnia</strong>\x20or\x20hypersomnia</li>\x0a<li>Psychomotor\x20agitation\x20or\x20retardation</li>\x0a<li><strong>Fatigue</strong>\x20or\x20loss\x20of\x20energy</li>\x0a<li>Feelings\x20of\x20worthlessness\x20or\x20excessive\x20or\x20inappropriate\x20guilt</li>\x0a<li><strong>Difficulty\x20thinking\x20or\x20concentrating</strong>,\x20or\x20indecisiveness</li>\x0a<li>Recurrent\x20thoughts\x20of\x20death,\x20suicidal\x20ideation,\x20or\x20a\x20suicide\x20attempt\u00a0</li>\x0a</ul>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20A\x20and\x20D:\x20<strong>Imipramine</strong>\x20and\x20<strong>amitriptyline</strong>\x20are\x20<strong>tricyclic\x20antidepressants</strong>\x20(TCAs),\x20which\x20are\x20associated\x20with\x20a\x20higher\x20risk\x20of\x20<strong>cardiac\x20side\x20effects</strong>\x20(e.g.,\x20arrhythmias,\x20QT\x20prolongation).\x20Therefore,\x20they\x20are\x20not\x20preferred\x20in\x20this\x20patient\x20with\x20a\x20history\x20of\x20MI.</p>\x0a<p>Option\x20B:\x20<strong>Duloxetine</strong>\x20is\x20a\x20<strong>serotonin-norepinephrine\x20reuptake\x20inhibitor</strong>\x20(SNRI),\x20which\x20is\x20associated\x20with\x20<strong>cardiac\x20side\x20effects</strong>.\x20Hence,\x20it\x20is\x20not\x20preferred\x20in\x20this\x20patient\x20with\x20a\x20history\x20of\x20MI.</p>','kJTzi','Famotidine','kmsvX','DeLvp','toISOString','https://cdn1.dailyrounds.org/uploads/e2fbfcd7026a422b87211570339a0108.PNG','NvxCw','forEach','XrEiH','dvzne','HZsid','Lipid-soluble\x20irreversible\x20inhibitor\x20of\x20acetylcholinesterase','You\x20have\x20reached\x20the\x20end\x20of\x20the\x20quiz.\x20Would\x20you\x20like\x20to\x20submit\x20your\x20answers\x20now?','index.html','name','fzeJZ','return\x20(function()\x20','selected','38\x20mg','GXDJr','<p><strong>Intracavernous\x20injection\x20</strong>of\u00a0<strong>p</strong><strong>henylephrine</strong>\x20can\x20be\x20given\x20to\x20this\x20patient\x20to\x20relieve\x20the\x20priapism\x20and\x20prevent\x20ischemic\x20damage.</p>\x0a<p><strong>Priapism</strong>\x20(sustained\x20painful\x20penile\x20erection\x20&gt;4\x20hours)\x20is\x20a\x20common\x20and\x20serious\x20side\x20effect\x20of\x20<strong>s</strong><strong>ildenafil.</strong>\u00a0Other\x20causes\x20of\x20priapism\x20include\x20<strong>trazodone</strong>\x20(serotonin\x20receptor\x20antagonist)\x20and\x20cantharidin\x20from\x20<strong>Spanish\x20fly</strong>.</p>\x0a<p>Phenylephrine\x20is\u00a0an<strong>\u00a0α<sub>1</sub>\x20selective\x20adrenergic\x20agonist.\x20</strong>It\x20serves\x20as\x20a\x20<strong>vasoconstrictor\u00a0</strong>of\x20the\x20arterioles\x20and\x20reduces\x20the\x20engorgement\x20of\x20cavernosal\x20space,\x20thus\x20<strong>reversing\x20priapism</strong>.</p>\x0a<p>Phenylephrine\x20is\x20a\x20pure\u00a0<strong>α<sub>1\u00a0</sub></strong><strong>adrenergic\x20agonist.\u00a0</strong>By\x20means\x20of\x20acting\x20on\u00a0<strong>α1\x20receptors</strong>,\x20it\x20increases\x20the\u00a0<strong>peripheral\x20arterial\x20resistance,</strong>\u00a0and\x20decreases\x20the\x20capacity\x20of\u00a0<strong>venous\x20capacitance\x20vessels,\u00a0</strong>leading\x20to\x20an\x20increased\x20venous\x20return\x20to\x20the\x20heart.\x20There\x20is\x20a\u00a0<strong>baroreceptor\x20reflex-mediated</strong>\u00a0increase\x20in\x20vagal\x20tone\x20due\x20to\x20which\x20there\x20is\x20marked\u00a0<strong>bradycardia</strong>.\x20However,\x20due\x20to\x20increased\x20venous\x20return,\x20<strong>stroke\x20volume\x20remains\x20high</strong>\x20and\x20so\x20does\x20the\x20cardiac\x20output.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Oxymetazoline</strong>\x20is\x20a\x20vasoconstrictor\x20used\x20in\x20<strong>nasal\x20congestion</strong>\x20and\x20sinus\x20surgeries.\x20It\x20is\x20available\x20generally\x20as\x20a\x20<strong>nasal\x20spray</strong>.</p>\x0a<p>Options\x20C\x20and\x20D:\x20<strong>Papaverine</strong>\x20(with\x20or\x20without\x20<strong>phentolamine</strong>)\x20and\x20<strong>alprostadil</strong>\x20are\x20used\x20in\x20the\x20<strong>treatment\x20of\x20erectile\x20dysfunction</strong>.</p>','findIndex','QZtmU','<p>The\x20clinical,\x20laboratory,\x20and\x20genetic\x20features\x20are\x20suggestive\x20of\x20<strong>Liddle\x27s\x20syndrome</strong>.\x20It\x20occurs\x20due\x20to\x20the\x20increased\x20function\x20of\x20epithelial\x20sodium\x20channels.\x20<strong>Amiloride</strong>\x20blocks\x20these\x20channels\x20and\x20is\x20therefore\x20commonly\x20used\x20in\x20the\x20treatment\x20of\x20Liddle\x27s\x20syndrome.</p>\x0a<p>Amiloride\x20is\x20a\x20<strong>potassium-sparing\x20diuretic</strong>\x20that\x20<strong>blocks\x20epithelial\x20sodium\x20channels</strong>\x20in\x20collecting\x20tubules.\x20Therefore,\x20it\x20reduces\x20sodium\x20retention\x20and\x20potassium\x20wasting.\u00a0Triamterene\x20acts\x20similar\x20to\x20amiloride.\x20However,\x20it\x20is\x20less\x20potent\x20and\x20more\x20toxic\x20than\x20amiloride.</p>\x0a<p>It\x20is\x20used\x20to\x20treat\x20<strong>Liddle\x27s\x20syndrome</strong>,\x20hypokalemia\x20due\x20to\x20other\x20diuretics,\x20and\x20lithium-induced\x20polyuria.\x20Its\x20toxicity\x20can\x20cause\x20hyperkalemic\x20metabolic\x20acidosis.</p>\x0a<p>Liddle\x27s\x20syndrome\x20is\x20an\x20<strong>autosomal\x20dominant</strong>\x20condition\x20that\x20is\x20caused\x20due\x20to\x20the\x20<strong>gain\x20of\x20function\x20mutation\x20in\x20the\x20ENaC\x20gene</strong>\x20which\x20codes\x20for\x20the\x20epithelial\x20sodium\x20channels\x20present\x20in\x20the\x20kidney.\x20Due\x20to\x20increased\x20sodium\x20retention,\x20patients\x20present\x20with\x20hypertension\x20and\x20hypokalemic\x20alkalosis.\x20They\x20have\u00a0<strong>normal\x20aldosterone\x20levels.</strong>\x20They\x20respond\x20to\x20treatment\x20with\x20<strong>amiloride.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\u00a0Furosemide</strong>\x20is\x20a\x20loop\x20diuretic\x20and\x20acts\x20by\x20<strong>inhibiting\u00a0Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup>\x20transporter</strong>\x20in\x20the\x20ascending\x20loop\x20of\x20Henle.\x20Therefore\x20it\x20is\x20not\x20used\x20in\x20the\x20treatment\x20of\x20<strong>Liddle\x27s\x20syndrome.</strong>\x20A\x20condition\x20that\x20mimics\x20overdose\x20loop\x20diuretic\x20is\x20Bartter\x27s\x20syndrome.\x20This\x20syndrome\x20occurs\x20due\x20to\x20a\x20defect\x20in\x20the\u00a0<strong>Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup>\x20transporter</strong>\x20in\x20the\x20ascending\x20loop\x20of\x20Henle.\x20Patients\x20will\x20have\u00a0<strong>low\x20blood\x20pressure</strong>,\x20<strong>polyuria,\x20polydipsia</strong>,\x20hypokalemic\x20metabolic\x20alkalosis,\x20and\x20normal\x20to\x20increased\x20calcium\x20excretion.\u00a0</p>\x0a<p>Option\x20B:\x20<strong>Spironolactone\u00a0</strong>is\x20an\x20aldosterone\x20antagonist.\x20Since\x20the\x20levels\x20of\x20aldosterone\x20are\x20normal\x20in\x20Liddle\x27s\x20syndrome,\x20it\x20cannot\x20be\x20used\x20in\x20the\x20treatment\x20of\x20the\x20condition.\x20The\x20toxicity\x20of\x20spironolactone\x20can\x20cause\x20hyperkalemia\x20and\x20gynecomastia.</p>\x0a<p>Option\x20D:\x20<strong>Hydrochlorothiazide</strong>\x20is\x20a\x20thiazide\x20diuretic\x20and\x20acts\x20by\x20the\x20<strong>inhibition\x20of\x20the\x20Na<sup>+</sup>/Cl<sup>-</sup>\x20transporter</strong>\x20in\x20the\x20<strong>distal\x20convoluted\x20tubule.\u00a0</strong>Therefore\x20it\x20is\x20not\x20commonly\x20used\x20in\x20the\x20treatment\x20of\x20Liddle\x27s\x20syndrome.<strong>\u00a0</strong>A\x20condition\x20that\x20mimics\x20an\x20overdose\x20of\x20thiazide\x20diuretics\x20is\x20<strong>Gitelman\x20syndrome.</strong>\x20It\x20is\x20an\x20autosomal\x20recessive\x20disease\x20that\x20causes\x20a\x20defect\x20in\x20the\u00a0<strong>Na<sup>+</sup>/Cl<sup>-</sup>\x20transporter</strong>\x20in\x20the\x20<strong>distal\x20convoluted\x20tubule.\u00a0</strong>Patients\x20present\x20with\x20low\x20blood\x20pressure,\x20hypokalemic\x20metabolic\x20alkalosis,\x20hypomagnesemia,\x20and\x20<strong>hypocalciuria.</strong></p>','timerContainer','Govph','title','edEQd','keydown','dGJRf','question_images','bDvmx','VMUTf','nBNMo','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><img\x20src=\x22','If\x20a\x20drug\x20follows\x20first-order\x20kinetics,\x20how\x20much\x20drug\x20will\x20remain\x20at\x20the\x20end\x20of\x206\x20hours\x20when\x20a\x20patient\x20is\x20given\x20300\x20mg\x20drug\x20of\x20which\x20120\x20mg\x20is\x20excreted\x20in\x2090\x20min?','filter','2007213bMHBuv','cIpIp','It\x20is\x20used\x20in\x20pruritus','Pilocarpine','Which\x20of\x20the\x20following\x20is\x20not\x20an\x20S-phase\x20inhibitor?','Amiloride','pathname','ORPfs','WZzhC','exXKL','weyrw','JqcBp','bDPNf','<p><strong>0.8–1.2\x20mEq/L</strong>\x20of\x20serum\x20lithium\x20is\x20the\x20favoured\x20therapeutic\x20range\x20for\x20the\x20treatment\x20of\x20<strong>acute</strong>\x20manic\x20or\x20hypomanic\x20patients.</p>\x0a<p><strong>0.5–0.8\x20mEq/L</strong>\u00a0is\x20considered\x20adequate\x20and\x20safer\x20for\x20<strong>long-term\x20prophylaxis</strong>.</p>\x0a<p><strong>Lithium</strong>\x20is\x20a\x20mood\x20stabilizer\x20with\x20a\x20very\x20narrow\x20therapeutic\x20index\x20and\x20is\x20the\x20first\x20line\x20of\x20management\x20in\x20<strong>bipolar</strong>\x20<strong>disorder</strong>.\x20It\x20<strong>decreases</strong>\x20the\x20<strong>rate</strong>\x20<strong>of</strong>\x20<strong>suicide</strong>\x20and\x20is\x20also\x20used\x20in\x20<strong>depression</strong>\x20with\x20inadequate\x20response\x20to\x20monotherapy\x20and\x20cases\x20of\x20recurrent\x20depression.</p>','incorrectResult','performanceModal','rvdAN','No\x20question\x20text\x20available','accuracy','FKvsB','RUlUY','nfNAb','currentMode','apply','NnPPi','ZLBgK','slljj','pblSQ','removeItem','ZVJYg','Hydroxyurea','Are\x20you\x20sure\x20you\x20want\x20to\x20submit\x20the\x20quiz?','EHoJN','WNDbF','Duloxetine','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>English\x20Explanation:</p><audio\x20src=\x22','Dornase\x20alfa','Matzke','<p>The\x20mechanism\x20of\x20action\x20of\x20<strong>mycophenolate\x20mofetil\x20</strong>is\x20the\x20<strong>inhibition\x20of\x20inosine\x20monophosphate\x20dehydrogenase</strong>.</p>\x0a<p><strong>Mycophenolate\x20mofetil</strong>\x20is\x20a\x20<strong>prodrug</strong>\x20that\x20is\x20rapidly\x20converted\x20to\x20<strong>mycophenolic\x20acid</strong>.\x20It\x20is\x20a\x20<strong>selective</strong>,\x20non-competitive,\x20<strong>reversible\x20inhibitor\x20of\x20inosine\x20monophosphate\x20dehydrogenase\x20(IMPDH)</strong>,\x20an\x20important\x20enzyme\x20in\x20the\x20de\x20novo\x20pathway\x20of\x20guanine\x20nucleotide\x20synthesis\x20in\x20T\x20and\x20B\x20lymphocytes.\x20By\x20inhibiting\x20IMPDH,\x20mycophenolate\x20selectively\x20suppresses\x20lymphocyte\x20proliferation,\x20reducing\x20the\x20immune\x20response\x20against\x20the\x20transplanted\x20organ.\x20Hence,\x20used\x20in\x20the\x20prophylaxis\x20of\x20organ\x20transplants.</p>\x0a<p>Other\x20options</p>\x0a<p>Option\x20A:\x20<strong>Cyclosporine</strong>\x20and\x20<strong>tacrolimus</strong>\x20act\x20by\x20<strong>inhibiting\x20calcineurin</strong>.\x20Cyclosporine\x20is\x20an\x20immunomodulatory\x20drug\x20that\x20inhibits\x20calcineurin\x20activity\x20by\x20forming\x20a\x20complex\x20with\x20cyclophilin,\x20a\x20cytoplasmic-receptor\x20protein\x20in\x20target\x20cells,\x20forming\x20a\x20cyclosporine-cyclophilin\x20complex.\x20Tacrolimus\x20is\x20a\x20calcineurin\x20inhibitor\x20that\x20blocks\x20FKBP\x2012.\x20This\x20immunophilin\x20ultimately\x20<strong>inhibits</strong>\x20<strong>calcineurin</strong>\x20phosphatase\x20and\x20exerts\x20its\x20actions.\u00a0</p>\x0a<p>Option\x20B:\x20<strong>Sirolimus</strong>\x20is\x20an\x20antimetabolic\x20and\x20antiproliferative\x20drug.\x20It\x20acts\x20by\x20forming\x20a\x20complex\x20with\x20an\x20immunophilin\x20called\x20FKBP-12,\x20inhibiting\x20the\x20mammalian\x20target\x20of\x20rapamycin\x20(<strong>mTOR</strong>).\x20mTOR\x20is\x20a\x20protein\x20kinase\x20that\x20blocks\x20cell\x20cycle\x20progression\x20at\x20the\x20G1\x20phase\x20to\x20S\x20phase\x20transition.\x20It\x20is\x20used\x20in\x20the\x20prophylaxis\x20of\x20organ\x20transplant\x20rejection</p>\x0a<p>Option\x20C:<strong>\x20Infliximab</strong>\x20is\x20a\x20chimeric\x20IgG1\x20monoclonal\x20antibody\x20against\x20<strong>TNF-α.\x20</strong>It\x20binds\x20with\x20high\x20affinity\x20to\x20TNF-α\x20and\x20prevents\x20the\x20cytokine\x20from\x20binding\x20to\x20its\x20receptors.\u00a0</p>','Pharmacology\x20Test','<p>The\x20symptoms\x20of\u00a0excruciating\x20and\x20paroxysmal\x20facial\x20pain\x20are\x20suggestive\x20of\x20<strong>trigeminal\x20neuralgia.</strong>\u00a0<strong>Carbamazepine</strong>\u00a0is\x20used\x20as\x20the\x20<strong>primary</strong><strong>\u00a0drug</strong>\u00a0in\x20this\x20condition.\x20The<strong>\x20incorrect</strong>\x20statement\x20about\x20carbamazepine\x20is\x20that\x20it\x20is\x20a\x20<strong>GABAc\x20receptor\x20modulator</strong>.\u00a0</p>\x0a<p>Carbamazepine\x20acts\x20by\u00a0<strong>slowing</strong>\u00a0the\x20<strong>recovery\x20rate</strong>\x20of\x20<strong>voltage-activated\x20sodium\x20channels</strong>\x20from\x20their\x20inactivated\x20state\u00a0and\x20acts\x20as\x20a<strong>\x20sodium\x20channel\x20blocker.\u00a0</strong></p>\x0a<p>It\x20is\x20used\x20as\x20the\x20primary\x20drug\x20in\x20both\x20<strong>trigeminal</strong>\x20and\x20<strong>glossopharyngeal\x20neuralgias</strong>.\x20It\x20is\x20also\x20the\x20primary\x20agent\x20for\x20treating\x20<strong>generalized\x20tonic-clonic</strong>\x20and<strong>\x20focal\x20seizures</strong>.\x20It\x20can\x20also\x20be\x20used\x20in\x20<strong>bipolar\x20affective\x20disorders</strong>.</p>\x0a<p>Carbamazepine\x20also\x20has\x20a\x20<strong>potentiating</strong>\x20effect\x20on\x20the\x20action\x20of\x20<strong>antidiuretic\x20hormone</strong>\x20(ADH).\x20It\x20can\x20result\x20in\u00a0water\x20retention\x20with\x20decreased\x20osmolarity\x20and\x20<strong>hyponatremia</strong>,\x20especially\x20in\x20<strong>elderly</strong>\x20patients\x20with\x20cardiac\x20disease.\x20Other\x20adverse\x20effects\x20include:</p>\x0a<ul>\x0a<li>Hypersensitivity\x20reactions\u00a0such\x20as:\x0a<ul>\x0a<li>Stevens-Johnson\x20syndrome</li>\x0a<li>Skin\x20rashes</li>\x0a<li><strong>Transient\x20leukopenia</strong></li>\x0a<li><strong>Aplastic\x20anemia\u00a0</strong></li>\x0a<li>Agranulocytosis</li>\x0a<li><strong>Hepatotoxicity</strong>\x20(on\x20concomitant\x20use\x20with\x20valproate)</li>\x0a</ul>\x0a</li>\x0a<li>Dose-related\x20<strong>neurotoxicity</strong>\x20such\x20as:\x0a<ul>\x0a<li>vertigo</li>\x0a<li>ataxia</li>\x0a<li>diplopia\x20and\x20blurred\x20vision</li>\x0a<li>worsening\x20of\x20seizures</li>\x0a<li>vomiting</li>\x0a</ul>\x0a</li>\x0a</ul>','SgLHD','style','FYUHO','resume','wflnd','XHyXJ','Subcutaneous\x20iron\x20dextran','hYdID','not_attempted','strokeDasharray','red','1-d,\x202-b,\x203-a,\x204-c','yyOUo','progressBar','hzSUk','nwFqr','navBtn_','classList','log','KyjzK','Sotalol','nav-btn-incorrect','floor','OUOZy','https://cdn1.dailyrounds.org/uploads/73e78df307ab449686e7e18b7b145007.JPEG','qlRBm','table','Tacrine\x20and\x20malathion\x20inhibit\x20the\x20Acetylcholine\x20esterase\x20enzyme\x20by\x20binding\x20to\x20which\x20of\x20the\x20following\x20site/sites?','explanation_video','https://cdn1.dailyrounds.org/uploads/cda9af4abc9841378a0d07e6dee3b224.JPEG','https://cdn1.dailyrounds.org/uploads/d9552ad6e0c144d799b50a3792d13d70.JPEG','.option-button','<p\x20class=\x22p1\x22><strong>Alirocumab</strong>\x20helps\x20in\x20lowering\x20lipids\x20by&nbsp;<strong>PCSK-9\x20inhibition.\x20</strong></p>\x0a<p\x20class=\x22p1\x22>It<strong>&nbsp;</strong>is\x20a\x20monoclonal\x20antibody\x20that\x20binds\x20to<strong>\x20proprotein\x20convertase\x20subtilisin\x20Kexin\x20type\x209\x20</strong>(PCSK-9).&nbsp;<strong>PCSK-9\x20is\x20a\x20protease</strong>\x20involved\x20in\x20the\x20<strong>degradation\x20</strong>of\x20<strong>LDL\x20receptors,\x20which\x20results&nbsp;</strong>in\x20higher\x20plasma\x20LDL\x20concentrations.\x20Alirocumab\x20binds\x20to\x20free\x20PCSK-9,\x20thereby\x20interfering\x20with\x20its\x20binding\x20to\x20the\x20LDL\x20receptor,\x20leading\x20to\x20increased\x20liver\x20clearance\x20of\x20LDL\x20from\x20the\x20circulation\x20and\x20lower\x20serum\x20LDL\x20levels.</p>\x0a<p\x20class=\x22p1\x22><strong>Alirocumab</strong>\x20and\x20<strong>evolocumab&nbsp;</strong>are\x202\x20FDA-approved\x20PCSK9\x20inhibitors.\x20It\x20is\x20used\x20as\x20adjunctive\x20therapy\x20in\x20patients\x20with<strong>&nbsp;familial\x20hypercholesterolemia\x20</strong>or\x20established&nbsp;<strong>atherosclerotic\x20cardiovascular\x20disease</strong>,\x20in\x20whom\x20the\x20maximum\x20tolerated\x20statin\x20dose\x20is\x20not\x20able\x20to\x20achieve\x20target\x20LDL\x20reduction.</p>\x0a<p\x20class=\x22p1\x22>It\x20is\x20administered\x20as\x20<strong>subcutaneous\x20injections</strong>\x20every\x202\x20weeks\x20or\x20once\x20monthly\x20depending\x20on\x20the\x20indication.</p>','zXBTW','FIdLe','\x22\x20data-src=\x22','IspKf','WPlBG','UYJlJ','search','Lidocaine','qWEwS','JPvNF','A\x20patient\x20is\x20given\x20a\x20nicotinic\x20receptor\x20antagonist\x20as\x20a\x20muscle\x20relaxant.\x20Which\x20of\x20the\x20following\x20accurately\x20describes\x20the\x20drug\x20given\x20postoperatively\x20to\x20recover\x20from\x20muscle\x20weakness?','bind','block','Amikacin','QuClk','Bookmark','rMPFK','TeaCw','incomplete','sryrs','quizPerformanceData','hnqtF','lSdlC','Decreased\x20hydrostatic\x20pressure\x20in\x20the\x20lower\x20extremities','DnCQN','explanationVideoPlayer','AFcxo','Which\x20of\x20the\x20following\x20drugs\x20act\x20by\x20reversible\x20inhibition\x20of\x20P2Y12\x20receptor?','question_video','kgWBv','tEFMa','bookmarked','wskyD','A\x2034-year-old\x20man\x20is\x20seen\x20over\x20multiple\x20visits\x20for\x20complaints\x20of\x20gastric\x20ulcers\x20despite\x20the\x20use\x20of\x20ranitidine.\x20Further\x20evaluation\x20revealed\x20elevated\x20levels\x20of\x20gastrin\x20and\x20evidence\x20of\x20ulcers\x20involving\x20the\x20jejunum\x20suggesting\x20a\x20diagnosis\x20of\x20Zollinger-Ellison\x20syndrome.\x20Which\x20of\x20the\x20following\x20agents\x20would\x20be\x20most\x20useful\x20in\x20the\x20management\x20of\x20this\x20patient?','ZeqzP','Pimavanserin','open','ArrowLeft','No\x20questions\x20available\x20for\x20this\x20quiz.','Furosemide','UsWYd','fGnPL','correctAnswers','hXVHD','The\x20following\x20finding\x20was\x20seen\x20on\x20performing\x20a\x20DAT\x20scan\x20in\x20a\x20patient\x20who\x20presented\x20with\x20bradykinesia,\x20rigidity,\x20and\x20tremors.\x20Which\x20of\x20the\x20following\x20drugs\x20could\x20be\x20used\x20in\x20the\x20treatment\x20of\x20this\x20condition?','YnAuW','Leuprolide','Zsxzz','strokeDashoffset','1-d,\x202-a,\x203-b,\x204-c','DimEq','bLDqt','parse','Esteratic\x20site','Lamotrigine','369465JhnuLG','ExgfD','Ftcmy','Procainamide','<div\x20class=\x22p-3\x20rounded-lg\x20border\x20','jmvmP','OEZil','<p><strong>Ticagrelor</strong>\x20is\x20a\x20<strong>reversible\x20inhibitor</strong>\u00a0of\x20<strong>P2Y12\x20receptor</strong>.</p>\x0a<p>Injury\x20to\x20the\x20vessel\x20wall\x20exposes\x20the\x20subendothelial\x20collagen\x20and\x20causes\x20platelets\x20to\x20adhere\x20and\x20activate\x20at\x20the\x20site.\x20<strong>Activated\x20platelets\x20release\x20ADP</strong>,\x20which\x20<strong>binds\x20to\x20P2Y12\x20receptors</strong>\x20on\x20other\x20platelets\x20in\x20the\x20circulation\x20and\x20causes\x20their\x20activation.\x20This\x20can\x20cause\x20<strong>amplifying\x20cycles\x20of\x20clot\x20formation</strong>\x20and\x20<strong>complete\x20occlusion\x20of\x20the\x20blood\x20vessels</strong>.\x20This\x20is\x20especially\x20dangerous\x20in\x20patients\x20with\x20atherosclerotic\x20plaques\x20in\x20the\x20coronary\x20arteries.\x20Any\x20<strong>acute\x20plaque\x20change</strong>,\x20such\x20as\x20ulceration,\x20can\x20lead\x20to\x20<strong>thrombosis</strong>\x20and\x20<strong>acute\x20coronary\x20syndromes</strong>.\u00a0</p>\x0a<p>This\x20is\x20where\x20anti-platelet\x20drugs\x20such\x20as\x20P2Y12\x20inhibitors\x20come\x20in.\x20P2Y12\x20inhibitors\x20include\x20clopidogrel,\x20prasugrel,\x20ticagrelor\x20and\x20cangrelor.\x20Some\x20of\x20the\x20features\x20of\x20these\x20drugs\x20are\x20summarized\x20below:</p>\x0a<table\x20style=\x22width:\x2082.4864%;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x209.62761%;\x22><strong>Clopidogrel</strong></td>\x0a<td\x20style=\x22width:\x2014.1689%;\x22><strong>Irreversible</strong>\x20P2Y12\x20antagonist,\x20oral</td>\x0a<td\x20style=\x22width:\x2076.2035%;\x22>\x0a<p>It\x20is\x20a\x20<strong>prodrug</strong>;\x20that\x20requires\x20activation\x20by\x20<strong>CYP\x202C19</strong>\x20to\x20work.</p>\x0a<p>Blocks\x20platelet\x20aggregation\x20for\x20the\x20entire\x20lifetime\x20of\x20platelets</p>\x0a<p><strong>PPIs</strong>\x20such\x20as\x20omeprazole\x20and\x20pantoprazole\x20<strong>inhibit\x20CYP\x202C19</strong>,\x20thus\x20r<strong>educing\x20the\x20formation\x20of\x20the\x20active\x20metabolite</strong>\x20of\x20clopidogrel\x20and\x20leading\x20to\x20therapeutic\x20failure.</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x209.62761%;\x22><strong>Prasugrel</strong></td>\x0a<td\x20style=\x22width:\x2014.1689%;\x22><strong>Irreversible</strong>\x20P2Y12\x20antagonist,\x20oral</td>\x0a<td\x20style=\x22width:\x2076.2035%;\x22>It\x20has\x20a\x20more\x20<strong>rapid\x20onset</strong>\x20of\x20action\x20compared\x20to\x20clopidogrel.</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x209.62761%;\x22><strong>Ticagrelor</strong></td>\x0a<td\x20style=\x22width:\x2014.1689%;\x22><strong>Reversible</strong>\x20P2Y12\x20antagonist,\x20oral</td>\x0a<td\x20style=\x22width:\x2076.2035%;\x22>\x0a<p>More\x20<strong>rapid\x20onset\x20and\x20offset</strong>\x20of\x20action\x20compared\x20to\x20clopidogrel.</p>\x0a<p>Associated\x20with\x20<strong>dyspnea</strong>\x20and\x20<strong>higher\x20risk\x20of\x20intracranial\x20bleeding</strong>;\x20contraindicated\x20in\x20patients\x20with\x20a\x20history\x20of\x20intracranial\x20bleeding.</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x209.62761%;\x22><strong>Cangrelor</strong></td>\x0a<td\x20style=\x22width:\x2014.1689%;\x22><strong>Reversible</strong>\x20P2Y12\x20antagonist,\x20<strong>intravenous</strong></td>\x0a<td\x20style=\x22width:\x2076.2035%;\x22>The\x20action\x20begins\x20within\x20minutes\x20and\x20lasts\x20for\x20one\x20hour\x20following\x20the\x20stoppage\x20of\x20the\x20drug.</td>\x0a</tr>\x0a</tbody>\x0a</table>','A\x20patient\x20who\x20has\x20undergone\x20renal\x20transplantation\x20is\x20started\x20on\x20mycophenolate\x20mofetil\x20as\x20prophylaxis\x20for\x20transplant\x20rejection.\x20What\x20is\x20the\x20mechanism\x20of\x20action\x20of\x20this\x20drug?','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><video\x20src=\x22','NMUsa','Pegloticase','</span>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20mb-4\x22>','A\x20patient\x20with\x20chronic\x20angina\x20was\x20prescribed\x20a\x20new\x20drug,\x20ranolazine.\x20This\x20drug\x20acts\x20by\x20which\x20of\x20the\x20following\x20mechanism?','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>','cSYSs','markReviewBtn','<p>The\x20ECG\x20of\x20this\x20patient\x20shows\u00a0<strong>wide\x20QRS\x20complexes\x20</strong>and\x20an<strong>\u00a0undulating\x20baseline\x20</strong>suggesting\x20the\x20diagnosis\x20of\u00a0<strong>torsades\x20de\x20pointes</strong>.\x20It\x20is\x20associated\x20with\u00a0<strong>prolonged\x20QT\x20interval.\u00a0Lidocaine</strong>\x20does\x20not\x20prolong\x20the\x20QT\x20interval,\x20hence,\x20it\x20is<strong>\x20unlikely</strong>\x20to\x20cause\x20torsades\x20de\x20pointes.\u00a0</p>\x0a<p><strong>Lidocaine</strong>\x20belongs\u00a0to\x20the\x20<strong>class\x20IB</strong>\x20antiarrhythmic\x20agent.\x20It\x20is\x20considered\x20to\x20have\x20the\x20least\x20arrhythmogenic\x20potential\x20among\x20antiarrhythmic.\x20QT\x20interval\x20is\x20usually\x20unaltered\x20or\x20slightly\x20reduced\x20with\x20lidocaine\x20use.</p>\x0a<p>Among\x20the\x20antiarrhythmics,\x20class\x20Ia\x20and\x20class\x20III\x20drugs\x20prolong\x20action\x20potential\x20duration\x20and\x20thus\x20prolong\x20QT\x20interval\x20and\x20are\x20also\x20prone\x20to\x20cause\x20Torsades\x20de\x20pointes.</p>','oMywW','BTxmC','<div\x20class=\x22mt-4\x22><video\x20id=\x22review-video-','Hyperkalemia','Sildenafil','Azathioprine','\x22\x20data-option-index=\x22','Misoprostol','dkdLP','Rho-kinase\x20inhibitor','button','incorrectAnswers','cHQYi','Lamivudine','tAykd','iUzte','mQgkq','It\x20does\x20not\x20cross\x20the\x20blood-brain\x20barrier','gradient-yellow\x20px-6\x20py-3\x20text-white\x20transition-all\x20duration-300\x20flex\x20items-center','Ndcjy','Propylthiouracil','width','PvBwc','Benztropine','gHzOo','stringify','Halsted','cDUfH','Diuretic\x20resistance','15391512aAMdvU','cbCVm','kHOiK','60\x20ng/min','qbzVp','Ticagrelor','incorrect','<p><strong>Metformin</strong>\x20is\x20the\x20most\x20likely\x20cause\x20of\x20<strong>low\x20TSH\x20levels</strong>\x20and\x20<strong>normal\x20free\x20T4\x20and\x20T3\x20levels</strong>\x20in\x20this\x20patient.</p>\x0a<p><strong>Metformin</strong>\x20belongs\x20to\x20the\x20<strong>biguanide</strong>\x20class\x20of\x20oral\x20hypoglycemic\x20drugs.\x20Metformin\x20is\x20accepted\x20as\x20the\x20<strong>first-line\x20treatment</strong>\x20of\x20<strong>type\x202\x20diabetes</strong>\x20and\x20is\x20the\x20most\x20commonly\x20used\x20oral\x20agent\x20for\x20this\x20condition.\x20It\x20acts\x20primarily\x20by\x20inhibiting\x20hepatic\x20gluconeogenesis.\x20It\x20activates\x20<strong>AMP-dependent\x20protein\x20kinase</strong>,\x20leading\x20to\x20stimulation\x20of\x20hepatic\x20fatty\x20acid\x20oxidation,\x20glucose\x20uptake,\x20and\x20nonoxidative\x20glucose\x20metabolism\x20and\x20reduction\x20of\x20lipogenesis\x20and\x20gluconeogenesis.</p>\x0a<p>Metformin\x20is\x20associated\x20with\x20<strong>decreased\x20TSH</strong>\x20levels.\x20It\x20also\x20prevents\x20an\x20increase\x20in\x20the\x20thyroid\x20volume.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Dapagliflozin</strong>,\x20a\x20sodium-glucose\x20co-transporter-2\x20<strong>(SGLT-2)\x20inhibitor</strong>,\x20is\x20not\x20known\x20to\x20affect\x20thyroid\x20function.</p>\x0a<p>Option\x20C:\x20<strong>Sitagliptin</strong>,\x20a\x20dipeptidyl\x20peptidase-4<strong>\x20(DPP-4)\x20inhibitor</strong>,\x20has\x20no\x20significant\x20effects\x20on\x20thyroid\x20function.</p>\x0a<p>Option\x20D:\x20<strong>Glibenclamide</strong>,\x20a\x20<strong>sulfonylurea</strong>,\x20also\x20does\x20not\x20impact\x20thyroid\x20function.</p>','https://cdn1.dailyrounds.org/uploads/38cc05b0933e4f65a83a650431d5c197.JPEG','LrzzW','It\x20increases\x20the\x20risk\x20of\x20fractures','<p><strong>Graph\x204</strong>\x20represents\x20an\x20<strong>inverse\x20agonist</strong>.\x20Among\x20the\x20given\x20options,\x20<strong>varenicline</strong>\x20is\x20<strong>not\x20</strong>an\x20<strong>inverse\x20agonist</strong>.\x20It\x20is\x20a\x20<strong>partial\x20agonist</strong>.</p>\x0a<p><strong>Inverse\x20agonist</strong>\x20(graph\x204):\x20An\x20agent\x20that\x20activates\x20a\x20receptor\x20to\x20produce\x20an\x20effect\x20in\x20the\x20opposite\x20direction\x20of\x20the\x20agonist.\x20<br\x20/>Examples:</p>\x0a<ul>\x0a<li><strong>Pimavanserin</strong>\x20is\x20an\x20inverse\x20agonist\x20at\x205HT2A\u00a0</li>\x0a<li><strong>β-Carboline</strong>\x20is\x20an\x20inverse\x20agonist\x20at\x20the\x20benzodiazepine\x20site\x20of\x20the\x20GABA-A\x20receptor.</li>\x0a<li><strong>Rimonabant</strong>\x20is\x20an\x20inverse\x20agonist\x20at\x20cannabinoid\x20receptor.\u00a0\u00a0</li>\x0a</ul>\x0a<div><strong>Graph\x201\x20</strong>represents\x20the\x20<strong>agonist:\x20</strong>An\x20agonist\x20is\x20an\x20agent\x20that\x20initiates\x20the\x20<strong>normal</strong>\x20<strong>physiological\x20response</strong>\x20when\x20combined\x20with\x20a\x20receptor.\x20Eg:\x20<strong>Salbutamol</strong>\x20is\x20a\x20beta-2\x20receptor\x20agonist.</div>\x0a<div\x20style=\x22padding-left:\x2030px;\x22>\u00a0</div>\x0a<div><strong>Graph\x202</strong>\x20represents\x20a\x20<strong>partial\x20agonist</strong>:\x20An\x20agent\x20that\x20produces\x20a\x20<strong>submaximal\x20or\x20partial\x20effect</strong>\x20when\x20combined\x20with\x20a\x20receptor.\x20Eg:\x20<strong>B</strong><span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22><strong>uprenorphine</strong>\x20and\x20butorphanol\x20are\x20partial\x20agonists\x20at\x20opioid\x20receptors.</span></span></div>\x0a<div\x20style=\x22padding-left:\x2030px;\x22>\u00a0</div>\x0a<div><strong>Graph\x203\x20</strong>represents\x20the\x20<strong>competitive</strong>\u00a0<strong>antagonist</strong>:\x20An\x20agent\x20which\x20blocks\x20or\x20reduces\x20the\x20action\x20of\x20an\x20agonist\x20on\x20a\x20receptor,\x20but\x20does\x20not\x20have\x20any\x20effect\x20of\x20its\x20own.\x20Eg:\x20N<span\x20class=\x22ILfuVd\x22\x20lang=\x22en\x22><span\x20class=\x22hgKElc\x22>altrexone\x20and\x20<strong>naloxone</strong>\x20are\x20antagonists\x20at\x20opioid\x20receptors</span></span></div>\x0a<div\x20style=\x22padding-left:\x2030px;\x22>\u00a0</div>\x0a<div>The\x20image\x20given\x20below\x20shows\x20the\x20action\x20of\x20various\x20types\x20of\x20selective\x20receptor\x20modulators:</div>','Efzvg','YMKxD','<p>The\x20drug\x20prescribed\x20is\u00a0<strong>bosentan</strong>.\u00a0</p>\x0a<p>The\x20clinical\x20scenario\x20of\x20the\x20development\x20of\x20<strong>nasal\x20congestion\x20and\x20pharyngitis</strong>\x20after\x20administration\x20of\x20an\x20<strong>endothelin\x20receptor\x20antagonis</strong>t\x20given\x20for\x20the\x20treatment\x20of\x20pulmonary\x20artery\x20hypertension\x20suggests\x20that\x20the\x20drug\x20prescribed\x20is\x20bosentan.</p>\x0a<ul>\x0a<li><strong>ET</strong><sub><strong>A</strong>\x20-\u00a0</sub>This\x20receptor\x20is\x20localized\x20on\x20the<strong>\x20pulmonary\x20artery\x20smooth\x20muscle\x20cell</strong>.\x20It\x20is\x20a\x20<strong>G-protein\x20coupled\x20receptor\u00a0</strong>and\x20acts\x20via\x20the\x20<strong>IP<sub>3</sub>-DAG</strong>\x20pathway\x20elevating\x20cytosolic\x20Ca<sup>2+\u00a0</sup>thus\x20causing\x20<strong>vasoconstriction</strong>.</li>\x0a<li><strong>ET<sub>B</sub></strong>\x20-\x20This\x20receptor\x20is\x20present\x20on\x20the\x20pulmonary\x20artery\x20smooth\x20muscle\x20cell\x20and\x20<strong>endothelial\x20cell</strong>.\x20It\x20is\x20a\u00a0<strong>G-protein\x20coupled\x20receptor\u00a0</strong>and\x20on\x20activation,\x20the\u00a0ET<sub>B\u00a0</sub>receptors\x20on\x20the\x20endothelial\x20cells\x20increase\x20the\x20production\x20of\x20<strong>PGI<sub>2,\u00a0</sub>NO\x20and\x20inhibit\x20ET-1\x20production.</strong></li>\x0a</ul>\x0a<p>Endothelin\x20receptor\x20antagonists\x20act\x20by\x20either\x20non-selectively\x20inhibiting\x20both\x20endothelin\x20receptors\x20or\x20by\x20selectively\x20inhibiting\u00a0ET<sub>A\x20</sub>receptors\x20only.\x20The\x20<strong>nonselective\x20</strong>endothelin\x20receptor\x20antagonists\x20are\u00a0<strong>bosentan\u00a0</strong>and\u00a0<strong>macitentan.\u00a0</strong>The\x20<strong>selective</strong>\x20endothelin\x20receptor\x20antagonists\x20are\u00a0<strong>ambrisentan\u00a0</strong>and\u00a0<strong>sitaxsentan.\u00a0</strong><strong>Sitaxsentan</strong>\x20is\x20the\x20<strong>most\x20selective</strong>\u00a0<strong>ET<sub>A</sub></strong>\x20receptor\x20<strong>antagonist.</strong>\u00a0These\x20drugs\x20are\x20predominantly\x20used\x20in\x20the\x20treatment\x20of\x20pulmonary\x20artery\x20hypertension.</p>\x0a<p>Side\x20effects:</p>\x0a<ul>\x0a<li><strong>Headache</strong></li>\x0a<li><strong>Pulmonary\x20edema</strong></li>\x0a<li><strong>Nasal\x20congestion</strong>/<strong>pharyngitis</strong></li>\x0a<li><strong>Hepatotoxicity\x20-\u00a0</strong>\x20needs\x20monitoring\x20and\u00a0<strong>contraindicated\u00a0</strong>in\x20patients\x20with\x20mild-moderate\x20liver\x20disease.</li>\x0a<li><strong>Teratogenic</strong>\x20-\u00a0<strong>contraindicated\u00a0</strong>in\u00a0<strong>pregnancy</strong>.</li>\x0a</ul>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A-\x20<strong>Epoprostenol</strong>\x20is\x20a\x20<strong>synthetic\u00a0PGI</strong><sub><strong>2</strong>,\u00a0</sub>It\x20acts\x20by\x20inhibiting\x20myosin\x20light\x20chain\x20kinase\x20and\x20activating\x20K+\x20channels.\x20It\x20is\x20the\x20mainstay\x20of\x20treatment\x20of\x20pulmonary\x20artery\x20hypertension,\x20particularly\x20in\x20advanced\x20stages.\x20The\x20important\x20side\x20effects\x20include\u00a0<strong>myalgia,\x20jaw\x20pain,\x20nausea,\x20flushing,\x20and\x20systemic\x20hypotension.</strong></p>\x0a<p>Option\x20C-\x20<strong>Inhaled\x20NO</strong>\u00a0acts\x20by\x20<strong>activation</strong>\x20of<strong>\x20soluble\x20guanylyl\x20cyclase</strong>\x20→\x20activates\x20cyclic\x20guanosine\x20monophosphate\x20(cGMP).\x20An\x20important\x20side\x20effect\x20is\x20<strong>methemoglobinemia.</strong></p>\x0a<p>Option\x20D-\x20<strong>Sildenafil</strong>\x20acts\x20by\x20competitive\x20<strong>inhibition</strong>\x20of\x20<strong>phosphodiesterase</strong>\u00a0<strong>5</strong>\x20(PDE5).\x20Important\x20side\x20effects\x20are\u00a0<strong>headache,\x20flushing\u00a0</strong>and\u00a0<strong>blue-green\x20vision</strong>.</p>','Vmqjw','(((.+)+)+)+$','1-b,\x202-a,\x203-c,\x204-d','WEXSk','cHSaA','Rimonabant','QJqQN','ArrowRight','BSlio','voutI','Schedule\x20H\x20drugs','split','Oxymetazoline','PCSK-8\x20inhibition','BbgiV','\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-letter\x22>','CwBPO','Inhaled\x20nitric\x20oxide\x20(NO)','Option\x20','ugNsZ','Neuromodulator','ALFnR','Spironolactone','50\x20ng/min','\x22\x20alt=\x22Explanation\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','pmJPn','HhSBc','HkQBt','Loperamide','<p>The\x20clinical\x20features\x20and\x20investigations\x20showing\x20elevated\x20PSA\x20osteoblastic\x20lesions\x20in\x20the\x20pelvis\x20are\x20suggestive\x20of\x20<strong>metastatic</strong>\u00a0<strong>prostate</strong>\x20<strong>cancer</strong>.\x20<strong>Leuprolide\x20</strong>is\x20a\x20<strong>GnRH</strong>\x20<strong>agonist</strong>\x20used\x20in\x20the\x20treatment\x20of\x20prostate\x20cancer.</p>\x0a<p><strong>Androgen\x20deprivation\x20therapy</strong>\x20is\x20the\x20primary\x20medical\x20therapy\x20for\x20prostate\x20cancer.\x20The\x20drugs\x20used\x20for\x20this\x20indication\x20are\u00a0<strong>GnRH\x20agonists</strong>\x20such\x20as\x20<strong>goserelin</strong>,\x20<strong>buserelin</strong>,\x20<strong>leuprolide</strong>,\x20<strong>nafarelin,</strong>\x20and\x20triptorelin.\u00a0The\x20agonist\x20action\x20of\x20the\x20GnRH\x20analogs\x20causes\x20an\x20<strong>initial\x20increase\x20in\x20LH</strong>,\x20leading\x20to\x20<strong>increased\x20testosterone</strong>\x20production.\x20This\x20causes\x20a\x20<strong>tumor\x20flare</strong>.\x20This\x20can\x20be\x20<strong>prevented\x20by</strong>\x20concomitant\x20administration\x20of\x20an\x20<strong>androgen\x20receptor\x20antagonist\u00a0</strong>such\x20as\x20<strong>flutamide</strong>\x20or\x20<strong>bicalutamide</strong>.</p>\x0a<p>After\x20the\x20initial\x20period,\x20there\x20is\x20a\x20<strong>downregulation</strong>\x20<strong>of\x20GnRH\x20receptors</strong>\x20and\x20changes\x20in\x20the\x20downstream\x20pathways,\x20leading\x20to\x20a\x20decrease\x20in\x20gonadotropins\x20and\x20testosterone\x20(hypogonadotropic\x20hypogonadism).\u00a0The\x20androgen\x20deprivation\x20therapy\x20with\x20continuous\x20GnRH\x20agonist\x20and\x20an\x20androgen\x20receptor\x20antagonist\x20is\x20<strong>as\x20effective\x20as\x20surgical\x20castration</strong>\x20in\x20reducing\x20the\x20levels\x20of\x20serum\x20testosterone.</p>\x0a<p><strong>GnRH\x20antagonists</strong>\x20such\x20as\x20<strong>degarelix</strong>\x20can\x20also\x20be\x20used\x20for\x20androgen\x20deprivation\x20therapy.\x20It\x20has\x20the\x20advantage\x20of\x20<strong>not</strong>\x20<strong>having\x20a\x20tumor\x20flare\x20phenomenon</strong>.\x20However,\x20because\x20of\x20the\x20long-term\x20safety\x20profile\x20of<strong>\x20GnRH\x20agonists</strong>,\x20they\x20are\x20the\x20<strong>preferred</strong>\x20<strong>drugs</strong>\x20for\x20androgen\x20deprivation\x20therapy.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A:<strong>\x20Anastrozole</strong>\x20is\x20an\x20<strong>aromatase\x20inhibitor\u00a0</strong>used\x20in\x20the\x20treatment\x20of\x20advanced\x20breast\x20cancer.</p>\x0a<p>Option\x20B:\u00a0<strong>Desogestrel</strong>\x20is\x20a\x20<strong>synthetic\x20progestin</strong>\x20without\x20androgenic\x20activity.\x20It\x20is\x20used\x20in\x20combination\x20with\x20ethinyl\x20estradiol\x20for\x20<strong>oral\x20contraception</strong>.</p>\x0a<p>Option\x20D:<strong>\x20Spironolactone</strong>\u00a0is\x20a\x20potassium-sparing\x20diuretic\x20and\x20<strong>aldosterone\x20antagonist</strong>.\x20It\x20is\x20a\x20<strong>weak\x20inhibitor\x20of\x20the\x20androgen\x20receptor</strong>\x20and\x20causes\x20<strong>gynecomastia</strong>\x20as\x20a\x20common\x20side\x20effect.\x20It\x20has\x20been\x20used\x20in\x20women\x20to\x20treat\x20<strong>hirsutism</strong>.</p>','Which\x20of\x20the\x20following\x20drugs\x20does\x20not\x20represent\x20the\x20action\x20of\x20the\x20graph\x20labelled\x20as\x20\x274\x27?','disabled','questionIndex','FFzem','border-green-500','A\x20young\x20patient\x20presents\x20with\x20a\x20persistent\x20and\x20painful\x20penile\x20erection.\x20He\x20had\x20been\x20taking\x20sildenafil\x20without\x20proper\x20medical\x20consultation.\x20Which\x20of\x20the\x20following\x20drugs\x20can\x20be\x20given\x20as\x20an\x20intracavernosal\x20injection\x20to\x20this\x20patient?','Radioactive\x20iodine','1-b,\x202-c,\x203-a,\x204-d','aAwaM','test','solutionVideo','nav-btn-answered','questionText','MUkuQ','scoreCircle','KJcGY','toggle','Carbamazepine','\x20>\x20','Secukinumab','https://dhmbxeygs57ff.cloudfront.net/uploads/ee45ba38cfce413fbfb460f29cb399ecx1280x1343.JPEG','none','doimF','EleQt','RpsDh','pfjAi','getItem','JJuxh','A\x20drug\x20is\x20instilled\x20into\x20the\x20right\x20eye\x20of\x20the\x20rabbit,\x20and\x20the\x20left\x20eye\x20is\x20used\x20as\x20the\x20control.\x20The\x20findings\x20obtained\x20after\x20some\x20time\x20are\x20shown\x20in\x20the\x20table\x20and\x20image\x20given\x20below.','{}.constructor(\x22return\x20this\x22)(\x20)','0.8\x20-\x201.2','TImZN','jOFJH','A\x20young\x20man\x20is\x20diagnosed\x20with\x20hypertension.\x20His\x20laboratory\x20studies\x20reveal\x20hypokalemia\x20and\x20metabolic\x20alkalosis.\x20He\x20says\x20that\x20his\x20mother\x20was\x20also\x20diagnosed\x20with\x20hypertension\x20at\x20a\x20younger\x20age.\x20Genetic\x20testing\x20revealed\x20the\x20presence\x20of\x20a\x20mutation\x20in\x20ENaC\x20gene.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20commonly\x20used\x20in\x20the\x20treatment\x20of\x20the\x20given\x20condition?','URief','mFOXw','DsxvK','hGZMC','A\x20middle-aged\x20male\x20patient\x20was\x20found\x20to\x20have\x20multidrug-resistant\x20tuberculosis.\x20\x20He\x20is\x20started\x20on\x20the\x20intensive\x20phase\x20of\x20treatment\x20according\x20to\x20standard\x20RNTCP\x20guidelines.\x20A\x20week\x20after\x20treatment,\x20he\x20develops\x20features\x20of\x20frank\x20psychosis.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20likely\x20to\x20have\x20caused\x20this?','remove','44\x20mg','Adalimumab','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22space-y-2\x20mb-4\x22>','Late\x20sodium\x20current\x20inhibition','lWpoC','Bookmarked','nRWoG','NjLfp','key','NAIGy','IjMuj','review-question\x20','Bromhexine','map','Intravenous\x20iron\x20sucrose','ilQhZ','fvtxd','Amitriptyline','aXYkr','YlvUa','Which\x20of\x20the\x20following\x20drugs\x20is\x20most\x20likely\x20to\x20produce\x20the\x20following\x20adverse\x20effect?','Hypoglycemia','https://cdn1.dailyrounds.org/uploads/fe43662bbbb94690a89bc30089d0cde3.JPEG','zqMwn','IuVWe','<p><strong>Option\x20B\x20</strong>is<strong>\x20correctly\x20matched.</strong></p>\x0a<table\x20style=\x22height:\x2061px;\x20width:\x20285px;\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x20121.367px;\x20text-align:\x20center;\x22><strong>Drug\u00a0</strong></td>\x0a<td\x20style=\x22width:\x20135.414px;\x20text-align:\x20center;\x22><strong>Antidote</strong></td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20121.367px;\x22><strong>1</strong>.\x20Heparin</td>\x0a<td\x20style=\x22width:\x20135.414px;\x22><strong>b</strong>.\x20Protamine\x20sulfate</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20121.367px;\x22><strong>2</strong>.\x20Dabigatran</td>\x0a<td\x20style=\x22width:\x20135.414px;\x22><strong>c</strong>.\x20Idarucizumab</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20121.367px;\x22><strong>3</strong>.\x20Warfarin</td>\x0a<td\x20style=\x22width:\x20135.414px;\x22><strong>a</strong>.\u00a0Vitamin\x20K</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x20121.367px;\x22><strong>4</strong>.\x20Rivaroxaban</td>\x0a<td\x20style=\x22width:\x20135.414px;\x22><strong>d</strong>.\x20Andexanet\x20alfa</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><br\x20/>Heparin\x20-\x20Protamine\x20sulfate(1-b)\x20:</p>\x0a<p><strong>Protamine\x20sulfate</strong>\x20is\x20indicated\x20for\x20the\x20reversal\x20of<strong>\x20heparin\x20overdose</strong>.\x20It\x20binds\x20to\x20<strong>long\x20heparin\x20molecules</strong>\x20with\x20high\x20affinity\x20and\x20neutralizes\x20anticoagulant\x20activity.\x20Therefore,\x20it\x20<strong>completely\x20reverses</strong>\x20the\x20action\x20of\x20unfractionated\x20heparin\x20but\x20only\x20<strong>partially\x20reverses\x20the\x20action</strong>\x20of\x20low-molecular-weight\x20heparin\x20(LMWH).\x20It\x20has\x20no\x20effect\x20on\x20fondaparinux.</p>\x0a<p>Dabigatran\x20-\x20Idarucizumab\x20(2-c)\x20:</p>\x0a<p><strong>Idarucizumab</strong>\u00a0is\x20a\x20monoclonal\x20antibody\x20that\x20specifically\x20acts\x20as\x20a\x20<strong>reversal\x20agent\x20</strong>for<strong>\x20dabigatran</strong>.\x20It\x20has\x20a\x20350\x20times\x20higher\x20affinity\x20for\x20dabigatran\x20than\x20dabigatran\x20for\x20thrombin.\x20Hence,\x20it\x20forms\x20a\x20complex\x20with\x20dabigatran,\x20which\x20is\x20excreted\x20by\x20the\x20kidneys.</p>\x0a<p>Warfarin\x20-\x20Vitamin\x20K\x20(3-a)\x20:</p>\x0a<p><strong>Vitamin\x20K</strong>\x20is\x20given\x20orally\x20as\x20well\x20as\x20intravenously\x20to\x20treat\x20<strong>warfarin\x20toxicity</strong>.\x20It\x20causes\x20the\x20reversal\x20of\x20anticoagulation\x20effects\x20of\x20warfarin\x20by\x20synthesis\x20of\x20vitamin\x20K–dependent\x20coagulation\x20factors\x20(II,\x20VII,\x20IX,\x20X).</p>\x0a<p>Rivaroxaban\x20-\x20Andexanet\x20alfa\x20(4-d)\x20:</p>\x0a<p><strong>Andexanet\x20alfa</strong>\x20is\x20a\u00a0recombinant\x20analog\x20of\x20factor\x20Xa\x20and\x20is\x20used\x20as\x20a\x20<strong>reversal\x20agent</strong>\x20for\u00a0<strong>oral\x20factor\x20Xa\x20inhibitors</strong>\u00a0like\x20rivaroxaban,\x20edoxaban,\x20and\x20apixaban.\u00a0It\x20rapidly\x20reverses\x20the\x20action\x20of\x20these\x20drugs\x20and\x20restores\x20thrombin\x20generation.\x20It\x20is\x20given\x20intravenously.</p>\x0a<p>Note:</p>\x0a<div>\x0a<p><strong>Ciraparantag\u00a0</strong>is\x20considered\x20a\x20potential\x20<strong>reversal\x20agent\x20agains</strong>t\x20<strong>all\x20direct\x20</strong><strong>anticoagulants,\u00a0</strong>including\x20dabigatran,\x20rivaroxaban,\x20apixaban,\x20and\x20edoxaban,\x20as\x20well\x20as\x20heparin\x20and\x20LMWH.\x20This\x20drug\x20is\x20in\x20the\x20early\x20stages\x20of\x20development.</p>\x0a</div>','<p>The\x20clinical\x20presentation\x20of\x20fatigue,\x20weight\x20loss,\x20anorexia,\x20generalized\x20lymphadenopathy,\x20and\x20the\x20presence\x20of\x20<strong>smudge</strong>\x20<strong>cells</strong>\x20on\x20a\x20peripheral\x20smear\x20suggest\x20<strong>chronic\x20lymphocytic\x20leukaemia\x20(CLL)</strong>.\x20Smudge\x20cells\x20are\x20characteristic\x20of\x20CLL.\x20The\x20preferred\x20antimetabolite\x20in\x20this\x20case\x20is\x20<strong>Fludarabine</strong>.</p>\x0a<p><strong>Fludarabine</strong>\x20is\x20a\x20<strong>purine\x20analogue</strong>\x20and\x20an\x20antimetabolite\x20commonly\x20used\x20in\x20the\x20treatment\x20of\x20<strong>CLL</strong>.\x20It\x20acts\x20by\x20<strong>inhibiting\x20DNA\x20synthesis</strong>\x20in\x20rapidly\x20dividing\x20cells,\x20including\x20malignant\x20lymphocytes.\x20It\x20is\x20the\x20preferred\x20choice\x20in\x20this\x20scenario\x20for\x20managing\x20CLL.</p>\x0a<p><strong>Chronic</strong>\x20<strong>lymphocytic</strong>\x20<strong>leukaemia</strong>\x20(CLL)\x20is\x20associated\x20with\x20the\x20deletions\x20of\x2013q,\x2011q,\x2017q,\x20and\x20trisomy\x2012q.\x20Lymph\x20nodes\x20are\x20diffusely\x20effaced\x20by\x20small\x20lymphocytes\x20with\x20proliferation\x20centres.\x20The\x20peripheral\x20smear\x20shows\x20small\x20round\x20lymphocytes\x20with\x20scant\x20cytoplasm\x20and\x20smudge\x20cells\x20as\x20seen\x20below.</p>','Parecoxib','toString','ekbgn','Familial\x20periodic\x20paralysis','correctCount','<p><span\x20data-preserver-spaces=\x22true\x22>The\x20drug\x20given\x20in\x20this\x20case\x20is\u00a0</span><strong>Linezolid</strong>\u00a0which\x20binds\x20to\x20the\u00a0<strong>P\x20site\x20</strong>of\x20the<strong>\x2050s\x20ribosomal\x20subunit\u00a0</strong>and<strong>\u00a0</strong>inhibits\x20bacterial\x20protein\x20synthesis.\x20It\x20is\x20an\u00a0<strong>oxazolidinone\u00a0</strong>that\u00a0is\x20active\x20against\x20various\x20resistant\x20organisms\x20including\x20methicillin-resistant\x20staphylococci,\x20vancomycin-resistant\x20staphylococci.\u00a0Linezolid\x20is\x20well\x20absorbed\x20orally\x20and\x20the<strong>\u00a0bioavailability\x20</strong>approaches<strong>\x20100%.</strong></p>\x0a<p>Linezolid\x20and\x20tedizolid\x20are\x20FDA\x20approved\x20for\x20the\x20treatment\x20of\x20skin\x20and\x20soft\x20tissue\x20infections\x20caused\x20by\x20streptococci\x20and\x20staphylococcus\x20aureus\x20(MSSA\x20and\x20MRSA).\u00a0Linezolid\x20is\x20also\x20approved\x20for\x20the\x20treatment\x20of\x20community-acquired\x20pneumonia\x20due\x20to\x20S.\x20pneumoniae\x20and\x20nosocomial\x20pneumonia\x20due\x20to\x20S.\x20aureus.</p>\x0a<p>Adverse\x20efffects\x20of\x20linezolid:</p>\x0a<ul>\x0a<li><strong>Myelosuppression\u00a0</strong>(anemia,\x20leukopenia,\x20pancytopenia)</li>\x0a<li><strong>Thrombocytopenia</strong><strong>\u00a0</strong>(most\x20common\x20side\x20effect)\u00a0</li>\x0a<li><strong>Serotonin\x20syndrome</strong>\x20if\x20given\x20along\x20with\x20serotonergic\x20drugs\x20due\x20to\x20<strong>monoamine\x20oxidase\u00a0</strong>(MAO)<strong>\x20inhibition</strong></li>\x0a<li>Mitochondrial\x20toxicities\x20like\x20peripheral\x20neuropathy,\x20optic\x20neuropathy,\x20lactic\x20acidosis</li>\x0a</ul>\x0a<p>Clinical\x20correlate-\x20Intravenous\x20and\x20oral\x20doses\x20for\x20linezolid\x20are\x20the\x20same\x20because\x20of\x20100%\x20bioavailability.</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A\x20-\u00a0<strong><span\x20data-preserver-spaces=\x22true\x22>Chloramphenicol</span></strong>\u00a0primarily\x20binds<strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0reversibly\x20</span></strong>to\x20the<strong><span\x20data-preserver-spaces=\x22true\x22>\x2050S\x20ribosomal\x20subunit.</span></strong><span\x20data-preserver-spaces=\x22true\x22>\u00a0It\x20blocks\x20the\x20amino\x20acid–containing\x20end\x20of\x20the\x20aminoacyl\x20tRNA\x20from\x20binding\x20to\x20the\x20acceptor\x20site\x20on\x20the\x2050S\x20ribosomal\x20subunit.\x20This\x20prevents\x20the\x20peptide\x20bond\x20formation\x20by\x20breaking\x20the\x20interaction\x20between\x20peptidyl\x20transferase\x20and\x20its\x20amino\x20acid\x20substrate.\x20One\x20of\x20the\x20most\x20important\x20adverse\x20effects\x20of\x20chloramphenicol\x20is\u00a0<strong>grey\x20baby\x20syndrome.</strong></span></p>\x0a<p>Option\x20C\x20-\u00a0<strong>Vancomycin</strong>\x20is\x20a\x20glycopeptide.<strong>\u00a0</strong>It<strong>\u00a0</strong>inhibits\x20bacterial\x20cell\x20wall\x20synthesis\x20by\x20binding\x20with\x20<strong>D-alanyl-D-alanine.\u00a0</strong>It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20MRSA,\x20clostridium\x20difficile,\x20and\x20enterococci.\u00a0<strong>Redman\x20syndrome,\x20ototoxicity,\u00a0</strong>and<strong>\x20nephrotoxicity\u00a0</strong>are\x20the\x20most\x20important\x20adverse\x20effects.</p>\x0a<p>Option\x20D\x20-\u00a0<strong>Gentamicin\u00a0</strong>is\x20an\u00a0<strong>aminoglycoside.\x20</strong>Aminoglycoside\x20antibiotics\x20act\x20by\u00a0binding\x20to\x20the\x20<strong>30s\x20ribosome</strong>\x20and\x20interfere\x20with\x20the\x20initiation\x20of\x20protein\x20synthesis.\x20Their\x20ability\x20to\x20cause\x20misreading\x20of\x20DNA\x20template\x20and\x20the\x20formation\x20of\x20aberrant\x20proteins\x20that\x20get\x20incorporated\x20into\x20bacterial\x20cell\x20membrane\x20makes\x20them\u00a0bactericidal\x20agents.\x20Their\x20antimicrobial\x20activity\x20reduces\x20in\x20an\x20anaerobic\x20environment.\x20<strong>Ototoxicity,\x20nephrotoxicity,\u00a0</strong>and\x20<strong>neuromuscular\x20blockade</strong>\x20are\x20the\x20most\x20important\x20adverse\x20effects.</p>','sBjvI','vavvy','UMSEt','1579688WdVeDy','7qlSQtI','<p>The\x20drug\x20that\x20catalyzes\x20the\x20enzymatic\x20oxidation\x20of\x20uric\x20acid\x20into\x20allantoin\x20for\x20the\x20treatment\x20of\x20chronic\x20gout\x20is<strong>\x20pegloticase.\x20</strong></p>\x0a<p>Pegloticase\x20is\x20a\x20<strong>pegylated\x20uricase</strong>\x20(urate\x20oxidase)\x20that\x20catalyzes\x20the\x20enzymatic\x20oxidation\x20of\x20<strong>uric\x20acid\x20into\x20allantoin</strong>,\x20which\x20is\x20a\x20more\x20soluble\x20and\x20inactive\x20metabolite.\u00a0It\x20is\x20used\x20in\x20the\x20treatment\x20of\x20<strong>severe</strong>,\u00a0<strong>refractory\x20chronic\x20gout</strong>\x20or\x20in\x20cases\x20where\x20other\x20urate-lowering\x20therapies\x20are\x20contraindicated.\x20The\x20efficacy\x20of\x20this\x20drug\x20gets\x20lowered\x20if\x20antibodies\x20are\x20produced\x20against\x20the\x20drug,\x20which\x20occurs\x20in\x20many\x20patients.\x20This\x20also\x20increases\x20the\x20risk\x20of\x20infusion\x20reactions.\u00a0</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20711\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20711\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p><strong>Rasburicase</strong>\x20is\x20a\x20<strong>recombinant\x20uricase</strong>.\x20It\x20is\x20indicated\x20for\x20the\x20initial\x20management\x20of\x20elevated\x20plasma\x20uric\x20acid\x20levels\x20in\x20patients\x20with\x20malignancies\x20who\x20are\x20on\x20chemotherapy.\x20The\x20efficacy\x20is\x20limited\x20by\x20the\x20production\x20of\x20antibodies\x20to\x20the\x20drug.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p><strong>Gout</strong>\x20occurs\x20due\x20to\x20the\x20precipitation\x20of\x20urate\x20crystals\x20in\x20the\x20tissues\x20with\x20a\x20subsequent\x20inflammatory\x20response.\x20In\x20an\x20acute\x20episode\x20of\x20gout,\x20there\x20is\x20painful\x20distal\x20monoarthritis\x20which\x20can\x20lead\x20to\x20joint\x20destruction,\x20subcutaneous\x20tophi,\x20and\x20renal\x20calculi.\x20Management\x20of\x20gout\x20includes:</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20708\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<ul>\x0a<li>Reduction\x20of\x20pain\x20and\x20inflammation:\x20NSAIDs,\x20colchicine,\x20glucocorticoids</li>\x0a<li>Inhibition\x20of\x20the\x20formation\x20of\x20urate:\x20Allopurinol,\x20febuxostat</li>\x0a<li>Promotion\x20of\x20urate\x20excretion:\x20Probenecid,\x20lesinurad</li>\x0a</ul>\x0a</div>\x0a</div>\x0a</div>\x0a</div>\x0a<p>Other\x20options:\u00a0</p>\x0a<p>Option\x20A:\x20<strong>Colchicine</strong>\x20acts\x20by\x20<strong>preventing\x20the\x20polymerization\x20of\x20microtubules\x20by\x20tubulin</strong>,\x20this\x20<strong>reduces\x20neutrophil\x20recruitment</strong>\x20to\x20inflamed\x20tissue\x20and\x20also\x20<strong>decreases\x20the\x20secretion\x20of\x20chemotactic\x20factors</strong>\x20by\x20activated\x20neutrophils.\x20Overall\x20reducing\x20the\x20inflammatory\x20response.</p>\x0a<p>Option\x20B:\u00a0<strong>Febuxostat</strong>\x20is\x20a\u00a0<strong>xanthine\x20oxidase\x20inhibitor</strong>\x20approved\x20for\x20the\x20<strong>treatment\x20of\x20hyperuricemia</strong>\x20in\x20patients\x20with\x20gout.</p>\x0a<p>Option\x20D:\x20<strong>Allopurinol</strong>\x20by\x20<strong>inhibiting\x20the\x20xanthine\x20oxidase</strong>\x20enzyme\x20prevents\x20the\x20conversion\x20of\x20xanthine\x20to\x20uric\x20acid.</p>','geDhL','WoHFd','odFgm','EzdiH','https://cdn1.dailyrounds.org/uploads/ddeeb99a9e674b1086961125676f7764.JPEG','umtjJ','UIlfD','kABCB','<div\x20class=\x22glass-light\x20p-4\x20mb-4\x22><audio\x20src=\x22','vOyhj','KqrzT','w-8\x20h-8\x20text-sm\x20font-medium\x20rounded\x20','jKjGD','https://cdn1.dailyrounds.org/uploads/47a42dafb55b40a8a33cfebc2d871081.JPEG','IQkjD','<p><strong>Vincristine</strong>\x20is\x20a\x20vinca\x20alkaloid\x20that\x20acts\x20during\x20the\x20<strong>M\x20phase</strong>\x20of\x20the\x20cell\x20cycle\u00a0</p>\x0a<p>It\x20causes\x20microtubule\x20disruptions,\x20thereby\x20preventing\x20cellular\x20replication.</p>\x0a<p><strong>Vincristine</strong>\x20prevents\x20the\x20polymerization\x20of\x20the\x20microtubular\x20protein\x20tubulin,\x20causing\x20<strong>metaphase</strong>\x20<strong>arrest</strong>.\x20It\x20is\x20very\x20useful\x20for\x20inducing\x20remission\x20in\x20childhood\x20<strong>acute</strong>\x20<strong>lymphoblastic</strong>\x20<strong>leukaemia</strong>.\x20Prominent\x20<strong>adverse</strong>\x20<strong>effects</strong>\x20are\x20<strong>peripheral</strong>\x20<strong>neuropathy</strong>\x20and\x20reversible\x20<strong>alopecia</strong>.\x20It\x20also\x20causes\x20ataxia,\x20nerve\x20palsies,\x20autonomic\x20dysfunction\x20and\x20seizures.</p>','urjTJ','https://dhmbxeygs57ff.cloudfront.net/uploads/8d7167c153aa42a5bdc0787fd454473ex1280x1252.JPEG','ljAvt','Salazar','SqgXh','Varenicline','A\x20patient\x20who\x20was\x20being\x20treated\x20for\x20an\x20arrhythmia\x20presented\x20with\x20palpitations\x20and\x20chest\x20discomfort.\x20His\x20ECG\x20has\x20been\x20given\x20below.\x20Which\x20of\x20the\x20following\x20drugs\x20would\x20be\x20least\x20likely\x20to\x20cause\x20this\x20condition?','mGaeg','hidden','JSofN','\x22\x20alt=\x22Question\x20Image\x22\x20class=\x22w-full\x20rounded-lg\x22></div>','MAMuz','jsEGJ','bkxAW','xvKfg','An\x20HIV-positive\x20patient\x20diagnosed\x20with\x20CMV\x20retinitis\x20was\x20initiated\x20on\x20ganciclovir.\x20Which\x20ART\x20drug\x20among\x20the\x20following\x20should\x20be\x20avoided?','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20','<p><strong>Schedule\x20J\x20</strong>contains\x20a\x20list\x20of\x20diseases\x20that\x20a\x20<strong>drug\x20may\x20not\x20prevent\x20or\x20cure</strong>.\u00a0E.g.\x20-\x20<strong>HIV\x20</strong>&amp;\x20<strong>Atherosclerosis</strong>.</p>\x0a<p><strong>The\x20Drugs\x20and\x20Cosmetics\x20Rules,\x201945</strong>\x20are\x20the\x20set\x20of\x20rules\x20under\x20The\x20Drugs\x20and\x20Cosmetics\x20Act,1940\x20which\x20contains\x20provisions\x20for\x20the\x20classification\x20of\x20drugs\x20under\x20given\x20schedules\x20and\x20there\x20are\x20guidelines\x20for\x20the\x20storage,\x20sale,\x20display,\x20and\x20prescription\x20of\x20each\x20schedule.</p>','Valbenazine','hWboU','Chronic\x20kidney\x20disease','XEXuh','modeModal','A\x20pregnant\x20female\x20at\x2036\x20weeks\x20gestation,\x20presents\x20with\x20palpitations,\x20protrusion\x20of\x20the\x20eyeball,\x20and\x20heat\x20intolerance.\x20On\x20blood\x20investigations,\x20it\x20was\x20found\x20that\x20she\x20had\x20increased\x20T3\x20and\x20T4\x20levels\x20and\x20decreased\x20TSH\x20levels.\x20\x20Which\x20of\x20the\x20following\x20should\x20be\x20the\x20next\x20step\x20in\x20the\x20management\x20of\x20this\x20patient?','round','choices','FYWNJ','notAttempted','appendChild','Local\x20anesthetic','Rifampicin','<p><strong>Cromolyn</strong>\x20<strong>sodium</strong>\x20(Sodium\x20cromoglycate)\x20is\x20administered\x20through\x20the\x20<strong>inhalation\x20route</strong><strong>\u00a0</strong>as\x20an\x20<strong>aerosol,</strong>\x20through\x20a\x20metered-dose\x20inhaler\x20(MDI)\x20in\x20bronchial\x20asthma.<br\x20/><br\x20/>Sodium\x20cromoglycate\x20is\x20a\x20<strong>mast\x20cell\x20stabilizer,</strong>\x20which\x20inhibits\x20the\x20degranulation\x20of\x20mast\x20cells\x20and\x20restricts\x20the\x20release\x20of\x20inflammatory\x20cytokines.\x20It\x20<strong>prevents\x20bronchoconstriction</strong>\x20but\x20does\x20not\x20act\x20as\x20a\x20direct\x20bronchodilator\x20and\x20hence\x20cannot\x20be\x20used\x20once\x20bronchoconstriction\x20is\x20established\x20or\x20during\x20an\x20asthmatic\x20attack.\u00a0</p>\x0a<p>It\x20is\x20not\x20absorbed\x20orally.\x20It\x20is\x20administered\x20through\x20the\x20inhalation\x20route\x20for\x20the\x20treatment\x20of\x20bronchial\x20asthma.\x20It\x20can\x20also\x20be\x20used\x20in\x20the\x20treatment\x20of\x20allergic\x20conjunctivitis\x20as\x20a\x20topical\x20application.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20266\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>The\x20therapeutic\x20benefit\x20develops\x20slowly\x20over\x202-4\x20weeks\x20and\x20lasts\x201-\x202\x20weeks\x20after\x20discontinuation\x20of\x20the\x20drug.\x20Its\x20use\x20has\x20declined\x20due\x20to\x20the\x20widespread\x20usage\x20of\x20inhaled\x20corticosteroids.</p>\x0a<p><strong>Drugs\x20used\x20in\x20the\x20treatment\x20of\x20bronchial\x20asthma</strong></p>\x0a<p><strong>Bronchodilators</strong></p>\x0a<ul>\x0a<li>Beta-2\x20sympathomimetics:\x20Salmeterol,\x20Formoterol</li>\x0a<li>Methylxanthines:\x20Theophylline,\x20Aminophylline</li>\x0a<li>Anticholinergics:\x20Ipratropium\x20bromide,\x20Tiotropium\x20bromide</li>\x0a</ul>\x0a<p><strong>Anti-inflammatory</strong></p>\x0a<ul>\x0a<li>Corticosteroids\x20(Inhalational):\x20Beclomethasone,\x20Budesonide,\x20Fluticasone</li>\x0a<li>Corticosteroids\x20(Systemic):\x20Prednisolone,\x20Hydrocortisone</li>\x0a<li>Mast\x20cell\x20stabilizers:\x20Sodium\x20cromoglycate,\x20Ketotifen</li>\x0a<li>Leukotriene\x20antagonists:\x20Montelukast,\x20Zafirlukast</li>\x0a<li>anti-IgE\x20-\x20Omalizumab</li>\x0a</ul>\x0a</div>\x0a</div>\x0a</div>','text','iAadR','MoiOC','data-option-index','\x22><span\x20class=\x22font-bold\x20mr-3\x22>','FQsGn','bxqTk','DYqdY','Correct','kSwRQ','Etoricoxib','warn','<p>Gastroparesis\x20can\x20be\x20treated\x20with\x20<strong>prokinetic\x20agents\x20</strong>such\x20as\x20<strong>metoclopramide,\x20cisapride,\x20</strong>and<strong>\x20motilin</strong>.\x20<strong>Loperamide</strong>\x20is\x20an\x20orally\x20active\x20<strong>antimotility</strong>\x20and\x20<strong>antisecretory\x20agent\u00a0</strong>and\x20<strong>cannot</strong>\x20be\x20used\x20to\x20treat\x20gastroparesis.</p>\x0a<p>Loperamide\x20acts\x20by\x20<strong>increasing</strong>\x20the\x20mouth\x20to\x20the\x20caecum\x20and\x20small\x20intestine\x20<strong>transit\x20times</strong>\x20and\x20increases\x20the\x20tone\x20of\x20the\x20anal\x20sphincter.</p>\x0a<div\x20class=\x22page\x22\x20title=\x22Page\x20928\x22>\x0a<div\x20class=\x22section\x22>\x0a<div\x20class=\x22layoutArea\x22>\x0a<div\x20class=\x22column\x22>\x0a<p>Prokinetic\x20agents\x20enhance\x20coordinated\x20GI\x20motility\x20and\x20the\x20transit\x20of\x20material\x20in\x20the\x20GI\x20tract.\x20They\x20do\x20not\x20interfere\x20with\x20the\x20normal\x20physiological\x20pattern\x20and\x20rhythm\x20of\x20motility.\x20They\x20act\x20through\x20the\x20following\x20mechanisms\x20of\x20action:</p>\x0a<ul>\x0a<li><strong>Dopamine</strong>\x20receptor\x20<strong>antagonists</strong>:\x20Metoclopramide\x20and\x20domperidone</li>\x0a<li><strong>Serotonin</strong>\x20receptor\x20<strong>agonists</strong>:\x20cisapride\x20and\x20prucalopride</li>\x0a<li>Mimicking<strong>\x20motilin</strong>\x20action:\x20Erythromycin\x20and\x20other\x20macrolide\x20antibiotics</li>\x0a</ul>\x0a<p>Indications\x20for\x20use\x20of\x20prokinetic\x20agents\x20such\x20as\x20metoclopramide\x20include\x20gastroparesis,\x20in\x20medical\x20or\x20diagnostic\x20procedures\x20such\x20as\x20<strong>upper\x20endoscopy</strong>\x20or\x20contrast\x20radiography\x20of\x20the\x20GI\x20tract\x20and\x20ameliorate\x20nausea\x20and\x20vomiting\x20that\x20often\x20accompany\x20GI\x20dysmotility\x20syndromes.</p>\x0a</div>\x0a</div>\x0a</div>\x0a</div>','border-gray-600','testModeReviewLegend','HayqI','dQQoP','preventDefault','ttpOG','</span><span>','Imipramine','slVuh','bUiMA','tSBdK','tylGV','yUlnb','nav-btn-bookmarked','Water-soluble\x20irreversible\x20inhibitor\x20of\x20acetylcholinesterase','1-b,\x202-d,\x203-a,\x204-c','hobuJ','mGent','uRuZP','dYZYB','createElement','explanation_images','isArray','src','fromCharCode','HmxAe','<p><strong>Ranitidine\x20increases\x20gastric\x20pH</strong>\x20and\x20hence\x20<strong>sucralfate</strong>\x20is\x20not\x20able\x20to\x20polymerize\x20as\x20it\x20requires\x20an\x20acidic\x20pH\x20to\x20form\x20a\x20protective\x20layer\x20over\x20the\x20ulcer.\x20Hence\x20it\x20is\x20<strong>not</strong>\x20a\x20rational\x20combination.</p>\x0a<p><strong>Sucralfate</strong>,\x20in\x20an\x20acidic\x20environment\x20(<strong>pH\x20&lt;\x204</strong>)\x20acts\x20by\x20producing\x20a\x20viscous,\x20sticky\x20polymer\x20that\x20adheres\x20to\x20ulcer\x20craters\x20and\x20epithelial\x20cells\x20for\x20<strong>up\x20to\x206\x20hours</strong>\x20after\x20a\x20single\x20dose.\x20This\x20viscous\x20layer\x20produced\x20in\x20the\x20stomach\x20leads\x20to\x20the\x20inhibition\x20of\x20absorption\x20of\x20other\x20drugs,\x20like\x20phenytoin,\x20digoxin,\x20cimetidine,\x20ketoconazole,\x20and\x20fluoroquinolone\x20antibiotics.\u00a0</p>\x0a<p><strong>Constipation</strong>\x20is\x20the\x20most\x20common\x20<strong>side</strong>\x20<strong>effect</strong>\x20of\x20sucralfate.\x20It\x20should\x20be\x20<strong>avoided\x20in\x20patients\x20with\x20renal\x20failure</strong>\x20who\x20are\x20at\x20risk\x20of\x20aluminium\x20overload.\x20Aluminium-containing\x20antacids\x20should\x20not\x20be\x20combined\x20with\x20sucralfate\x20in\x20these\x20patients.\x20\u00a0As\x20the\x20viscous\x20gel\x20produced\x20by\x20sucralfate\x20is\x20sticky,\x20it\x20may\x20eventually\x20lead\x20to\x20bezoar\x20formation.</p>\x0a<p>It\x20is\x20generally\x20used\x20for\x20prophylaxis\x20of\x20peptic\x20ulcers,\x20but\x20rarely\x20so\x20because\x20its\x20side\x20effects\x20and\x20its\x20risks\x20outweigh\x20its\x20benefits.</p>','Propranalol','Schedule\x20J\x20drugs','EuUSt','Sucralfate\x20interferes\x20with\x20absorption\x20of\x20ranitidine','A\x2017-year-old\x20girl\x20was\x20admitted\x20with\x20a\x20large\x20wound\x20on\x20her\x20thigh\x20for\x20the\x20past\x203\x20months.\x20Cultures\x20from\x20the\x20wound\x20margin\x20revealed\x20an\x20MRSA\x20infection.\x20She\x20was\x20given\x20an\x20antibiotic\x20that\x20binds\x20to\x20the\x20subunit\x20of\x20the\x20ribosome\x20marked\x20by\x20the\x20red\x20cross\x20and\x20inhibits\x20bacterial\x20protein\x20synthesis.\x20Identify\x20the\x20drug\x20given\x20to\x20this\x20patient.','testModeLegend','Mqgol','submitSection','CILcR','KjpaT','pOlET','gWZmJ','bgobe','Schedule\x20G\x20drugs','Sertraline','MsFjq','rhGfp','userHistory','constructor','\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<button\x20type=\x22button\x22\x20class=\x22option-button\x20','lOeqM','Zidovudine','replace','Dextromethorphan\x20used\x20as\x20an\x20antitussive\x20agent\x20is\x20a:','display','You\x20have\x20completed\x20all\x20questions.\x20Would\x20you\x20like\x20to\x20review\x20from\x20the\x20beginning?','APmgU','uGhKJ','1-b,\x202-a,\x203-d,\x204-c','rPReC','not-attempted','NCSID','.m3u8','Anionic\x20site','UzIEU','Tscjb','kgGfq','QtHTy','6-mercaptopurine','tQZbh','LZiaR','Vincristine','AJdVc','AFeKe','<div\x20class=\x22mt-2\x22><p\x20class=\x22text-sm\x20text-white\x20text-opacity-70\x20mb-1\x22>Hinglish\x20Explanation:</p><audio\x20src=\x22','JKkcJ','5-fluorouracil','JFmvt','Epoprostenol','Ranitidine\x20increases\x20gastric\x20pH\x20so\x20sucralfate\x20is\x20not\x20able\x20to\x20act','currentQuestionIndex','AqXWR','eLxzF','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22bg-green-900\x20bg-opacity-20\x20p-4\x20rounded-lg\x20border\x20border-green-700\x22>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<h5\x20class=\x22text-green-400\x20font-bold\x20mb-2\x22>Explanation:</h5>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22text-white\x20text-opacity-90\x22>','UqqJQ','WErIo','wRQLN','Low\x20molecular\x20weight\x20heparin,\x20short\x20half\x20life','Ciprofloxacin','exception','gRXgI','HqvJv','gAibH','TEyAP','markReviewText','JMDzu','referrer','veuDc','mSnzo','</div>\x0a\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20\x20<div\x20class=\x22option-text\x22>','accuracyScore','isSupported','questions','It\x20belongs\x20to\x20first-generation\x20antihistamines','solutionImages','textContent','VijuJ','IicNj','Previous\x20progress\x20cleared.','oIQFW','jqBUm','question_audio','EMGlv','ZTIbi','Inhibition\x20of\x20inosine\x20monophosphate\x20dehydrogenase','Esteratic\x20site,\x20Anionic\x20site','lpYAK','Interferon\x20beta','Warfarin,\x20long\x20half\x20life','padStart','pLdXl','GGfcd','Ranitidine\x20combines\x20with\x20sucralfate\x20and\x20interferes\x20with\x20its\x20absorption','dataset','1-a,\x202-c,\x203-d,\x204-b','status','glass-light\x20px-6\x20py-3\x20text-white\x20hover:bg-yellow-500\x20hover:bg-opacity-20\x20transition-all\x20duration-300\x20flex\x20items-center','JYpzh','xKsZH','cMmZW','VBbGG','Ticlopidine','nBopj','BXkPv','uQvrp','mHWsY','1.5\x20-\x202.0','addEventListener','Prasugrel','FddYP','iJniV','https://dhmbxeygs57ff.cloudfront.net/uploads/c349cba35a56473aaefe2164a2bd9990x242x160.JPEG','Rofecoxib','DOMContentLoaded','hjwBK','incoD','EhVrj','pbcKG','uPwti','IWYhr','Oral','seGYf','custom_quiz.html','nav-btn-current','Your\x20senior\x20asks\x20you\x20to\x20administer\x20a\x20selective\x20COX-2\x20inhibitor\x20intravenously\x20to\x20a\x20patient\x20for\x20post-op\x20analgesia.\x20Which\x20of\x20the\x20following\x20will\x20you\x20choose?','uZufX','OnHrU','Hydrochlorothiazide','ZvkJH','<p><strong>Dextromethorphan\u00a0</strong>is\x20a<strong>\x20centrally-acting\x20NMDA\u00a0receptor\x20antagonist\x20</strong>that\x20is\x20used\x20as\x20an\x20<strong>antitussive</strong>.</p>\x0a<p>The\x20<strong>antitussive</strong>\x20action\x20of\x20<strong>dextromethorphan</strong>\x20is\x20due\x20to\x20the\x20<strong><em>d</em>-isomer</strong>,\x20whereas\x20the\x20<strong><em>l</em>-isomer</strong>\x20is\x20an\x20<strong>analgesic.</strong></p>\x0a<p><strong>Hallucinations</strong>\x20at\x20higher\x20doses,\x20gastrointestinal\x20discomfort,\x20and\x20dizziness\x20are\x20well-known\x20side\x20effects.\x20Dextromethorphan\x20must\x20be\x20administered\x20with\x20caution\x20to\x20those\x20with\x20abuse\x20potential.</p>\x0a<p><strong>Antitussives</strong>\x20are\x20a\x20group\x20of\x20drugs\x20that\x20act\x20centrally\x20to\x20<strong>raise\x20the\x20threshold\x20of\x20the\x20cough\x20centre</strong>\x20or\x20peripherally\x20on\x20the\x20respiratory\x20tract\x20to\x20reduce\x20the\x20tussal\x20impulse\x20or\x20both.</p>\x0a<p>The\x20mechanism\x20of\x20action\x20of\x20other\x20antitussives\x20is\x20as\x20follows:\u00a0</p>\x0a<ul>\x0a<li><strong>Local\x20anaesthetic\x20action\x20</strong>(option\x20A)<strong>\u00a0</strong>is\x20seen\x20in\x20benzonatate<strong>\u00a0</strong>which\x20acts<strong>\x20peripherally\x20</strong>by<strong>\x20anaesthetising\x20the\x20stretch\x20receptors</strong>\x20located\x20in\x20the\x20respiratory\x20passages,\x20lungs\x20and\x20pleura.\x20By\x20decreasing\x20the\x20activity\x20of\x20these\x20stretch\x20receptors,\x20benzonatate\x20may\x20<strong>reduce\x20the\x20cough\x20reflex</strong>.\x20Side\x20effects\x20include\x20<strong>dysphagia</strong>\x20and\x20<strong>dizziness</strong>.\x20Acute\x20ingestion\x20may\x20cause\x20<strong>seizures</strong>\x20and\x20<strong>cardiac\x20arrest</strong>.</li>\x0a<li><strong>Neuromodulators</strong>\x20(Option\x20B)\x20such\x20as\x20<strong>gabapentin</strong>\x20and\x20pregebalin\u00a0inhibits\x20neurotransmission.They\x20are\x20beneficial\x20in\x20neuropathic\x20pain\x20syndrome\x20and\x20<strong>chronic</strong>\x20<strong>idiopathic</strong>\x20<strong>cough</strong>.\x20Side\x20effects\x20are\x20somnolence\x20and\x20dizziness.</li>\x0a<li><strong>Opioids</strong>\x20(Option\x20C)\x20such\x20as\x20<strong>codeine</strong>\x20and\x20pholcodine\x20act\x20centrally\x20on\x20the\x20<strong>medullary\x20opioid\x20receptor</strong>\x20in\x20the\x20medullary\x20cough\x20centre.\x20Side\x20effects\x20include\x20sedation\x20and\x20constipation.</li>\x0a</ul>','bbocG','A\x2026-year-old\x20man\x20with\x20a\x20history\x20of\x20severe\x20psoriasis\x20has\x20been\x20planned\x20to\x20be\x20initiated\x20on\x20a\x20monoclonal\x20antibody\x20that\x20targets\x20the\x20IL-17A\x20cytokine.\x20Which\x20of\x20the\x20following\x20drugs\x20is\x20he\x20most\x20likely\x20to\x20be\x20prescribed?','<p><strong>Secukinumab</strong>\x20is\x20a\x20<strong>monoclonal\x20antibody</strong>\x20that\x20targets\x20the<strong>\x20IL-17A\x20cytokine</strong>.\x20It\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>moderate\x20to\x20severe\x20plaque\x20psoriasis</strong>,\x20psoriatic\x20arthritis,\x20and\x20ankylosing\x20spondylitis.\x20Secukinumab\x20is\x20administered\x20as\x20a\x20<strong>subcutaneous</strong>\x20injection\x20every\x20<strong>4\x20or\x2012\x20weeks</strong>.</p>\x0a<p><strong>Newer</strong>\x20drugs\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>psoriatic</strong>\x20<strong>arthritis</strong>\x20include:</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2048.3747%;\x20height:\x20255.955px;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr\x20style=\x22height:\x2022.3958px;\x22>\x0a<td\x20style=\x22width:\x2050.0423%;\x20text-align:\x20center;\x20height:\x2022.3958px;\x22>Class\x20of\x20drug</td>\x0a<td\x20style=\x22width:\x2050.0423%;\x20text-align:\x20center;\x20height:\x2022.3958px;\x22>Drugs</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x20143.976px;\x22>\x0a<td\x20style=\x22width:\x2050.0423%;\x20height:\x20143.976px;\x20text-align:\x20center;\x22>Anti-TNF\x20α</td>\x0a<td\x20style=\x22width:\x2050.0423%;\x20height:\x20143.976px;\x22>\u00a0<strong>Infliximab</strong>\x20(only\x20<strong>IV</strong>\x20drug,\x20rest\x20all\x20are\x20s/c)<br\x20/>\x0a<ul>\x0a<li>Etanercept\u00a0</li>\x0a<li>Adalimumab\u00a0</li>\x0a<li>Golimumab</li>\x0a<li>Certolizumab</li>\x0a</ul>\x0a</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3958px;\x22>\x0a<td\x20style=\x22width:\x2050.0423%;\x20height:\x2022.3958px;\x20text-align:\x20center;\x22>Anti-IL-17</td>\x0a<td\x20style=\x22width:\x2050.0423%;\x20height:\x2022.3958px;\x22>Secukinumab</td>\x0a</tr>\x0a<tr\x20style=\x22height:\x2022.3958px;\x22>\x0a<td\x20style=\x22width:\x2050.0423%;\x20height:\x2022.3958px;\x20text-align:\x20center;\x22>Anti-IL-23\x20and\x20IL-12</td>\x0a<td\x20style=\x22width:\x2050.0423%;\x20height:\x2022.3958px;\x22>Ustekinumab</td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Ustekinumab</strong>\x20is\x20a\x20fully\x20human\x20IgG1\x20\u00a0<strong>monoclonal\x20antibody</strong>\x20against\x20the\x20<strong>p40\x20subunit</strong>\x20that\x20is\x20common\x20to\x20both\x20<strong>IL‐12\x20and\x20IL‐23</strong>.\x20Ustekinumab\x20is\x20indicated\x20for\x20<strong>severe\x20plaque\x20psoriasis</strong>,\x20psoriatic\x20arthritis,\x20and\x20Crohn\x27s\x20disease.\x20Dizziness,\x20sore\x20throat\x20and\x20joint\x20pain\x20are\x20the\x20most\x20common\x20side\x20effects\x20associated\x20with\x20Ustekinumab.\x20Ustekinumab\x20is\x20administered\x20as\x20a\x20subcutaneous\x20injection\x20every\x2012\x20weeks.</p>\x0a<p>Option\x20C:\x20<strong>Brodalumab</strong>\x20is\x20a\x20<strong>monoclonal\x20antibody\x20</strong>that\x20targets\x20the<strong>\x20IL-17RA\x20receptor</strong>.\x20It\x20is\x20approved\x20for\x20the\x20treatment\x20of\x20<strong>moderate\x20to\x20severe\x20plaque\x20psoriasis</strong>.\x20Brodalumab\x20is\x20administered\x20as\x20a\x20subcutaneous\x20injection\x20every\x202\x20weeks.\x20It\x20leads\x20to\x20black\x20tarry\x20stools,\x20lethargy,\x20and\x20joint\x20pain\x20as\x20the\x20most\x20common\x20adverse\x20effects.</p>\x0a<p>Option\x20D:\x20\u00a0<strong>Adalimumab</strong>\x20is\x20an\x20<strong>anti-TNF-𝛂\x20antibody</strong>.\x20It\x20is\x20approved\x20for\x20the\x20use\x20of\x20rheumatoid\x20arthritis,\x20juvenile\x20idiopathic\x20arthritis,\x20<strong>plaque\x20psoriasis</strong>,\x20Crohn\x27s\x20disease,\x20and\x20ulcerative\x20colitis.\x20\u00a0</p>','ydsSY','aBTAK','explanation_audio_hin','prevBtn','Gentamicin','Twrxo','getElementById','PCSK-6\x20inhibition','totalQuestionsResult','Muscle\x20tremors','questionNav','PVqgG','incorrectCount','<p>In\x20the\x20given\x20clinical\x20scenario,\x20the\x20most\x20likely\x20diagnosis\x20is\x20<strong>thyrotoxicosis</strong>.\x20As\x20she\x20is\x20in\x20her<strong>\x20third\x20trimester</strong>,\x20the\x20drug\x20of\x20choice\x20for\x20the\x20treatment\x20of\x20thyrotoxicosis\x20is\x20<strong>methimazole.</strong></p>\x0a<p>Treatment\x20of\x20thyrotoxicosis\x20in\x20pregnancy\x20has\x20been\x20summarized\x20in\x20the\x20table\x20below.</p>\x0a<table\x20style=\x22border-collapse:\x20collapse;\x20width:\x2038.5561%;\x22\x20border=\x221\x22>\x0a<tbody>\x0a<tr>\x0a<td\x20style=\x22width:\x2050.0766%;\x20text-align:\x20center;\x22>Trimester</td>\x0a<td\x20style=\x22width:\x2049.9234%;\x20text-align:\x20center;\x22>Treatment\x20options</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2050.0766%;\x22>First\x20trimester</td>\x0a<td\x20style=\x22width:\x2049.9234%;\x22>\x0a<p>Propylthiouracil</p>\x0a</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2050.0766%;\x22>Second\x20trimester</td>\x0a<td\x20style=\x22width:\x2049.9234%;\x22>Methimazole\x20(preferred)<br\x20/>Subtotal\x20thyroidectomy</td>\x0a</tr>\x0a<tr>\x0a<td\x20style=\x22width:\x2050.0766%;\x22><strong>Third\x20trimester</strong></td>\x0a<td\x20style=\x22width:\x2049.9234%;\x22><strong>Methimazole</strong></td>\x0a</tr>\x0a</tbody>\x0a</table>\x0a<p><strong>Thyrotoxicosis</strong>\x20during\x20pregnancy\x20is\x20usually\x20controlled\x20by\x20thioamide\x20drugs.\x20<strong>Propylthiouracil</strong>\x20was\x20preferred\x20previously\x20because\x20it\x20partially\x20inhibits\x20the\x20conversion\x20of\x20T4\x20to\x20T3\x20and\x20crosses\x20the\x20placenta\x20less\x20readily\x20than\x20methimazole.\x20However,\x20since\x20it\x20has\x20a\x20<strong>higher\x20risk\x20</strong>of\x20causing\x20<strong>propylthiouracil-associated\x20liver\x20failure\x20in\x20pregnancy</strong>,\x20<strong>methimazole</strong>\x20is\x20prescribed\x20according\x20to\x20guidelines\x20in<strong>\u00a0</strong>the<strong>\x20</strong>second\x20trimester<strong>\x20and\x20third\x20trimesters</strong>.\u00a0Methimazole\x20is\x20usually\x20avoided\x20in\x20the\x20first\x20trimester\x20due\x20to\x20<strong>methimazole-associated\x20embryopathy.</strong>\u00a0</p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20B:\x20<strong>Subtotal\x20thyroidectomy</strong>\x20is\x20done\x20once\x20the\x20hyperthyroidism\x20is\x20medically\x20controlled.\x20It\x20is\x20usually\x20avoided\x20during\x20pregnancy,\x20however,\x20may\x20be\x20done\x20in\x20some\x20cases\x20in\x20the\x20second\x20trimester\x20where\x20it\x20can\x27t\x20be\x20controlled\x20via\x20medication.</p>\x0a<p>Option\x20D:\x20<strong>Radioactive\x20iodine</strong>\x20is\x20<strong>contraindicated</strong>\x20in\x20pregnant\x20women\x20as\x20it\x20may\x20cause\x20<strong>fetal\x20thyroid\x20gland\x20destruction</strong>.</p>','WAiAY','It\x20is\x20a\x20GABAc\x20receptor\x20modulator','solutionText','getAttribute','<p><strong>Lansoprazole\u00a0</strong>is\x20the\x20most\x20useful\x20in\x20the\x20management\x20of\x20this\x20patient.</p>\x0a<p><strong>Lansoprazole</strong>\x20is\x20an\x20H1/K1-ATPase\x20proton\x20pump\x20inhibitor\x20useful\x20in\x20the\x20treatment\x20of\x20patients\x20who\x20have\x20failed\x20histamine\x20H2-blocker\x20therapy\x20and\x20patients\x20with\x20Zollinger-Ellison\x20syndrome.</p>\x0a<p>Patients\x20with\x20Zollinger-Ellison\x20syndrome\x20develop\x20<strong>pancreatic\x20or\x20duodenal\x20gastrinomas</strong>\x20that\x20stimulate\x20the\x20secretion\x20of\x20very\x20large\x20amounts\x20of\x20acid,\x20sometimes\x20in\x20the\x20setting\x20of\x20<strong>multiple\x20endocrine\x20neoplasia,\x20type\x20I.\u00a0</strong>This\x20can\x20lead\x20to\x20<strong>severe\x20gastroduodenal\x20ulceration</strong>\x20and\x20other\x20consequences\x20of\x20uncontrolled\x20hyperchlorhydria.</p>\x0a<p><strong>Proton\x20pump\x20inhibitors</strong>\u00a0are\x20activated\x20by\x20the\x20proton-catalyzed\x20formation\x20of\x20a\x20tetracyclic\x20sulfenamide.\x20This\x20leads\x20to\x20the\x20trapping\x20of\x20the\x20drug\x20so\x20that\x20it\x20does\x20not\x20diffuse\x20back\x20across\x20the\x20canalicular\x20membrane.\x20The\x20activated\x20compound\x20forms\x20a\x20covalent\x20bond\x20with\x20sulfhydryl\x20groups\x20of\x20cysteines\x20in\x20the\x20<strong>H<sup>+</sup>/K<sup>+\u00a0</sup>ATPase</strong>\x20irreversibly,\x20thus\x20inactivating\x20the\x20pump\x20molecule.\x20They\x20primarily\x20promote\x20healing\x20of\x20gastric\x20and\x20duodenal\x20ulcers\x20and\x20is\x20used\x20to\x20treat\x20gastroesophageal\x20reflux\x20disease,\x20including\x20erosive\x20esophagitis,\x20that\x20is\x20complicated\x20or\x20unresponsive\x20to\x20treatment\x20with\x20H2\x20receptor\x20antagonists.\x20They\x20are\x20used\x20along\x20with\x20antibiotics\x20for\x20the\x20eradication\x20of\x20<em>Helicobacter\x20pylori</em>.\x20They\x20are\x20used\x20as\x20the\x20mainstay\x20treatment\x20of\x20pathological\x20hypersecretory\x20conditions,\x20including\x20the\x20<strong>Zollinger-Ellison\x20syndrome.</strong></p>\x0a<p>Other\x20options:</p>\x0a<p>Option\x20A-\x20<strong>Famotidine</strong>\x20is\x20a\x20histamine\x20H2-blocker.</p>\x0a<p>Option\x20C-\x20<strong>Misoprostol</strong>\x20is\x20a\x20prostaglandin\x20analogue\x20used\x20to\x20prevent\x20ulcers\x20in\x20patients\x20taking\x20nonsteroidal\x20anti-inflammatory\x20drugs\x20(NSAIDs).</p>\x0a<p>Option\x20D-\x20<strong>Propantheline</strong>\x20is\x20a\x20quaternary\x20ammonium\x20anticholinergic\x20agent\x20which\x20inhibits\x20the\x20muscarinic\x20actions\x20of\x20acetylcholine\x20on\x20autonomic\x20nerve\x20endings.\x20Propantheline\x20were\x20being\x20used\x20to\x20alleviate\x20symptoms\x20of\x20irritable\x20bowel\x20syndrome,\x20painful\x20gastrointestinal\x20motility\x20disorders\x20and\x20peptic\x20ulcer\x20disease.\x20It\x20has\x20been\x20replaced\x20by\x20more\x20effective\x20antiulcer\x20agents.\u00a0</p>','Desogestrel','join','gnESK','<p>In\x20this\x20clinical\x20scenario,\x20<strong>zidovudine</strong>\x20has\x20to\x20be\x20<strong>avoided</strong>.\x20<strong>Ganciclovir</strong>\x20used\x20to\x20treat\x20<strong>CMV\x20retinitis</strong>\x20is\x20associated\x20with\x20the\x20risk\x20of\x20<strong>bone\x20marrow\x20suppression</strong>,\x20leading\x20to\x20anaemia\x20and\x20neutropenia.\x20<strong>Zidovudine</strong>,\x20an\x20<strong>antiretroviral\x20drug,\x20</strong>a\x20nucleoside\x20reverse\x20transcriptase\x20inhibitor,\x20is\x20also\x20known\x20to\x20cause\x20<strong>bone\x20marrow\x20suppression\x20</strong>and\x20can\x20exacerbate\x20these\x20hematologic\x20side\x20effects\x20when\x20used\x20with\x20ganciclovir.\x20Hence\x20zidovudine\x20has\x20to\x20be\x20avoided\x20in\x20patients\x20receiving\x20ganciclovir\x20to\x20prevent\x20enhanced\x20bone\x20marrow\x20suppression.</p>\x0a<p>Other\x20options</p>\x0a<p>Option\x20B:\x20<strong>Efavirenz</strong>\x20is\x20a\x20non-nucleoside\x20reverse\x20transcriptase\x20inhibitor\x20that\x20does\x20not\x20have\x20significant\x20bone\x20marrow\x20toxicity.\x20Hence,\x20it\x20can\x20be\x20given\x20along\x20with\x20ganciclovir.</p>\x0a<p>Option\x20C:\x20<strong>Lamivudine\x20</strong>is\x20a\x20nucleoside\x20reverse\x20transcriptase\x20inhibitor\x20that\x20is\x20safe\x20for\x20patients\x20receiving\x20ganciclovir.</p>\x0a<p>Option\x20D:\x20<strong>Dolutegravir</strong>,\x20an\x20integrase\x20inhibitor,\x20is\x20safe\x20for\x20patients\x20receiving\x20ganciclovir\x20and\x20does\x20not\x20have\x20bone\x20marrow\x20side\x20effects.</p>','<p><strong>The\x20graph\x20</strong>represents\x20the<strong>\x20time-dependent\x20killing</strong>\x20and\x20is\x20demonstrated\x20by<strong>\x20penicillin\x20(Beta-lactam\x20antibiotics)</strong>\x20and\x20<strong>macrolides.\u00a0</strong></p>\x0a<p>In\x20antimicrobial\x20pharmacodynamics,\x20antibiotics\x20are\x20generally\x20categorised\x20based\x20on\x20how\x20their\x20antimicrobial\x20action\x20depends\x20on\x20time\x20or\x20concentration.\x20\u00a0</p>\x0a<p>1.<strong>\x20Time-dependent\x20killing</strong>:\x20These\x20antibiotics\x20rely\x20on\x20the\x20<strong>amount\x20of\x20time</strong>\x20the\x20<strong>drug\x20concentration</strong>\x20remains\x20<strong>above\x20</strong>the\x20<strong>minimum\x20inhibitory\x20concentration</strong>\x20(MIC)\x20to\x20exert\x20their\x20effect.\x20Once\x20the\x20concentration\x20is\x20above\x20the\x20MIC,\x20increasing\x20the\x20concentration\x20further\x20does\x20not\x20significantly\x20increase\x20the\x20rate\x20of\x20bacterial\x20killing.\x20Instead,\x20the\x20duration\x20of\x20exposure\x20is\x20key\x20to\x20effective\x20bacterial\x20eradication.\x20This\x20type\x20is\x20typically\x20seen\x20in\x20<strong>beta-lactam\x20antibiotics</strong>.\u00a0</p>\x0a<p><strong>Penicillins</strong>,\x20<strong>cephalosporins</strong>,\x20and\x20<strong>vancomycin</strong>\x20are\x20examples\x20of\x20medications\x20that\x20demonstrate\x20<strong>time-dependent\x20killing</strong>.\x20For\x20these\x20drugs,\x20multiple\x20daily\x20doses\x20are\x20preferred\x20over\x20single\x20doses.</p>\x0a<p>The\x20image\x20below\x20shows\x20time-dependent\x20killing.</p>','Brodalumab','VSqXj','bookmarkBtn','answered','selectedAnswer','qKBGU','explanation_audio_eng','\x20-\x20Brain\x20And\x20Scalpel','zQqPM','true','hzMYW','cSHUs','Incorrect','GxNqR','stats','IjDOr','totalAttempted','Capreomycin','timed_exam','Clopidogrel','ZJsKi','PZojz','HoENu','Decreased\x20intravascular\x20oncotic\x20pressure','https://dhmbxeygs57ff.cloudfront.net/uploads/aebe207b9383439782344d945a2e3201x355x512.JPEG','A\x2062-year-old\x20woman\x20came\x20to\x20the\x20hospital\x20with\x20complaints\x20of\x20excruciating\x20paroxysmal\x20pain\x20on\x20the\x20right\x20side\x20of\x20her\x20lips,\x20gums,\x20and\x20cheek.\x20The\x20episodes\x20last\x20for\x202-3\x20min\x20and\x20have\x20been\x20present\x20for\x20the\x20past\x202\x20months.\x20\x20Which\x20of\x20the\x20following\x20is\x20incorrect\x20regarding\x20the\x20primary\x20drug\x20used\x20in\x20the\x20treatment\x20of\x20this\x20condition?','dQmpl','correct_choice_id','Combination\x20produces\x20serious\x20adverse\x20effect\x20like\x20agranulocytosis','uQIKV','Which\x20of\x20the\x20following\x20forms\x20of\x20iron\x20may\x20be\x20preferred\x20in\x20a\x20patient\x20with\x20CKD\x20already\x20being\x20treated\x20with\x20darbepoietin?','Febuxostat','Guaifenesin'];_0x53f1=function(){return _0x707631;};return _0x53f1();}function toggleSidebar(){const _0x34b010=_0x2e8c1b,_0x338500={'qWEwS':'quizSidebar','kLFFB':_0x34b010(0x498)};document[_0x34b010(0x2e5)](_0x338500[_0x34b010(0x47c)])['classList'][_0x34b010(0x1c3)](_0x338500['kLFFB']);}document[_0x2e8c1b(0x2c5)](_0x2e8c1b(0x2cb),()=>{const _0x722818=_0x2e8c1b,_0xa2b265={'qZmkF':function(_0x52a2d3){return _0x52a2d3();},'KUpRE':function(_0x14ce4f,_0x5d56ec){return _0x14ce4f<_0x5d56ec;},'oVUFA':function(_0x2e53a3,_0x3e5b7c){return _0x2e53a3===_0x3e5b7c;},'pvtNL':function(_0x14c97a){return _0x14c97a();},'uPwti':_0x722818(0x228),'lvrTb':'none','tVPIZ':function(_0x5fc010){return _0x5fc010();},'NMUsa':function(_0x12d47c,_0x5d5fac){return _0x12d47c!==_0x5d5fac;},'IuVWe':_0x722818(0x41e),'unvAP':_0x722818(0x28d),'XrEiH':'flex','wRQLN':_0x722818(0x2d4),'wkWOq':function(_0x5f6c3a){return _0x5f6c3a();}};if(resume){if(_0xa2b265['oVUFA'](_0x722818(0x367),'cySec'))_0x288c48=0x0,_0x576ead(),_0xa2b265[_0x722818(0x3dc)](_0x82702f);else{if(_0xa2b265['pvtNL'](loadProgress))document[_0x722818(0x2e5)](_0xa2b265[_0x722818(0x2d0)])[_0x722818(0x454)][_0x722818(0x272)]=_0xa2b265[_0x722818(0x337)],_0xa2b265[_0x722818(0x32a)](initializeQuiz);else{if(_0xa2b265[_0x722818(0x4b5)](_0xa2b265[_0x722818(0x1f3)],_0xa2b265['unvAP']))clearProgress(),document[_0x722818(0x2e5)](_0x722818(0x228))[_0x722818(0x454)]['display']=_0xa2b265[_0x722818(0x40d)];else{const _0x291ce1=_0x5dc696[_0x722818(0x4a8)](_0x464637[_0x722818(0x1cd)](_0x722818(0x339)))||[];_0x291ce1[_0x722818(0x40c)](_0x4447dc=>{const _0x597f62=_0x722818;_0x4447dc[_0x597f62(0x335)][_0x597f62(0x341)](_0x2b3134[_0x597f62(0x3cc)]()[_0x597f62(0x270)](/ /g,'-'))&&(_0xa2b265['KUpRE'](_0x4447dc['questionIndex'],_0x4a77c4[_0x597f62(0x3af)])&&(_0x342cc3[_0x4447dc[_0x597f62(0x1b5)]][_0x597f62(0x493)]=!![]));});}}}}else!window[_0x722818(0x352)]['pathname'][_0x722818(0x347)](_0xa2b265[_0x722818(0x292)])?(_0xa2b265[_0x722818(0x3b1)](clearProgress),document[_0x722818(0x2e5)](_0xa2b265[_0x722818(0x2d0)])[_0x722818(0x454)][_0x722818(0x272)]=_0xa2b265['XrEiH']):_0xa2b265[_0x722818(0x32a)](initializeQuiz);}),document[_0x2e8c1b(0x2c5)](_0x2e8c1b(0x421),function(_0x3aef70){const _0x312dfd=_0x2e8c1b,_0x454ec8={'OUOZy':_0x312dfd(0x2d5),'yHOCE':_0x312dfd(0x1be),'EOFld':_0x312dfd(0x377),'nBopj':'none','weyrw':function(_0x3c51a4,_0x589a55){return _0x3c51a4===_0x589a55;},'uQvrp':_0x312dfd(0x439),'aqJAa':'hidden','mGent':function(_0x154b57,_0x2a4dc3){return _0x154b57>=_0x2a4dc3;},'EMGlv':function(_0x183364,_0x305c6f){return _0x183364<=_0x305c6f;},'pheJm':function(_0x441105,_0x1d3b6a){return _0x441105-_0x1d3b6a;},'StBBy':function(_0x25afac,_0x4bc796){return _0x25afac(_0x4bc796);},'QtHTy':_0x312dfd(0x472),'PvBwc':function(_0xf413e5,_0x545f63){return _0xf413e5<_0x545f63;},'PaByr':function(_0x385313,_0x29f9ef){return _0x385313(_0x29f9ef);},'PoNWe':function(_0x7fb95a,_0x4537d9){return _0x7fb95a===_0x4537d9;},'kSwRQ':_0x312dfd(0x499),'BTxmC':_0x312dfd(0x3a9),'FYBUl':function(_0x2bd7a0){return _0x2bd7a0();},'HkQBt':function(_0x17ed78,_0x44b6f4){return _0x17ed78===_0x44b6f4;},'GGfcd':function(_0x47cb48,_0x3930c5){return _0x47cb48===_0x3930c5;},'hzSUk':function(_0x1885e3,_0x249608){return _0x1885e3===_0x249608;},'NCSID':_0x312dfd(0x1bc),'MfyQV':function(_0x201ce8,_0x10abba){return _0x201ce8===_0x10abba;},'FQsGn':_0x312dfd(0x309),'bQuVX':function(_0x2bd5b9){return _0x2bd5b9();},'kgGfq':function(_0x19bc2a,_0xc7c886){return _0x19bc2a===_0xc7c886;},'WMEFa':function(_0x2ece71,_0x13953b){return _0x2ece71===_0x13953b;}};if(document[_0x312dfd(0x2e5)](_0x312dfd(0x228))['style'][_0x312dfd(0x272)]!==_0x454ec8[_0x312dfd(0x2c0)])return;if(_0x454ec8[_0x312dfd(0x434)](document[_0x312dfd(0x2e5)](_0x454ec8[_0x312dfd(0x2c2)])[_0x312dfd(0x464)]['contains'](_0x454ec8[_0x312dfd(0x3a1)]),![]))return;if(_0x454ec8[_0x312dfd(0x250)](_0x3aef70[_0x312dfd(0x1e3)],'1')&&_0x454ec8[_0x312dfd(0x2ac)](_0x3aef70[_0x312dfd(0x1e3)],'4')){if(_0x312dfd(0x383)!==_0x312dfd(0x474)){const _0x141b95=_0x454ec8['pheJm'](_0x454ec8[_0x312dfd(0x331)](parseInt,_0x3aef70[_0x312dfd(0x1e3)]),0x1),_0x221623=document[_0x312dfd(0x399)](_0x454ec8[_0x312dfd(0x27f)]);if(_0x454ec8[_0x312dfd(0x17f)](_0x141b95,_0x221623[_0x312dfd(0x3af)]))_0x454ec8['PaByr'](selectOption,_0x141b95);}else _0x44360d=_0x454ec8[_0x312dfd(0x46a)];}else{if(_0x454ec8[_0x312dfd(0x37d)](_0x3aef70[_0x312dfd(0x1e3)],_0x454ec8[_0x312dfd(0x23b)])){if(_0x454ec8[_0x312dfd(0x434)](_0x454ec8[_0x312dfd(0x16a)],'RJChz'))_0x454ec8['FYBUl'](previousQuestion);else{if(_0x3b6fa4['selectedAnswer']!==null)_0xa80766=_0x454ec8['yHOCE'];else _0x4897e6=_0x454ec8['EOFld'];}}else{if(_0x3aef70[_0x312dfd(0x1e3)]===_0x312dfd(0x19c)||_0x454ec8[_0x312dfd(0x1b0)](_0x3aef70[_0x312dfd(0x1e3)],'\x20'))_0x3aef70[_0x312dfd(0x243)](),nextQuestion();else{if(_0x454ec8['HkQBt'](_0x3aef70[_0x312dfd(0x1e3)][_0x312dfd(0x3cc)](),'b')&&(currentMode===_0x312dfd(0x38b)||_0x454ec8[_0x312dfd(0x2b5)](currentMode,_0x312dfd(0x401))))_0x454ec8['FYBUl'](toggleBookmark);else{if(_0x454ec8[_0x312dfd(0x461)](_0x3aef70[_0x312dfd(0x1e3)]['toLowerCase'](),'m')&&(_0x454ec8[_0x312dfd(0x2b5)](currentMode,_0x454ec8[_0x312dfd(0x279)])||_0x454ec8[_0x312dfd(0x322)](currentMode,_0x454ec8[_0x312dfd(0x237)])))_0x454ec8['bQuVX'](toggleMarkForReview);else _0x454ec8[_0x312dfd(0x27e)](_0x3aef70[_0x312dfd(0x1e3)]['toLowerCase'](),'s')&&(_0x454ec8['WMEFa'](currentMode,_0x312dfd(0x1bc))||_0x454ec8['GGfcd'](currentMode,_0x454ec8[_0x312dfd(0x237)]))&&_0x454ec8[_0x312dfd(0x3b3)](submitQuiz);}}}}});</script>

</body></html>